

**JENNIFER W. TIDEY, PH.D.**  
**CURRICULUM VITAE**  
**02/19/26**

**Table of Contents**

EDUCATION .....	2
ACADEMIC APPOINTMENTS .....	2
OTHER APPOINTMENTS .....	3
HONORS AND AWARDS .....	3
MEMBERSHIP IN PROFESSIONAL SOCIETIES .....	4
NATIONAL OR INTERNATIONAL SERVICE .....	5
PUBLICATIONS IN PEER-REVIEWED JOURNALS .....	8
BOOKS AND BOOK CHAPTERS .....	26
NON-PEER REVIEWED PUBLICATIONS .....	27
INVITED PRESENTATIONS .....	28
OTHER PRESENTATIONS .....	33
GRANTS .....	62
UNIVERSITY TEACHING AND MENTORING ROLES .....	74
MEDIA ENGAGEMENT .....	77

**CURRICULUM VITAE**  
**JENNIFER W. TIDEY, PH.D.**

Center for Alcohol and Addiction Studies, Brown University, Box G-S121-5

Phone: 401-863-6418      Fax: 401-863-6697

Email: Jennifer\_Tidey@Brown.edu

Research page: <https://vivo.brown.edu/display/jtidey>

**EDUCATION**

Undergraduate	Tufts University, Medford, Massachusetts B.S., Psychology, 1986
Graduate	Tufts University, Medford, Massachusetts M.S., Experimental Psychology, 1988 – 1990 Ph.D., Experimental Psychology, 1990 – 1995
Post-Doctoral Fellowship	Harvard University School of Medicine/ New England Regional Primate Research Center Southborough, Massachusetts Division of Behavioral Biology Area: Behavioral Pharmacology August 1994 – July 1996
NIDA T32 Post-Doctoral Fellowship	University of Vermont School of Medicine Burlington, Vermont Department of Psychiatry Area: Human Behavioral Pharmacology July 1996 – June 1999
NIAAA T32 Post-Doctoral Fellowship	Brown University School of Medicine Providence, Rhode Island Center for Alcohol and Addictions Studies Area: Human Behavioral Pharmacology November 1999 – October 2000

**ACADEMIC APPOINTMENTS**

Associate Dean for Research	Brown University School of Public Health Providence, Rhode Island 2020 – present
Professor	Department of Behavioral and Social Sciences Department of Psychiatry and Human Behavior Brown University, Providence, Rhode Island 2016 – present

NIDA T32 Associate Director	Center for Alcohol and Addiction Studies Brown University Providence, Rhode Island 2013 – present
Associate Professor (Research)	Department of Psychiatry and Human Behavior Department of Behavioral and Social Sciences Brown University Providence, Rhode Island 2009 – 2016
Laboratory Director	Addictive Behaviors Research Laboratory Center for Alcohol and Addiction Studies Brown University, Providence, Rhode Island 2009 – present
Assistant Professor (Research)	Department of Psychiatry and Human Behavior Alpert Medical School of Brown University, Providence, Rhode Island 2000 – 2009

### **OTHER APPOINTMENTS**

Research Health Science Specialist	Research and Education Service Veterans Affairs Medical Center, Providence, RI 2002 – 2008
Project Coordinator	Research and Education Service Veterans Affairs Medical Center, Providence, RI 1999 – 2002

### **HONORS AND AWARDS**

December 2020	Fellow, Society for Research on Nicotine & Tobacco (SRNT)
August 2019	Fellow, American Psychological Association (APA) Division 28
June 2019	Fellow, College on Problems of Drug Dependence (CPDD)
January 2015	Board of Directors, College on Problems of Drug Dependence (CPDD)
June 2010	Masters of Arts <i>ad eundem</i> , Brown University
March 2006	Service Award, Society for Research on Nicotine and Tobacco (SRNT)
October 2002	Research Excellence Award, Center for Alcohol and Addiction Studies (CAAS), Brown University
June 2002	Memorial Travel Award, American College of Neuropsychopharmacology
April 2000	Research Excellence Award, Center for Alcohol and Addiction Studies (CAAS), Brown University
November 1999	Post-Doctoral Fellowship, National Institute on Alcohol Abuse and Alcoholism
March 1999	NIDA Director's Travel Award, National Institute on Drug Abuse
July 1998	Senator Proctor Research Award, American Lung Association of Vermont
June 1997	CPDD Early Career Investigator Award (Travel Award)

**MEMBERSHIP IN PROFESSIONAL SOCIETIES**

2002 – present	<u>College on Problems of Drug Dependence (CPDD)</u> <ul style="list-style-type: none"> <li>• Fellow, 2019 – present</li> <li>• Chair, Tobacco Regulatory Ad Hoc Committee, 2019 – 2020</li> <li>• Program Committee, 2019 – 2022</li> <li>• Board of Directors, 2015 – 2019</li> <li>• Advocacy Day participant, 2017, 2019</li> <li>• CPDD Meeting Mentorship Program 2017 – 2019</li> <li>• Awards Committee, 2016 – 2019</li> <li>• Membership Committee, 2013 – 2016</li> <li>• Human Research Committee, 2010 – 2013</li> <li>• Program Committee, 2007 – 2010</li> <li>• Organizer of “Brunch with Champions” mentoring event, 2005 – 2007</li> <li>• Travel Awards and Mentoring Committee, 2002 – 2007</li> </ul>
2000 – present	<u>Society for Research on Nicotine and Tobacco</u> <ul style="list-style-type: none"> <li>• Fellow, 2020 – present</li> <li>• Membership Committee, 2017 – 2019</li> <li>• Program Co-Chair, 2005-2006</li> <li>• Abstract Reviewer, 2002 – 2006, 2013, 2020</li> <li>• Session Co-Chair, 2006</li> </ul>
2015 – present	<u>American Psychological Association</u> <ul style="list-style-type: none"> <li>• Division 28 Fellow, 2019 – present</li> </ul>
2019 – present	<u>Rhode Island Public Health Association</u>
2020 – present	<u>Association of Schools &amp; Programs of Public Health (ASPPH)</u>
2001 – 2017	<u>Research Society on Alcoholism</u>
1996 – present	<u>International Study Group Investigating Drugs as Reinforcers</u>
1992 – present	<u>Behavioral Pharmacology Society</u>

**DEPARTMENT, CENTER, AFFILIATED HOSPITAL, OR UNIVERSITY SERVICE**

2025 – present	Member, Research Systems Advisory Committee, Brown University
2024 – present	Co-Chair, Provost’s Task Force on Human Remains at Brown University
2023 – present	Member, Research Advisory Council, Brown Innovation and Research Collaborative for Health (BIRCH)
2023 – present	Member, Internal Advisory Committee, Advance Clinical and Translational Research (Advance-CTR) (U54GM115677), Warren Alpert Medical School of Brown University
2023 – present	Member, Internal Advisory Board, Mindfulness Center, Brown University School of Public Health
2023 – 2024	Member, Research Faculty Working Group, Brown University
2023 – 2024	Member, Search Committee for the Brown University Vice President of Research
2022 – 2023	Member, Search Committee for the Director of the Center for Alcohol and Addictions Research (CAAS), Brown University School of Public Health

2020 – present	Member, Research Advisory Board to the Office of the Vice President for Research, Brown University
2020 – present	Member, Brown University Research Associate Deans Committee
2020 – present	Member, Brown School of Public Health Executive Committee
2021	Certificate of Completion, Advance-CTR Mentoring Training facilitated by NRMN and CIMER faculty mentors
2020 – 2021	Committee Member and Human Research Subcommittee Chair, Brown University Research Continuity Committee
2020 – 2021	Member, Brown University COVID Research Task Force
2019	Co-Chair, Addictions Workgroup, Brown University School of Public Health
2016 – 2018	Member, Academic Faculty Appointments, Reappointments & Promotions Committee, Department of Psychiatry and Human Behavior, Brown University
2016	Member, Workgroup on Evidence-Based Healthcare, Brown University School of Public Health
2015	Member, Search Committee for the Director of the Institute for Community Health Promotion (ICHP), Brown University School of Public Health
2012 – 2019	Chair, Research Excellence Awards and Research Achievement Awards Committees, Brown University Center for Alcohol & Addiction Studies
2012 – 2014	Member, Medical Faculty Policy Task Force (Research) track subcommittee, Brown University
2010 – present	Member, Alcohol and Addictions Post-Doctoral Training and Admissions Committee, Brown University Center for Alcohol & Addiction Studies
2004 – 2011	Ad-hoc Member, Research Excellence Awards Committee, Brown University Center for Alcohol & Addiction Studies
2003 – 2006	Member, Adolescent Forensics Post-Doctoral Training Program Search Committee, Brown University Center for Alcohol & Addiction Studies
2002 – 2007	Member, Brown University Institutional Review Board (IRB)
2002 – 2004	Member, Alcohol and Addictions Post-Doctoral Training and Admissions Committee, Brown University Center for Alcohol & Addiction Studies
2002 – 2005	Alternate Member, Providence VAMC Institutional Review Board, Providence VAMC Research and Development Committee

### **NATIONAL OR INTERNATIONAL SERVICE**

#### **NIH Grant Review Panels**

July 2025	Review panel, 2025/10 ZAG1 EPH-P (90): Career Development in Population Health Sciences
Aug 2024	Special Emphasis Panel, Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)
Feb 2024	Review panel, NCI R01/R34 Advancing Adolescent Tobacco Cessation Interventions
Nov 2021	Review panel, Special Emphasis Panel/Scientific Review Group 2022/01 ZRG1 RPHB-P (57) R in Tobacco Regulatory Science

November 2019	Reviewer, Review Co-Chair, NIH PAR “Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research” (R01, R21)
December 2018	Reviewer, NIDA DP5 Early Independence Awards
June 2018	Reviewer, NIDA Special Emphasis Panel (SEP) ZDA1-JXB-N (12), “Evaluating the NIDA SREC in Risk Reduction and Related Studies (U01)”
February 2017	Ad Hoc reviewer, Addiction Risks and Mechanisms (ARM) study section
June 2016	Ad Hoc reviewer, Addiction Risks and Mechanisms (ARM) study section
February 2016	Ad Hoc reviewer, Addiction Risks and Mechanisms (ARM) study section
March 2015	Reviewer, NIDA SEP ZDA1 JXR-G (15), “Exploratory Studies of Smoking Cessation Interventions for Smokers with Schizophrenia (R21 & R33)”
October 2014	Reviewer, NIDA SEP “Exploratory Studies of Smoking Cessation Interventions for Smokers with Schizophrenia (R21 & R33)”
November 2013	Reviewer, NIDA SEP ZRG1 BBBP-X (03) M
November 2012	Reviewer, NIDA SEP ZRG1 BBBP-T (04) M
March 2012	Reviewer, NIDA SEP ZDA1 GXM-A (08)
June 2011	Reviewer, NIDA SEP ZDA1 GXM-A (05)
June 2009	Reviewer, NIAAA/NIDA SEP ZRG1 IFCN-L (50) R-SOAR
March 2009	Reviewer, “Medications Development Centers of Excellence (P50)” NIDA SEP ADA1 SXC-E 13
October 2007	Ad Hoc Reviewer, NIDA-L Medications Development committee
October 2006	Ad Hoc Reviewer, NIH-CSR Biobehavioral Regulation, Learning and Ethology Study Section [BRLE]
March 2006	Reviewer, NIMH SEP ZMH1 ERB-B (03)
March 2004	Ad Hoc Reviewer, NIDA B/START (R03) Awards

#### VA Grant Review Panels

2010- 2014	Reviewer, Neurobiology-A IRG, Biomedical Laboratory Research & Development Service, Department of Veterans Affairs
------------	--

#### Foundation Grant Review Panels

October 2007	Reviewer, Donaghue Medical Research Foundation, West Hartford, CT
--------------	---

#### Advisory Boards and Working Groups

2025 – present	Member, NIDA T32 External Advisory Board, University of Vermont Center on Behavior and Health
2025 – present	Member, Data Safety and Monitoring Board (DSMB), R01CA239308 “Communicating about Nicotine and Differential Risks of Tobacco Products in Priority Populations” (Popova, PI).
2024 – present	Member, Data Safety and Monitoring Board (DSMB), Yale Tobacco Center of Regulatory Science (TCORS)
2023 – present	Scientific Advisory Committee, R01DA058264 “Assessing the Real-World Impact of a Low Nicotine Product Standard for Smoked Tobacco in New Zealand” (Denlinger-Apte, Donny, MPIs).

2020 – present	Member, External Advisory Board, University of Vermont COBRE Center on Behavior and Health
2021 – 2024	Associate Director, University of Vermont Center of Regulatory Science
2017 – 2021	Chair, Data and Safety Monitoring Board (DSMB), R21DA049289 “Working Memory Training Combined with Transcranial Magnetic Stimulation in Smokers: 2x2 Factorial Study” (William Lechner, PI).
2014 – 2015	Chair, FDA/NIH Tobacco Centers of Regulatory Science (TCORS) Behavioral Pharmacology Laboratory Working Group
2014 – 2019	Member, FDA/NIH Tobacco Centers of Regulatory Science (TCORS) Vulnerable Populations Working Group
2014 – 2019	Member, FDA/NIH Tobacco Centers of Regulatory Science (TCORS) Nicotine Working Group
2013 – 2015	Advisory Board Member for Nicotine Anonymous feasibility study, National Health Care for the Homeless Council

#### Promotion and Tenure Review

Albert Einstein College of Medicine; Colorado State University; Dartmouth University Geisel School of Medicine; Fordham University; Harvard Medical School; Harvard University T.H. Chan School of Public Health; McGovern Medical School at UTHealth; Medical University of South Carolina; University of Houston; University of Nevada, Reno; University of Pennsylvania Perelman School of Medicine; University of Vermont Larner College of Medicine; Washington State University Elson S. Floyd College of Medicine; Virginia Commonwealth University; Yeshiva University Ferkauf Graduate School of Psychology, Ohio State University, University of Utah, Yale University

#### Editorial Responsibilities

Senior Scientific Editor and Chapter Lead, Surgeon General’s Report on Tobacco Use in People with Mental Health Conditions (anticipated release in September 2025)

Deputy Editor, Nicotine & Tobacco Research, 2019 – 2023

Associate Editor, Nicotine & Tobacco Research, 2008 – 2019

Associate Editor, Tobacco Regulatory Science, 2014 – 2020

Editorial Board, Experimental and Clinical Psychopharmacology, 2017 - present

Guest Editor (with A. Weinberger, M. Steinberg), Themed section of Nicotine & Tobacco Research: “Non-Pharmacological Treatments for Tobacco Users with Mental Health Symptoms”, 2019.

#### Manuscript Reviews

Reviewer for: Addiction, Addictive Behaviors, Alcohol: Clinical and Experimental Research, Appetite, Drug and Alcohol Dependence, Drug and Alcohol Reviews, Experimental and Clinical Psychopharmacology, JAMA Network Open, JAMA Psychiatry, Journal of Applied Behavior Analysis, Journal of Pharmacology and Experimental Therapeutics, Journal of Psychiatric Research, Journal of Substance Abuse Treatment, Neuropsychopharmacology, Nicotine & Tobacco Research, Preventive Medicine, Psychopharmacology

**PUBLICATIONS LIST (\* indicates mentee at the time of the work). h-index 50****PUBLICATIONS IN PEER-REVIEWED JOURNALS****1989 – 1999**

1. Miczek KA, Haney M, Tidey J, Vatne T, Weerts E, DeBold JF (1989). Temporal and sequential patterns of agonistic behavior: Effects of alcohol, anxiolytics and psychomotor stimulants. Psychopharmacology, 97, 149-151. doi: 10.1007/BF00442237
2. Tidey JW, Miczek KA (1992). Heightened aggressive behavior during morphine withdrawal: Effects of d-amphetamine. Psychopharmacology, 107, 297-302. doi: 10.1007/BF02245151
3. Tidey JW, Miczek KA (1992). Morphine withdrawal aggression: Modification with D1 and D2 receptor agonists. Psychopharmacology, 108, 177-184. doi: 10.1007/BF02245304
4. Tidey JW, Miczek KA (1992). Effects of SKF 38393 and quinpirole on aggressive, motor and schedule-controlled behaviors in mice. Behavioral Pharmacology, 3, 553-565. PMID: 11224157
5. Miczek KA, Haney M, Weerts EM, Tidey JW (1994). Neurobiological mechanisms controlling aggression: Preclinical developments for pharmacotherapeutic interventions. Neuroscience and Behavioral Reviews, 18, 97-110. doi: 10.1016/0149-7634(94)90040-x
6. Tidey JW, Miczek KA (1996). Social defeat stress selectively alters mesocorticolimbic dopamine release: An *in vivo* microdialysis study. Brain Research, 721, 140-149. doi: 10.1016/0006-8993(96)00159-x
7. Tidey JW, Miczek KA (1997). Acquisition of cocaine self-administration after social stress: Role of accumbens dopamine. Psychopharmacology, 130, 203-212. doi: 10.1007/s00213005023
8. Roll JM, Higgins ST, Tidey JW (1997). Cocaine use can increase cigarette smoking: Evidence from laboratory and naturalistic settings. Experimental and Clinical Psychopharmacology, 5, 263-268. Doi: 10.1037//1064-1297.5.3.263
9. Tidey JW, Mehl-Madrona L, Higgins ST, Badger G (1998). Psychiatric symptom severity in cocaine-dependent outpatients: Relationships among demographics, drug use characteristics, and treatment outcome. Drug and Alcohol Dependence, 50, 9-18. doi: 10.1016/s0376-8716(97)00162-2
10. Tidey JW, Bergman J (1998). Drug discrimination in methamphetamine-trained monkeys: Agonist and antagonist effects of dopaminergic drugs. Journal of Pharmacology and Experimental Therapeutics, 285, 1163-1174. PMID 9618419
11. Tidey JW, Higgins ST, Bickel WK, Steingard S (1999). Effects of response requirement and the presence of an alternative reinforcer on cigarette smoking by schizophrenics. Psychopharmacology, 145, 52-60. doi: 10.1007/s002130051031
12. Tidey JW, O'Neill SC, Higgins ST (1999). Effects of abstinence on cigarette smoking among schizophrenic outpatients. Experimental and Clinical Psychopharmacology, 7, 347-353. doi: 10.1037/1064-1297.7.4.347

**2000-2008**

13. Tidey JW, O'Neill SC, Higgins ST (2000). d-Amphetamine increases choice of cigarette smoking over monetary reinforcement. *Psychopharmacology*, 153, 85-92. doi: 10.1007/s002130000600
14. Tidey JW, O'Neill SC, Higgins ST (2002) Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. *Experimental and Clinical Psychopharmacology*, 10, 241-247. doi: 10.1037//1064-1297.10.3.241
15. Heil SH, Tidey JW, Holmes HW, Higgins ST, Badger GJ (2003). A contingent payment model of smoking cessation: Effects on abstinence and withdrawal. *Nicotine & Tobacco Research*, 5, 205-213. doi: 10.1080/1462220031000074864
16. Sigmon SC, Tidey JW, Badger GJ, Higgins ST (2003). Acute effects of d-amphetamine on progressive-ratio performance maintained by cigarette smoking and money. *Psychopharmacology*, 167, 393-402. doi: 10.1007/s00213-003-1416-z
17. Monti PM, Tidey J, Czachowski, CL, Grant KA, Rohsenow DJ, Sayette M, Manners N, Pierre, P (2004). Building bridges: The transdisciplinary study of craving from the animal lab to the lamppost. *Alcoholism: Clinical and Experimental Research*, 26, 279-287. doi: 10.1097/01.alc.0000113422.04849.fa
18. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. (2005). Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. *Drug and Alcohol Dependence*, 80, 259-265. doi: 10.1016/j.drugalcdep.2005.04.002
19. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. (2005) Subjective and physiological responses to smoking cues in smokers with schizophrenia. *Nicotine & Tobacco Research*, 7, 421-429. doi: 10.1080/14622200500125724
20. McGeary JE, Monti PM, Rohsenow DJ, Tidey JW, Swift RM, Miranda R, Jr. (2006). Genetic moderators of naltrexone's effects on alcohol cue reactivity. *Alcoholism: Clinical and Experimental Research*, 30, 1288-1296. doi: 10.1111/j.1530-0277.2006.00156.x.
21. Tevyaw TO, Gwaltney C, Tidey JW, Colby SM, Kahler CW, Miranda R, Barnett NP, Rohsenow DJ, Monti PM (2007). Contingency management for adolescent smokers: An exploratory study. *Journal of Child and Adolescent Substance Abuse*, 16(4), 23-44. doi: 10.1300/J029v16n04\_02
22. Miranda Jr. R, Rohsenow DJ, Monti PM, Tidey JW, Ray R (2007). Effects of repeated days of smoking cue exposure on urge to smoke and physiological reactivity. *Addictive Behaviors*, 33(2), 347-353. PMC2254225. doi: 10.1016/j.addbeh.2007.09.011
23. Tidey JW, Williams JM (2007) Clinical indices of tobacco use among people with schizophrenia. *Journal of Dual Diagnosis*, 3 (3-4), 79-98. doi: 10.1300/J374v03n03\_07
24. Tidey JW, Monti P, Rohsenow D, Gwaltney C, Miranda R, McGeary J, MacKillop J, Swift, R, Abrams, D, Shiffman S, Paty J. (2008). Moderators of naltrexone's effects on drinking, urge and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. *Alcoholism: Clinical and Experimental Research*, 32(1), 58-66. PMC2743136. doi: 10.1111/j.1530-0277.2007.00545.x

25. Miranda Jr., R, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J. (2008). Effects of topiramate on urge to drink and the subjective effects of alcohol consumption: A preliminary laboratory study. Alcoholism: Clinical and Experimental Research, 32(3), 489-97. doi: 10.1111/j.1530-0277.2007.00592.x.
26. Tidey JW, Rohsenow DJ, Kaplan, GB, Swift RM, Adolfo, AB\*. (2008) Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls. Nicotine & Tobacco Research, 10(6), 1047-1056. PMC2952171. doi: 10.1080/14622200802097373.
27. Rohsenow DJ, Tidey JW, Miranda R, McGeary J, Swift R, Hutchison K, Sirota A, Monti PM. (2008). Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers. Experimental and Clinical Psychopharmacology, 16(3), 215-222. doi: 10.1037/1064-1297.16.3.215.

## **2009**

28. MacKillop, J., Murphy J, Tidey J, Kahler C, Ray L, & Bickel W (2009). Latent structure of facets of alcohol reinforcement from a behavioral economic demand curve. Psychopharmacology, 203, 33-40. PMC2774887. doi: 10.1007/s00213-008-1367-5.
29. Adolfo AB\*, AhnAllen C\*, Tidey J (2009). Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia. Schizophrenia Research, 107, 192-197. PMC2765103. doi: 10.1016/j.schres.2008.10.009.
30. Tidey JW, Rohsenow DJ. (2009). Intention to quit moderates the effects of bupropion on smoking urge. Nicotine & Tobacco Research, 11(3), 308-312. PMC2666376. doi: 10.1093/ntr/ntn032.
31. Tevyaw T, Colby SM, Tidey JW, Kahler C, Rohsenow DJ, Barnett NP, Gwaltney CG, Monti PM (2009). Contingency management and motivational enhancement: A randomized clinical trial for college student smokers. Nicotine & Tobacco Research, 11(6), 739-749. PMC2688604. doi: 10.1093/ntr/ntp058.
32. Ray LA, Miranda RM, MacKillop J, McGeary JE, Tidey JW, Rohsenow, DJ, Gwaltney C, Swift RM, Monti PM (2009). A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Experimental and Clinical Psychopharmacology, 17(2):122-9. PMC3682424. doi: 10.1037/a0015700.
33. Tidey JW, Rohsenow DJ (2009). Smoking expectancies and intention to quit in smokers with schizophrenia, schizoaffective disorder and non-psychiatric controls. Schizophrenia Research, 115, 310-316. PMC2795352. doi: 10.1016/j.schres.2009.09.032.

## **2010**

34. MacKillop J, Miranda RM, Monti PM, Ray LA, Murphy JG, Rohsenow DJ, McGeary JG, Swift RM, Tidey JW, Gwaltney CJ (2010). Alcohol demand, delayed reward discounting, and craving in relation to drinking and alcohol use disorders. Journal of Abnormal Psychology, 119(1):106-114. PMC2862264. doi: 10.1037/a0017513.
35. Ray LA, Miranda RM, Tidey JW, McGeary, JE, MacKillop J, Gwaltney CJ, Rohsenow, DJ, Swift RM, Monti, PM (2010). Polymorphisms of the  $\mu$ -opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. Journal of Abnormal Psychology, 119(1):115-125. PMC3703617. doi: 10.1037/a0017550.

36. Sirota AD, Rohsenow DJ, MacKinnon SV, Martin RA, Eaton CA, Kaplan GB, Monti PM, Tidey J, Swift RS (2010). Intolerance for smoking abstinence, physical and emotional discomfort questionnaires: Psychometric properties and relationship to tobacco dependence and abstinence. Addictive Behaviors, 35(7), 686-693. PMC3746812. doi: 10.1016/j.addbeh.2010.02.014.
37. MacKillop J, O'Hagen S, Lisman SA, Murphy JG, Ray L, McGeary JE, Tidey JW, Monti PM (2010). Behavioral economic analysis of cue-elicited craving for alcohol. Addiction, 105(9), 1599-1607. doi: 10.1111/j.1360-0443.2010.03004.x.

## **2011**

38. Murphy JG, MacKillop J, Tidey JW, Brazil LA, Colby SM (2011). Validity of a demand curve measure of nicotine reinforcement with adolescent smokers. Drug and Alcohol Dependence, 113, 207-214. PMC3025087. doi: 10.1016/j.drugalcdep.2010.08.004.
39. MacKillop J, Tidey JW (2011). Cigarette demand and delayed reward discounting in nicotine dependent individuals with schizophrenia and controls: An initial study. Psychopharmacology, 216, 91-99. PMC3640631. doi: 10.1007/s00213-011-2185-8.
40. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N (2011). Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology, 217, 279-287. PMC3685403. doi: 10.1007/s00213-011-2282-8.
41. AhnAllen CG\*, Tidey JW (2011). Personalized smoking environment cue effects in smokers with schizophrenia and controls: A pilot study. Psychiatry Research, 188, 286-288. PMC3114290. doi: 10.1016/j.psychres.2011.04.005.
42. Barnett NP, Tidey J, Murphy J, Swift R, Colby SM. (2011). Contingency management for alcohol use reduction: A pilot study using a transdermal alcohol sensor. Drug and Alcohol Dependence, 118, 391-399. PMC3190068. doi: 10.1016/j.drugalcdep.2011.04.023.

## **2012**

43. Tidey JW (2012). Using incentives to reduce substance use and other health risk behaviors among people with serious mental illness. Preventive Medicine, 55 Suppl:S54-60. PMC3336027. doi: 10.1016/j.yjmed.2011.11.010.
44. Kahler CW, Metrik J, Spillane N, Leventhal A, McKee S, Tidey JW, McGeary J, Knopik V, Rohsenow D (2012). Sex differences in stimulus expectancy and pharmacologic effects of a moderate dose of alcohol on smoking lapse risk in a laboratory analogue study. Psychopharmacology, 222, 71-80. PMC3687530. doi: 10.1007/s00213-011-2624-6.
45. Leventhal AM, Munafò M, Tidey JW, Sussman S, Monterosso JR, Sun P, Kahler CW (2012). Anhedonia predicts altered processing of happy faces in abstinent cigarette smokers Psychopharmacology, 222, 343-351. PMC3383908. doi: 10.1007/s00213-012-2649-5.
46. Bidwell LC\*, MacKillop J, Murphy JG, Tidey JW, Colby SM (2012). Latent factor structure of a behavioral economic cigarette demand curve in adolescent smokers. Addictive Behaviors 37(11):1257-63. PMC3597467. doi: 10.1016/j.addbeh.2012.06.009.

**2013**

47. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, AhnAllen CG\* (2013). Separate and combined effects of very low nicotine cigarettes and nicotine replacement in smokers with schizophrenia and controls. Nicotine & Tobacco Research, 15(1), 121-129. PMC3524060/doi: 10.1093/ntr/nts098.
48. Bidwell LC\*, Leventhal AM, Tidey JW, Brazil L, Niaura, RS, Colby SM (2013). Effects of abstinence in adolescent tobacco smokers: withdrawal symptoms, urge, affect, and cue reactivity. Nicotine & Tobacco Research, 15(2), 457-464. PMC3611993. doi: 10.1093/ntr/nts155.
49. Rohsenow DJ, Martin RA, Tidey JW, Monti PM, Colby SM (2013). Comparison of the Cigarette Dependence Scale with four other measures of nicotine involvement: Correlations with smoking history and smoking treatment outcome in smokers with substance use disorders. Addictive Behaviors, 38(8), 2409 – 2413. PMC3705939. doi: 10.1016/j.addbeh.2013.03.019.

**2014**

50. Miranda R, Ray L, Blanchard A, Reynolds EK, Monti PM, Chun T, Justus A, Swift RM, Tidey J, Gwaltney CJ, Ramirez J (2014). Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: A randomized trial. Addiction Biology, 19, 941-954. PMC3729253. doi: 10.1111/adb.12050.
51. Esposito-Smythers C, Brown LK, Wolff J, Xu J, Thornton S, Tidey J, The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN 069) (2014). Substance abuse treatment for HIV infected young people: An open pilot trial. Journal of Substance Abuse Treatment, 46(2), 244-250. PMC3840092. doi: 10.1016/j.jsat.2013.07.008.
52. Tidey JW, Colby SM, Xavier EMH\* (2014). Effects of smoking abstinence on cigarette craving, nicotine withdrawal and nicotine reinforcement in smokers with and without schizophrenia. Nicotine and Tobacco Research, 16(3), 326-34. PMC3920337. doi: 10.1093/ntr/ntt152.
53. Miranda R, Monti PM, Ray L, Trelaor H, Reynolds EK, Ramirez J, Chun T, Gwaltney C, Justus A, Tidey J, Blanchard A, Magill M (2014). Characterizing subjective responses to alcohol among adolescent problem drinkers. Journal of Abnormal Psychology, 123(1), 117-129. PMC4102316. doi: 10.1037/a0035328.
54. Leventhal AM, Trujillo M, Ameringer K, Tidey JW, Sussman S, Kahler CS (2014). Anhedonia and the relative reward value of drug and non-drug reinforcers in cigarette smokers. Journal of Abnormal Psychology, 123(2), 375-386. doi: 10.1037/a0036384. PMC4411231.
55. Kahler CW, Metrik J, Spillane NS, Day A, Leventhal AM, McKee SA, Tidey JW, McGeary JE, Knopik VS, Rohsenow DJ (2014). Acute effects of low and high dose alcohol on smoking lapse behavior in a laboratory analogue task. Psychopharmacology, 231(24), 4649-57. PMC4232980. doi: 10.1007/s00213-014-3613-3.

**2015**

56. Leggio L, Zywiak WH, Edwards SM, Tidey JW, Swift RM, Kenna GA (2015). A preliminary double-blind, placebo-controlled randomized study of baclofen effects in alcoholic smokers. Psychopharmacology, 232(1), 233-43. PMC4278944. doi: 10.1007/s00213-014-3652-9.

57. Donny EC, Hatsukami DK, Benowitz NL, Sved AF, Tidey JW, Cassidy RN\* (2015). Reduced nicotine product standards for combustible tobacco: Building an empirical basis for effective regulation. Preventive Medicine, 68, 17-22. PMC4253911. doi: 10.1016/j.ypmed.2014.06.020.
58. AnhAllen CG\*, Bidwell LC\* and Tidey JW (2015). Cognitive effects of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls. Nicotine & Tobacco Research, 17(5), 510-514. PMC4402354. doi: 10.1093/ntr/ntu163.
59. Day AM, Kahler CW, Metrik J, Spillane NS, Tidey JW, Rohsenow DJ (2015). Working memory moderates the relationship between smoking urge and smoking lapse behavior after alcohol administration in a laboratory analogue task. Nicotine & Tobacco Research, 17(9):1173-7. PMC4542737. doi: 10.1093/ntr/ntu259.
60. Rohsenow DJ, Tidey JW, Kahler CW, Martin RA, Colby SM, Sirota AD (2015). Intolerance for withdrawal discomfort and motivation predict voucher-based smoking treatment outcomes for smokers with substance use disorders. Addictive Behaviors, 43, 18-24. PMC4304939. doi: 10.1016/j.addbeh.2014.12.003.
61. Cassidy RN\*, Tidey JW, Kahler CS, Wray TB, Colby SM (2015). Increasing the value of an alternative monetary reinforcer reduces cigarette choice in adolescents. Nicotine & Tobacco Research 17(12), 1449-1455. PMC4654760. doi: 10.1093/ntr/ntv033.
62. Rohsenow DJ, Tidey JW, Martin RA, Monti PM, Colby SM, Sirota AD, Swift RM (2015). Contingent vouchers and motivational interviewing for cigarette smokers in residential substance abuse treatment. Journal of Substance Abuse Treatment, 55, 29-38. PMC4456203. doi: 10.1016/j.jsat.2015.02.010.
63. Gaalema DE, Miller ME\*, Tidey JW (2015). Predicted impact of nicotine reduction on smokers with affective disorders. Tobacco Regulatory Science, 1(2): 154-165. PMC4517852. doi: 10.18001/TRS.1.2.5
64. Guillot CR, Stone MD, Geary BA, Kirkpatrick MG, Tidey JW, Cook JW, Leventhal AM (2015). Pharmacological, sensorimotor, and expectancy effects on tobacco withdrawal: A pilot study. Human Psychopharmacology: Clinical and Experimental, 30, 364-371. PMC4565749. doi: 10.1002/hup.2484.
65. Tidey JW, Miller ME\* (2015). Smoking cessation and reduction in people with chronic mental illness. BMJ, 351, h4065. doi: 10.1136/bmj.h4065. PMC4707528. *This paper was an invited "State of the Science" review.*
66. Lechner WV, Knopik VS, McGeary JE, Spillane NS, Tidey JW, McKee SA, Metrik J, Leventhal AN, Rohsenow DJ, Kahler CW (2015). Influence of the A118G polymorphism of the OPRM1 gene and exon 3 VNTR polymorphism of the DRD4 gene on cigarette craving after alcohol administration. Nicotine & Tobacco Research, 18(5):632-636. doi: 10.1093/ntr/ntv136.
67. Higgins ST, Kurti AN, Redner R, White TJ, Gaalema DE, Roberts ME, Doogan NJ, Tidey JW, Miller ME\*, Stanton CA, Henningfield JE, Atwood GS (2015). A literature review on prevalence of gender differences in current tobacco use in the United States, 2004-2014, and intersections with other vulnerabilities to tobacco use. Preventive Medicine, 80:89-100. PMC4592404. doi: 10.1016/j.ypmed.2015.06.009.

68. Donny EC, Denlinger RL, Tidey JW, Koopmeiners J, Benowitz N, Vandrey R, al'Absi M, Carmella SG, Cinciripini P, Dermody SS, Drobes D, Hecht SS, Jensen J, Lane T, Le CT, McClernon J, Montoya ID, Murphy SE, Robinson JD, Stitzer ML, Strasser AA, Tindle H, Hatsukami DK (2015). Randomized trial of reduced-nicotine standards for cigarettes. New England Journal of Medicine, 373, 1340-1349. PMC4642683. doi: 10.1056/NEJMsa1502403.

## **2016**

69. MacKillop J, Murphy CM, Martin RA, Stojek M, Tidey JW, Colby SM, Rohsenow DJ (2016). Predictive validity of a cigarette purchase task in a randomized controlled trial of contingent vouchers for smoking in individuals with substance use disorders. Nicotine & Tobacco Research, 18(5):531-537. doi: 10.1093/ntr/ntv233.
70. Miranda R, MacKillop J, Treloar H, Blanchard A, Tidey J, Swift RM, Chun T, Rohsenow D, Monti PM (2016). Biobehavioral mechanisms of topiramate's effects on alcohol use: An investigation pairing laboratory and ecological momentary assessments. Addiction Biology, 21(1):171-82. PMC4414660. doi: 10.1111/adb.12192.
71. Dermody SS, Tidey JW, Denlinger RL\*, Pacek LR, al'Absi M, Drobes DJ, Hatsukami DK, Vandrey R, Donny EM (2016). The impact of smoking very low nicotine content cigarettes on alcohol use. Alcohol: Clinical and Experimental Research 40(3):606-615. doi:10.1111/acer.12980.
72. Miranda R, Treloar H, Blanchard A, Justus A, Monti PM, Chun T, Swift R, Tidey J, Gwaltney C (2016). Topiramate and motivational enhancement therapy for cannabis use among youth: A proof-of-concept clinical trial. Addiction Biology. 22(3), 779-790. PMC4940362. doi: 10.1111/adb.12350.
73. Tidey JW, Cassidy RN\*, Miller ME\* (2016). Smoking topography characteristics of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controls. Nicotine & Tobacco Research. 18(9): 1807-12. doi: 10.1093/ntr/ntw089. *\*\*This paper was selected as an "Editor's Choice" article by the journal Nicotine & Tobacco Research and was accompanied by an editorial.*
74. Tidey JW (2016). A behavioral economic perspective on smoking persistence in serious mental illness. Preventive Medicine. 92, 31-35. doi: 10.1016/j.ypmed.2016.05.015.
75. Nardone N, Donny EC, Hatsukami DK, Koopmeiners JS, Murphy SE, Strasser AA, Tidey JW, Vandrey R, Benowitz NL (2016). Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. Addiction, 111(12), 2208-2216. doi: 10.1111/add.13519.
76. Tidey JW, Cassidy RC\*, Miller ME\*, Smith TT (2016). Applications of behavioral economic laboratory procedures to tobacco regulatory science. Tobacco Regulatory Science, 2(4): 440-451. doi: 10.18001/TRS.2.4.13. **PMC5453650.**
77. Pacek LR, Vandrey R, Dermody SS, Denlinger RL\*, Lemieux A, Tidey JW, Drobes DJ, al'Absi M, Hatsukami DK, Donny EC (2016). Evaluation of a reduced-nicotine product standard: Moderating effects of and impact on cannabis use. Drug and Alcohol Dependence, 167, 228-232. doi: 10.1016/j.drugaldep.2016.08.620.

**2017**

78. Tidey JW, Pacek LA, Koopmeiners JS, Vandrey R, Nardone N, Drobes DJ, Benowitz NL, Dermody SS, Lemieux A, Denlinger RL\*, Cassidy RN\*, al'Absi M, Hatsukami DK, Donny EC (2017). Effects of 6-week use of very low nicotine content cigarettes in people with and without elevated depressive symptoms. Nicotine & Tobacco Research, 19(1), 59-67. doi: 10.1093/ntr/ntw199. **PMC5157715**.
79. Rohsenow DJ, Martin RA, Tidey JW, Colby SM, Monti PM (2017). Treating smokers in substance treatment with contingent vouchers, nicotine replacement and brief advice adapted for sobriety settings. Journal of Substance Abuse Treatment, 72, 72-79. doi: 10.1016/j.jsat.2016.08.012.
80. Higgins ST, Heil SH, Sigmon SC, Tidey JW, Gaalema DE, Stitzer ML, Durand H, Bunn JY, Priest JS, Arger CA, Miller ME\*, Bergeria CL, Davis DR, Streck SM, Zvorsky I, Redner R, Vandrey R, Pacek LR (2017). Response to varying the nicotine content of cigarettes in vulnerable populations: An initial experimental examination of acute effects. Psychopharmacology, 234(1), 89-98. doi: 10.1007/s00213-016-4438-z.
81. Smith TT, Cassidy RC\*, Tidey JW, Luo X, Le CT, Hatsukami DK, Donny EC (2017). Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: Further results from a multi-site clinical trial. Addiction, 112(2), 349-359. doi: 10.1111/add.13636.
82. Rupperecht LE, Koopmeiners JS, Sved AF, Benowitz N, Hatsukami DK, Dermody S, Denlinger-Apte RL\*, Robinson J, Pacek LR, al'Absi M, Smith TT, Tidey J, Donny EC (2017). Reducing nicotine exposure results in weight gain in smokers randomized to very low nicotine content cigarettes. Tobacco Control, 26(e1), e43-e48. doi: 10.1136/tobaccocontrol-2016-053301.
83. Miller ME\*, Tidey JW, Rohsenow DJ, Higgins ST (2017). Electronic cigarette expectancies in smokers with psychological distress. Tob Regul Sci, 3(1), 108-114. PMC5482286. doi: 10.18001/TRS.3.1.11.
84. Cassidy RN\*, Tidey JW, Colby SM, Long V, Higgins ST (2017). Initial development of an e-cigarette purchase task: A mixed methods study. Tobacco Regulatory Science, 3(2): 139-150. doi: 10.18001/TRS.3.2.2.
85. Barnett NP, Celio MA, Tidey JW, Murphy JG, Colby SM, Swift RM (2017). A preliminary randomized controlled trial of contingency management for alcohol use reduction using a transdermal alcohol sensor. Addiction, 112(6), 1025-1035. doi: 10.1111/add.13767.
86. Murphy CM, MacKillop JM, Martin RA, Tidey JW, Colby SM, Rohsenow DJ (2017). Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders. Psychopharmacology, 234(16), 2443-2452. doi: 10.1007/s00213-017-4635-4.
87. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Swift RM, Leggio L, Monti PM (2017). Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: Effects on smoking, substance use and depressive symptoms. Addiction, 234(16), 2443-2452. doi: 10.1111/add.13861.
88. Higgins ST, Heil SH, Sigmon SC, Tidey JW, Gaalema DE, Hughes JR, Stitzer ML, Durand H, Bunn JY, Priest JS, Arger CA, Miller ME\*, Bergeria CL, Davis DR, Streck JM, Reed DD, Skelly JM, Tursi L. Addiction potential of reduced nicotine content cigarettes in smokers with psychiatric disorder and other vulnerabilities to tobacco addiction. JAMA Psychiatry, 2017 Oct 1;74(10), 1056-1064. doi: 10.1001/jamapsychiatry.2017.2355. PMC5710465

89. Arger CA, Heil SH, Sigmon SC, Tidey JW, Stitzer ML, Gaalema DE, Durand HJ, Bunn JY, Ruggieri EK, Higgins ST (2017). Preliminary validity of the modified Cigarette Evaluation Questionnaire in predicting the reinforcing effects of cigarettes that vary in nicotine content. Experimental and Clinical Psychopharmacology, 25(6), 473-478. doi: 10.1037/pha0000145.

## **2018**

90. Bidwell LC\*, Balestrieri S, Colby SM, Knopik V, Tidey JW (2018). Abstinence-induced withdrawal severity among adolescent smokers with and without ADHD: disentangling effects of nicotine and smoking reinstatement. Psychopharmacology, 235(1), 169-178. doi: 10.1007/s00213-017-4753-z.
91. Dermody SS, McClernon FJ, Benowitz N, Luo X, Tidey JW, Smith T, Vandrey R, Hatsukami D, Donny EC (2018). Effects of reduced nicotine content cigarettes on individual withdrawal symptoms over time and during abstinence. Experimental and Clinical Psychopharmacology, 26(3), 223-232. doi: 10.1037/pha0000179.
92. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Eissenberg T (2018). Effects of six weeks of electronic cigarette use on smoking rate, CO, cigarette dependence and motivation to quit smoking: A pilot study. Addictive Behaviors, 80, 65-70. doi: 10.1016/j.addbeh.2018.01.012.
93. Cassidy RN\*, Jackson KJ, Rohsenow DJ, Tidey JW, Tevyaw TO, Barnett NP, Monti PM, Miller ME\*, Colby SM (2018). Contingency management for college student smokers: The role of drinking as a moderator and mediator of smoking abstinence during treatment. Addictive Behaviors, 80, 95-101. doi: 10.1016/j.addbeh.2018.01.017.
94. Weinberger AH, Bandiera F, Leventhal AM, Dierker LC, Gbedemah M, Tidey J, Goodwin RD (2018). Socioeconomic disparities in smoking among US adults with depression, 2005-2014. American Journal of Preventive Medicine, 54(6), 765-775. doi: 10.1016/j.amepre.2018.02.008.
95. Smith TT, Hatsukami DK, Benowitz NL, Colby SM, McClernon FJ, Strasser AA, Tidey JW, White C, Donny EC (2018). Whether to push or pull? Nicotine reduction and non-combusted alternatives – two strategies for reducing smoking and improving public health. Preventive Medicine, 117, 8-14. doi: 10.1016/j.ympmed.2018.03.021.
96. Cassidy RN\*, Colby SM, Tidey JW, Jackson KM, Cioe PA, Krishnan-Sarin S, Hatsukami D (2018). Adolescent smokers' response to reducing the nicotine content of cigarettes: Acute effects on withdrawal symptoms and subjective evaluations. Drug and Alcohol Dependence, 2018 Jul 1;188:153-160. doi: 10.1016/j.drugalcdep.2018.04.006.
97. Higgins ST, Bergeria CL, Davis DR, Streck JM, Villanti AC, Hughes JR, Sigmon SC, Tidey JW, Heil SH, Gaalema DE, Stitzer ML, Priest JS, Skelly JM, Reed DD, Bunn JY, Tromblee MA, Arger CA, Miller ME\* (2018). Response to reduced nicotine content cigarettes among smokers differing in tobacco dependence severity. Preventive Medicine, 117, 15-23. doi: 10.1016/j.ympmed.2018.04.010.
98. Murphy CM, Martin RA, Tidey JW, Colby SM, Rohsenow DJ (2018). Smoking outcome expectancies predict smoking during voucher-based treatment for smokers with substance use disorders. Journal of Substance Abuse Treatment, 90, 73-78. doi: 10.1016/j.jsat.2018.04.013

99. Pericot-Valverde I, Elliott R, Miller ME\*, Tidey J, Gaalema D (2018). Posttraumatic stress disorder and tobacco use: A systematic review and meta-analysis. Addictive Behaviors, 84, 238-247. doi: 10.1016/j.addbeh.2018.04.024
100. Miller ME\*, Tidey JW, Bunn J, Gaalema D, Scott-Sheldon L, Pericot-Valverde I, Japuntich S (2018). Self-perceived mental health status and population-level tobacco use disparities. Tobacco Regulatory Science, 4(4), 3-11. doi: 10.18001/TRS.4.4.1
101. Parker MA, Streck JM, Bergeria CL, Bunn JY, Gaalema DE, Davis DR, Barrows AJ, Sigmon SC, Heil SH, Tidey JW, Higgins ST (2018). Reduced nicotine content cigarettes and cannabis use in vulnerable populations. Tobacco Regulatory Science, 4(5), 84-91. doi: 10.18001/TRS.4.5.8.
102. Villanti AC, Gaalema DE, Tidey JW, Kurti AN, Sigmon SC, Higgins ST (2018). Co-occurring vulnerabilities and menthol use in U.S. young adult cigarette smokers: Findings from Wave 1 of the PATH Study, 2013-2014. Preventive Medicine, 117, 43-51. doi: 10.1016/j.ypmed.2018.06.001.
103. Tidey JW, Davis DR, Miller ME\*, Pericot-Valverde I, Denlinger-Apte RL\*, Gaalema D (2018). Modeling nicotine regulation: A review of studies in smokers with mental health conditions. Preventive Medicine, 117, 30-37. doi: 10.1016/j.ypmed.2018.07.003.
104. Streck J, Bergeria CL, Parker MA, Davis DR, DeSarno M, Sigmon SC, Hughes JR, Gaalema DE, Heil SH, Tidey JW, Stitzer M, Rothman M, Higgins ST (2018). Response to reduced nicotine content cigarettes among smokers with chronic health conditions. Preventive Medicine, 12, 321-329. doi: 10.1016/j.pmedr.2018.10.001.

## **2019**

105. Cassidy RN\*, Miller ME\*, Tidey JW, DiGuseppi G, Denlinger-Apte RL\*, Colby SM (2019). The impact of nicotine dose on the reinforcing value of cigarettes in adolescents. Tobacco Regulatory Science, 5(2), 105-114. doi: 10.18001/TRS.5.2.2
106. Cassidy RN\*, Tidey JW, Cao Q, Colby SM, McClernon FJ, Koopmeiners JS, Hatsukami D, Donny EC (2019). Age moderates smokers' subjective response to very low nicotine content cigarettes: Evidence from a randomized controlled trial. Nicotine and Tobacco Research. 2018 Apr 28. doi: 10.1093/ntr/nty079.
107. Denlinger-Apte RL\*, Tidey JW, Koopmeiners J, Hatsukami DK, Smith TT, Pacek L, McClernon FJ, Donny EC (2019). Correlates of support for a nicotine reduction policy in smokers with 6-week exposure to very low nicotine cigarettes. Tobacco Control. 2019 May;28(3):352-355. doi: 10.1136/tobaccocontrol-2018-054622.
108. Denlinger-Apte RL\*, Cioe PA, Pacek LR, DeAtley T\*, Tidey JW. The potential impact of a low nicotine product standard for cigarettes in smokers living with HIV (2019) Journal of the Association of Nurses in AIDS Care. 2019 Mar-Apr;30(2):137-141. doi: 10.1097/JNC.000000000000027.
109. Bergeria CL, Heil SH, Davis DR, Streck JM, Sigmon SC, Bunn JY, Tidey JW, Arger CA, Reed DD, Gallagher T, Hughes JR, Gaalema DE, Stitzer ML, Higgins ST (2019). Evaluating the utility of the modified Cigarette Evaluation Questionnaire and Cigarette Purchase Task for predicting acute relative reinforcing efficacy of cigarettes varying in nicotine content. Drug and Alcohol Dependence, 197, 56-64. doi: 10.1016/j.drugalcdep.2019.01.004.

110. Davis DR, Miller ME\*, Streck JM, Bergeria CL, Sigmon SC, Tidey JW, Heil SH, Gaalema DE, Villanti AC, Hughes JR, Stitzer ML, Priest JS, Bunn JY, Skelly JM, Diaz V, Arger CA, Higgins ST (2019). Response to reduced nicotine content in vulnerable populations: Effect of menthol status. Tobacco Regulatory Science, 5(2), 135-142. doi: 10.18001/TRS.5.2.5.
111. Murphy CM, Cassidy RN\*, Martin RA, Tidey JW, MacKillop J, Rohsenow DJ (2019). Brief assessment of cigarette demand (BACD): Initial development and validation results from two samples of smokers. Experimental and Clinical Psychopharmacology. 2019 Oct;27(5):496-501. PMC6800201. doi: 10.1037/pha0000267.
112. Higgins ST, Kurti AN, Palmer M, Tidey JW, Cepeda-Benito A, Cooper MR, Krebs NM, Baezconde-Garbanati L, Hart JL, Stanton C (2019). A review of tobacco regulatory science research on vulnerable populations. Preventive Medicine. 2019 May 2. pii: S0091-7435(19)30163-X. doi: 10.1016/j.ypmed.2019.04.024.
113. Smith TT, Koopmeiners JS, Tessier K, Davis E, Conklin CA, Denlinger-Apte RL\*, Lane T, Murphy S, Tidey JW, Hatsukami DK, Donny EC (2019). Randomized trial of low nicotine cigarettes and transdermal nicotine. American Journal of Preventive Medicine, 2019 Oct;57(4):515-524. doi: 10.1016/j.amepre.2019.05.010.
114. Martin RA, Rohsenow DJ, Tidey JW. Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement. Journal of Substance Abuse Treatment 2019 Sep;104:22-27. doi: 10.1016/j.jsat.2019.06.005.
115. Davis DR, DeSarno MJ, Bergeria CL, Streck JM, Tidey JW, Sigmon SC, Heil SH, Gaalema DE, Higgins ST. Examining effects of unit price on preference for reduced nicotine content cigarettes and smoking rate. Preventive Medicine, 2019 Aug 27:105823. doi: 10.1016/j.ypmed.2019.105823.
116. Smith TT Heckman BW, Tidey JW, Colby SM, Cummings KM. Behavioral outcomes of nicotine reduction in current adult smokers. Nicotine & Tobacco Research. 2019 Dec 23;21(Supplement 1):S125-S127. doi: 10.1093/ntr/ntz102.
117. Colby SM, Cassidy RN\*, Denlinger-Apte RL\*, Smith TT, Pacek LR, McClernon FJ, Tidey JW. Anticipated effects of nicotine reduction on youth smoking initiation and maintenance. Nicotine & Tobacco Research, 2019 Dec 23;21(Supplement\_1):S46-S48. doi: 10.1093/ntr/ntz101.
118. Tidey JW, Muscat J, Foulds J, Evins AE, Gaalema DE, Denlinger-Apte RL\*. Reducing the nicotine content of cigarettes: Effects in smokers with mental health conditions and socioeconomic disadvantages. Nicotine & Tobacco Research. 2019 Dec 23;21(Supplement\_1):S26-S28. doi: 10.1093/ntr/ntz118.
119. Koopmeiners JS, Vock DM, Boatman JA, Carroll D, Colby SM, Donny EC, Hatsukami DK, Luo X, Tidey JW (authors 4-9 in alphabetical order). The importance of estimating causal effects for evaluating a nicotine standard for cigarettes. Nicotine & Tobacco Research, 2019 Dec 23;21(Supplement 1):S22-S25. doi: 10.1093/ntr/ntz119.
120. Denlinger-Apte R\*, Cassidy RN\*, Colby SM, Sokolovsky A, Tidey JW. Effects of cigarette nicotine content and menthol preference on perceived health risks, subjective ratings, and carbon monoxide exposure among adolescent smokers. Nicotine & Tobacco Research, in press. Nicotine Tob Res. 2019 Dec 23;21(Supplement 1):S56-S62. doi: 10.1093/ntr/ntz127.

121. Tidey JW, Colby SM, Denlinger-Apte RL\*, Goodwin C, Cioe PA, Cassidy RN, Swift RM, Lindgren BR, Rubin N, Murphy SE, Hecht SS, Hatsukami DK, Donny EC. Effects of 6-week use of very low nicotine content cigarettes in smokers with serious mental illness. Nicotine & Tobacco Research, 2019 Dec 23;21(Supplement 1):S38-S45. doi: 10.1093/ntr/ntz133.
122. Lee H, Hsieh P, Murphy J, Tidey JW, Savitz DA. Health research using Facebook to identify and recruit pregnant women who use e-cigarettes: protocol for a non-randomized pilot study. JMIR Research Protocols, 2019 Oct 18;8(10):e12444. doi: 10.2196/12444.
123. Davis DR, Parker MA, Villanti AC, Streck JM, Priest JS, Tidey JW, Gaalema DE, Sigmon SC, Heil SH, Higgins ST. Examining age as a potential moderator of response to reduced nicotine content cigarettes in vulnerable populations. Nicotine & Tobacco Research. 2019 Dec 23;21(Supplement 1):S49-S55. doi: 10.1093/ntr/ntz134.
124. Gaalema DE, Tidey JW, Davis DR, Sigmon SC, Heil SH, Stitzer ML, DeSarno M, Diaz V, Hughes JR, Higgins ST. Potential moderating effects of psychiatric diagnosis and symptom severity on subjective and behavioral responses to reduced nicotine content cigarettes. Nicotine & Tobacco Research, 2019 Dec 23;21(Supplement 1):S29-S37. doi: 10.1093/ntr/ntz139.
125. Denlinger-Apte RL\*, Kotlyar M, Koopmeiners JS, Tidey JW, Luo X, Benowitz NL, Jensen JA, Ikuemonisan JO, Pacek LR, Smith TT, Vandrey R, Donny EC, Hatsukami DK. Effects of very low nicotine content cigarettes on smoking behavior and biomarkers of exposure in menthol and non-menthol smokers. Nicotine & Tobacco Research. 2019 Dec 23; 21(Supplement 1):S63-S72. doi: 10.1093/ntr/ntz160. PubMed PMID: 31867637.

## **2020**

126. Denlinger-Apte RN\*, Donny EC, Lindgren BR, Rubin N, Goodwin C, DeAtley T\*, Colby SM, Cioe PA, Hatsukami DK, Tidey JW. Smoking topography characteristics during a six-week trial of very low nicotine cigarettes in smokers with serious mental illness. Nicotine & Tobacco Research, 2020 Jul 16;22(8):1414-1418. doi: 10.1093/ntr/ntz198.
127. Cassidy RN, Aston ER, Tidey JW, Colby SM (2020). Behavioral economic demand and delay discounting are differentially associated with cigarette dependence and use in adolescents. Addictive Behaviors, in press. 2020 Apr;103:106225. doi: 10.1016/j.addbeh.2019.106225. Epub 2019 Nov 30.
128. Cioe PA, Lechner W, Mercurio AN, Constantino CC, Tidey JW, Eissenberg TE, Kahler CS. A pilot study to examine the acceptability and health effects of electronic cigarettes in HIV-positive smokers. Drug and Alcohol Dependence, 2020 Jan 1;206:107678. doi: 10.1016/j.drugalcdep.2019.107678. Epub 2019 Oct 28. PMC9295550.
129. Smith TT, Koopmeiners JS, Hatsukami DK, Tessier K, Benowitz NL, Murphy S, Hecht S, Strasser AS, Tidey JW, Blount BC, Valentin L, Bravo R, Watson CH, Pirkle JL, Donny EC (2020). Using mouth-level nicotine intake estimates from discarded filter butts to examine compensatory smoking in low nicotine cigarettes. Cancer Epidemiology, Biomarkers & Prevention. 2020 Mar;29(3):643-649. doi: 10.1158/1055-9965.EPI-19-0905. Epub 2020 Feb 26.

130. Streck JM, Sigmon SC, Priest J, Bergeria CL, Davis DR, Hughes JR, Villanti AC, Tidey JW, Heil SH, Gaalema DE, Stitzer ML, Higgins ST (2020). Investigating tobacco withdrawal in response to reduced nicotine cigarettes among smokers with opioid dependence and other vulnerabilities. Experimental and Clinical Psychopharmacology. 2020 Feb 6:10.1037/pha0000350. doi: 10.1037/pha0000350.
131. Streck JM, Davis DR, Pang R, Sigmon SC, Bunn JY, Bergeria CL, Heil SH, Tidey JW, Gaalema DE, Hughes JR, Villanti AC, Stitzer ML, Reed E., Higgins ST. Potential moderating effects of sex/gender on the acute relative reinforcing and subjective effects of reduced nicotine content cigarettes in vulnerable populations. Nicotine & Tobacco Research, 2020 May 26;22(6)878-884. doi: 10.1093/ntr/ntz098.
132. Cassidy RN, Long V, Tidey JW, Colby SM (2020). Validation of an e-cigarette purchase task in advanced generation device users. Nicotine & Tobacco Research. 2020 Oct 8;22(10):1851-1859. doi: 10.1093/ntr/ntaa060.
133. Bloom EL, Hunt L, Tidey J, Ramsey SE. Pilot feasibility trial of dual contingency management for cigarette smoking cessation and weight maintenance among weight-concerned female smokers. Experimental and Clinical Psychopharmacology, 2020 Oct;28(5):609-615 doi: 10.1037/pha0000331.
134. DeAtley T\*, Denlinger-Apte RL\*, Cioe PA, Colby SM, Clark MA, Donny EC, Tidey JW (2020). Biopsychosocial mechanisms associated with tobacco use in people with and without serious mental illness. Preventive Medicine. 2020 Jul 3:106190. doi: 10.1016/j.ypmed.2020.106190.
135. Higgins ST, DeSarno M, Davis DR, Adise S, Garavan HP, Nighbor T, Streck J, Harfmann R, Nesheim-Case R, Markesich C, Chaarani B, Spechler P, Reed D, Tyndale RF, Gaalema DE, Heil SH, Sigmon SC, Tidey JW, Lee D, Hughes DR, Ivanciu A, Bunn JY (2020). Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations. Preventive Medicine. 2020 Jul 3:106189. doi: 10.1016/j.ypmed.2020.106189.
136. Higgins ST, Tidey JW, Sigmon SC, Heil SH, Gaalema DE, Lee D, Hughes JR, Villanti AC, Bunny JY, Davis DR, Bergeria CL, Streck JM, Parker M, Miller ME, DeSarno M, Priest JS, Cioe P, MacLeod D, Barrows A, Markesich C, Harfmann R (2020). Changes in cigarette consumption with reduced nicotine content cigarettes among smokers with psychiatric conditions or socioeconomic disadvantage: Three randomized clinical trials. JAMA Network Open. 2020;3(10):e2019311. doi:10.1001/jamanetworkopen.2020.19311
137. Cassidy RN, Tidey JW, Colby SM. Exclusive e-cigarette users report lower levels of respiratory symptoms relative to dual e-cigarette and cigarette users. Nicotine & Tobacco Research, Dec 15:22(Supplement\_1):S54-S60. doi: 10.1093/ntr/ntaa150.
138. Cioe PA, Tidey JW, Mercurio AN, Constantino CC, Kahler CK (2020). E-cigarette perceptions among HIV-positive smokers in a switching study. Tobacco Regulatory Science, 6(6), 384-391. doi: 10.18001/TRS.6.6.2.

**2021**

139. Denlinger-Apte RL\*. Cassidy RN, Carey KB, Kahler CW, Bickel WK, O'Connor R, Thussu S, Tidey JW. The impact of menthol flavoring in combusted tobacco on alternative product purchasing: A pilot study using the Experimental Tobacco Marketplace. Drug and Alcohol Dependence, 2021 Jan 1;218:108390. doi: 10.1016/j.drugalcdep.2020.108390. PMC7750267.
140. Dermody SS, Tessier KM, Meier E, al'Absi M, Denlinger-Apte R\*, Drobos D, Jensen J, Koopmeiners J, Pacek L, Tidey JW, Vandrey R, Donny EC, Hatsukami DK. An evaluation of potential unintended consequences of a nicotine product standard: A focus on drinking history and outcomes. Nicotine & Tobacco Research, 2021 Jun 8;23(7):1168-1175. doi: 10.1093/ntr/ntaa236.
141. Denlinger-Apte RL\*, Koopmeiners JS, Tidey JW, Luo X, Smith TT, Pacek LR, McClernon FJ, Jensen J, Colby S, Severson H, Donny EC, Hatsukami DK. Support for a nicotine reduction policy among smokers enrolled in a 20-week trial of very low nicotine content cigarettes. Addictive Behaviors, 2021 Mar;114:106727. doi: 10.1016/j.addbeh.2020.106727.
142. Cassidy RN, Tidey JW, Cao Q, Colby SM, McClernon FJ, Smith TT, Dermody S, Koopmeiners JS, Jensen JA, Strayer LG, Donny EC, Hatsukami DK. Responses to gradual and immediate reduction of nicotine in cigarettes in young vs. older adult smokers Nicotine & Tobacco Research, 2021 Aug 18;23(9):1559-1566. doi: <https://doi.org/10.1093/ntr/ntab049>.
143. DeAtley T\*, Colby SM, Clark MA, Sokolovsky A, Denlinger-Apte RL, Cioe PA, Cassidy RN, Donny EC, Tidey JW. Psychometric analysis of an environmental tobacco smoke questionnaire. International Journal of Environmental Research and Public Health, 2021 Apr 3;18(7):3753. doi: 10.3390/ijerph18073753
144. Carroll DM, Lindgren BR, Dermody SS, Denlinger-Apte R, Egbert A, Cassidy R, Smith T, Pacek LR, Allen AM, Tidey JW, Parks MJ, Koopmeiners J, Donny EC, Hatsukami DK. Impact of nicotine reduction in cigarettes on smoking behavior and exposure: Are there differences by race/ethnicity, educational attainment, or gender? Drug and Alcohol Dependence, 2021 Aug 1;225:108756. doi: 10.1016/j.drugalcdep.2021.108756.
145. Higgins ST, DeSarno M, Bunn JY, Gaalema DE, Leventhal AM, Davis DR, Streck JM, Harfmann RF, Markesich C, Orr E, Sigmon SC, Heil SH, Tidey JW, Lee D, Hughes JR. Cumulative vulnerabilities as a potential moderator of response to reduced nicotine content cigarettes. Preventive Medicine, 2021 Nov;152(Pt 2):106714. doi: 10.1016/j.ypmed.2021.106714.
146. Monnig MA, Padovano HT, Sokolovsky A, DeCost G, Aston ER, Haass-Koffler CL, Szapary C, Moyo P, Avila J, Tidey J, Monti PM, Ahluwalia JS. Associations of substance use with behavioral adherence to Centers for Disease Control and Prevention Guidelines for COVID-19 mitigation: A survey study. JMIR Publications, 2021 Nov 9;7(11):e29319. doi: 10.2196/29319. PMC8582757.

**2022**

147. Oliver AC, DeSarno M, Irvin CG, Kaminsky D, Tidey JW, Sigmon SC, Heil SH, Gaalema D, Lee D, Bunn JY, Davis DR, Streck JM, Gallagher T, Higgins ST. Effects of reduced nicotine content cigarettes on fractional exhaled nitric oxide (FeNO) and self-reported respiratory health outcomes among smokers with psychiatric conditions or socioeconomic disadvantage. Nicotine & Tobacco Research, 2022 Jan 1;24(1):135-140. doi: 10.1093/ntr/ntab145. PMC8826384.
148. Snell LM\*, Colby SM, DeAtley T\*, Cassidy RN, Tidey JW. Associations between nicotine knowledge and smoking cessation behaviors among US adults who smoke. Nicotine & Tobacco Research, 2022 Apr 28;24(6):855-863. doi: 10.1093/ntr/ntab246. PMC9048939.
149. Reed GL\*, Colby SM, Sokolovsky AW, Snell LM\*, DeAtley T\*, Tidey JW. Predicting non-adherence with very low nicotine content cigarettes among adults with serious mental illness who smoke. Nicotine & Tobacco Research, 2022 Apr 28;24(6):914-918. doi: 10.1093/ntr/ntab271. PMC9048920.
150. Denlinger-Apte RL\*, Lockhart DE, Stahley AE, Cassidy RN, Donny EC, O'Connor RJ, Tidey JW. "I think it's a good idea for the people that's young, the kids, but for someone like me it's a bad idea" Interviews about a US menthol ban with people who smoke menthol cigarettes. Drug and Alcohol Dependence, 2022 Mar 1;232:109293. doi: 10.1016/j.drugalcdep.2022.109293. Epub 2022 Jan 12. PMC8885970.
151. DeAtley T\*, Sokolovsky AW, Snell LM\*, Tidey JW. Mediation pathways of tobacco use among adult smokers with psychiatric symptoms in the Population Assessment of Tobacco and Health (PATH) Survey. Addictive Behaviors, 2022 Jun;129:107249. doi: 10.1016/j.addbeh.2022.107249. Epub 2022 Jan 15. PMC8969557.
152. Mead-Morse EL\*, Cassidy RN, Oncken C, Tidey JW, Delnevo CD, Litt M. Validity of a little cigars/cigarillos purchase task in dual users of cigars and cigarettes. Addictive Behaviors, 2022 Jul;130:107285. doi: 10.1016/j.addbeh.2022.107285. Epub 2022 Feb 17. PMC9254358.
153. Wiley RC, Oliver AC, Snow MB, Bunn JY, Barrows AJ, Tidey JW, Lee DC, Sigmon SC, Gaalema DE, Heil SH, Markesich C, Villanti AC, Higgins ST. The impact of the COVID-19 pandemic on smoking among vulnerable populations. Nicotine & Tobacco Research, 2023 Jan 5;25(2):282-290. doi: 10.1093/ntr/ntac135. PMC9384158.
154. Tidey J, Snell LM\*, Colby SM, Cassidy RN\*, Denlinger-Apte R\*. Effects of very low nicotine content cigarettes across vulnerable populations. Preventive Medicine, 2022 Dec;165(Pt B):107099. doi: 10.1016/j.ypmed.2022.107099. Epub 2022 May 26. PMC9699899.
155. DeAtley T\*, Cassidy R\*, Snell ML\*, Colby SM, Tidey JW. Effects of very low nicotine content cigarette use on cigarette reinforcement among smokers with serious mental illness. Addictive Behaviors, 2022 Oct;133:107376. doi: 10.1016/j.addbeh.2022.107376. Epub 2022 May 23. PMC9328411.
156. Snell LM\*, Reed G\*, Tidey JW, Bunn J, Harfmann R, Heil S, Sigmon S, Gaalema D, Higgins ST. Predictors of adherence among vulnerable populations of adults assigned to smoke very low nicotine content cigarettes. Nicotine & Tobacco Research. 2022 Nov 12;24(12):1959-1967. doi: 10.1093/ntr/ntac145. PMC9653083.

157. Japuntich S, Adkins-Hempel M, Lundtvedt C, Becker S, Helseth S, Fu S, Tidey J, Evins AE, Pratt R. Implementing chronic care model treatments for cigarette dependence into community mental health clinics. Journal of Dual Diagnosis, 2022 Jul-Sep;18(3):153-164. doi: 10.1080/15504263.2022.2090647. Epub 2022 Jun 28. PMC9472099.
158. Higgins ST, Erath TG, DeSarno M, Gaalema DE, Sigmon SC, Heil SH, Tidey JW. Leveraging the Cigarette Purchase Task to understand relations between cumulative vulnerabilities, the relative reinforcing effects of smoking, and response to reduced nicotine content cigarettes. Preventive Medicine, 2022 Dec;165(Pt B):107206. doi: 10.1016/j.ypmed.2022.107206. Epub 2022 Aug 19.
159. Meier E, Rubin N, Dermody SS, Tessier K, Hecht S, Jensen J, Donny E, al'Absi M, Drobos D, Koopmeiners J, Denlinger-Apte R, Tidey J, Vandrey R, Thorne C, Hatsukami D. Immediate switching to reduced nicotine cigarettes: The impact on cannabis use and related variables at 6 months. Nicotine & Tobacco Research, 2023 Apr 6;25(5):867-874. doi: 10.1093/ntr/ntac231. PMC10077930.
160. Gaalema DE, Snell LM\*, Tidey JW, Sigmon SC, Heil SH, Lee D, Bunn JY, Park C, Hughes JR, Higgins SH. Potential effects of nicotine content in cigarettes on use of other substances. Preventive Medicine. 2022 Dec;165(Pt B):107290. doi: 10.1016/j.ypmed.2022.107290. Epub 2022 Oct 5. PMC10275576.
161. Browning K, DeSarno M, Davis D, Streck J, Bergeria C, Harfmann R, Parker M, Heil S, Sigmon S, Gaalema D, Tidey JW, Lee D, Tetreault H, Higgins ST. Relating individual differences in dependence severity to nicotine exposure levels in vulnerable populations. Preventive Medicine. 2022 Dec;165(Pt B):107312. doi: 10.1016/j.ypmed.2022.107312. Epub 2022 Oct 19. PMC9986960.

## **2023**

162. Wagener TL, Mehta T, Hinton A, Schulz J, Erath T, Tidey JW, Villanti AC. Addiction potential of combustible menthol cigarette alternatives: A randomized cross-over trial. Tobacco Control, 2022 Nov 24;tobaccocontrol-2022-057421. doi: 10.1136/tc-2022-057421. Online ahead of print. PMC10227719.
163. Cassidy RN, Tidey JW, Jackson KJ, Cioe P, Murphy S, Krishnan-Sarin S, Hatsukami DK, Colby SM. The impact of reducing nicotine content on adolescent cigarette smoking and nicotine exposure: Results from a randomized controlled trial. Nicotine & Tobacco Research, 2022 Dec 9;ntac279. doi: 10.1093/ntr/ntac279. PMC10077938.
164. DeAtley T\*, Harrison A, Cassidy R, Kuo C, Higgins ST, Tidey JW. Subjective experiences, contexts, and risk perceptions of very low nicotine content cigarettes and electronic cigarettes among people with depression and anxiety disorders who smoke. Drug and Alcohol Dependence. 2023 Mar 1;244:109767. doi: 10.1016/j.drugalcdep.2023.109767. Epub 2023 Jan 9. PMC9974802.
165. Monnig M, Clark S, Avila J, Sokolovsky A, Treloar Padovano H, Goodyear K, Aston E, Haass-Koffler C, Tidey J, Ahluwalia J, Monti P. COVID-19-related stressors and clinical mental health symptoms in a Northeast US sample. International Journal of Environmental Research and Public Health. 2023 Jan 12;20(2):1367. doi: 10.3390/ijerph20021367. PMC9858791.

166. Snell LM\*, DeAtley T\*, Tidey JW, Colby SM, Cassidy RN\*. Impact of reduced nicotine content on behavioral economic measures of cigarette reinforcement in adolescent smokers. Drug and Alcohol Dependence. 2023 May 1;246:109786. doi: 10.1016/j.drugalcdep.2023.109786. Epub 2023 Jan 25. PMC in process.
167. Cassidy RN, Bello M, Denlinger-Apte RL, Goodwin C, Godin J, Strahley AE, Wiseman KD, Hatsukami D, Donny E, Tidey JW, Colby SM. The impact of the COVID-19 pandemic on a sample of US young adults who smoke cigarettes: a qualitative analysis. Addictive Behaviors. 2023 Jun;141:107650. doi: 10.1016/j.addbeh.2023.107650. Epub 2023 Feb 6. PMC9901227.
168. Denlinger-Apte RL\*, Cassidy RN, Donny EC, Godin J, Hatsukami DK, Strahley AE, Wiseman KD, Colby SM, Tidey JW. Qualitative reactions to a low nicotine product standard for cigarettes from adolescents living in the United States who smoke. Prev Med Rep. 2023 Feb 23;32:102163. doi: 10.1016/j.pmedr.2023.102163. PMC9989690.
169. Cioe PA, Lechner WV, Tidey JW, Kahler CW. Effects of electronic cigarette use on cardiovascular disease-related inflammatory biomarkers in smokers with HIV in a switching study in the United States. Pharmacoepidemiology, 2 (1), 106-113. doi: 10.3390/pharma2010010. PMC in process.
170. Murphy CM\*, Onu MC, Goodwin C, Williams DM, Tidey JW. Acute effects of exercise among individuals with schizophrenia who smoke cigarettes. Addictive Behaviors 2023 Sep;144:107749. doi: 10.1016/j.addbeh.2023.107749. Epub 2023 May 5. PMC10337786.
171. Denlinger-Apte RL\*, Strahley AE, Lockhart DE, Wiseman KD, Cassidy RN\*, Davis DR, O'Connor RJ, Tidey JW. Reactions to using other nicotine and tobacco products instead of menthol cigarettes: A qualitative study of people who smoke menthol cigarettes in the United States. Prev Med Rep. 2023 May 6;34:102228. doi: 10.1016/j.pmedr.2023.102228. PMC10203761.
172. Villanti AC, Hinton A, Schulz J, Erath TG, Mehta T, Reed D, Tidey JW, Businelle M, Wagener TL. Substitutability of menthol cigarette alternatives: A clinical trial. Tobacco Control 2023 Nov 14;tc-2023-058272. doi: 10.1136/tc-2023-058272.

## **2024**

173. Harfmann RF, Heil SH, Bunn JY, Snell LM\*, Tidey JW, Sigmon SC, Gaalema DE, Lee DC, Streck JM, Bergeria CL, Davis DR, Plucinski S, Higgins ST. Changes in weight among individuals with psychiatric conditions or socioeconomic disadvantage assigned to smoke very low nicotine content cigarettes. Exp Clin Psychopharmacol. 2024 Apr;32(2):181-188. doi: 10.1037/pha0000700. Epub 2024 Jan 18.
174. Mead-Morse EL\*, Cassidy RN\*, Kpormegbey D, Moore T, Oncken C, Tidey JW, Delnevo CD, Litt M. Examining demand and substitutability of usual brand little cigars/cigarillos in young adults who dual use. Nicotine Tob Res. 2024 Jul 22;26(8):1057-1065. doi: 10.1093/ntr/ntae025. PMC11519020.
175. Katz B, Gaalema DE, Dumas J, Heil SH, Sigmon SC, Tidey JW, Lee DC, DeSarno M, Higgins ST. Cigarette smoking and cognitive task performance: Experimental effects of very low nicotine content cigarettes. Exp Clin Psychopharmacol. 2024 Aug;32(4):436-444. doi: 10.1037/pha0000724.

176. Erath TG, Schulz JA, Hinton A, Mehta T, Reed DD, Tidey JW, Wagener TL, Villanti AC. Examining the predictive utility of behavioral economic demand indices and subjective effects on the actualized reinforcing value of menthol cigarettes and potential alternatives. *Nicotine Tob Res.* 2024 Sep 23;26(10):1429-1433. doi: 10.1093/ntr/ntae086. PMC11417116.
177. Hatsukami DK, Jensen JA, Carroll DM, Luo X, Strayer LG, Cao Q, Hecht SS, Murphy SE, Carmella SG, Denlinger-Apte RL, Colby S, Strasser AA, McClernon FJ, Tidey J, Benowitz NL, Donny EC. Reduced nicotine in cigarettes in a marketplace with alternative nicotine systems: randomized clinical trial. *Lancet Reg Health Am.* 2024 Jun 3;35:100796. doi: 10.1016/j.lana.2024.100796. Erratum in: *Lancet Reg Health Am.* 2025 Sep 27;51:101244. doi: 10.1016/j.lana.2025.101244. PMC11190722.
178. Reed GL\*, Colby SM, DiLorenzo J, Totten J, Tidey JW, Cassidy RN. Reactions to a nicotine reduction policy among adolescents who smoke: A qualitative study. *Nicotine Tob Res.* 2024 Nov 22;26(12):1692-1699. doi: 10.1093/ntr/ntae153. PMC11581997.
179. Higgins ST, Sigmon SC, Tidey JW, Heil SH, Gaalema DE, Lee DC, DeSarno MJ, Klemperer EM, Menson KE, Cioe PA, Plucinski S, Wiley RC, Orr E. Cigarette consumption with e-cigarettes and reduced nicotine content cigarettes among adults with psychiatric conditions or socioeconomic disadvantage: Three clinical randomized trials. *JAMA Netw Open.* 2024 Sep 3;7(9):e2431731. doi: 10.1001/jamanetworkopen.2024.31731. PMC11380105.
180. Cassidy RN, Tidey JW, Bello MS, Denlinger-Apte R, Goodwin C, Godin J, Cioe PA, Swift R, Demorest C, Koopmeiners JS, Donny E, Hatsukami D, Colby SM. Effects of very low nicotine content cigarettes and nicotine vaping device characteristics on choices to smoke, vape, or abstain in early young adults. *Nicotine Tob Res.* 2024 Aug 7;ntae194. doi: 10.1093/ntr/ntae194.

## **2025**

181. Bello MS, Wang CX, Maglalang D, Rosales R, Tidey JW, Denlinger-Apte RL, Sokolovsky AW, Colby SM, Cassidy RN. Racial/ethnic differences in acute effects of reduced nicotine content cigarettes among adolescents who smoke. *Addict Behav.* 2025 Jan;160:108147. doi: 10.1016/j.addbeh.2024.108147. Epub 2024 Sep 7. PMC11560610.
182. Regnier SD\*, Schulz JA, Nugent A, Mullis LC, Turner M, Marcum T, Knudsen HK, Surratt H, Tidey JW, Leslie, M, Stoops W. Drug use and disability: A call to action. *Drug Alcohol Depend.* 2025 June 1;271: <https://doi.org/10.1016/j.drugalcdep.2025.112637>.
183. Cioe PA, Lechner WV, Stang GS, Kahler CW, Tashima KT, Eissenberg T, Tidey JW. The effects of switching to the standardized research electronic cigarette in people with HIV who smoke in the United States. *Prev Med.* 2025 Jul;196:108309. doi: 10.1016/j.ypmed.2025.108309. Epub 2025 May 14.
184. Smith TT, Luo X, Benowitz NL, Colby SM, McClernon FJ, Strasser AA, Tidey JW, Donny EC, Hatsukami DK. The impact of nicotine reduction on cigarette reinforcement value within a marketplace containing alternative nicotine delivery products: A secondary analysis of a multi-site trial. *Nicotine Tob Res.* 2025 Nov 23;27(12):2240-2246. doi: 10.1093/ntr/ntaf138.

185. Klemperer EM, DeSarno MJ, Tidey JW, Gaalema DE, Nolder KA, Feinstein MJP, Wiley RC, Higgins ST. E-cigarette use frequency mediates effects in three randomized controlled trials of reduced nicotine cigarettes with tobacco vs preferred flavor e-cigarettes in high-risk populations in the U.S. *Prev Med.* 2025 Dec;201:108353. doi: 10.1016/j.ypmed.2025.108353. Epub 2025 Jul 6. PMC12291598.
186. Nolder KA, Gaalema DE, Katz BR, Tidey JW, Sigmon SC, Heil SH, Lee DC, DeSarno M, Klemperer EM, Menson KE, Cioe PA, Plucinski S, Wiley RC, Higgins ST. Effects of very low nicotine content cigarettes and concurrent provision of e-cigarettes on symptoms of depression and anxiety. *Exp Clin Psychopharmacol.* 2025 Dec;33(6):638-644. doi: 10.1037/pha0000803. Epub 2025 Sep 18. PMC12584977.
187. Menson KE, Gaalema DE, Katz BR, Tidey JW, Sigmon SC, Heil SH, Lee DC, Plucinski S, DeSarno M, Higgins ST. Cardiopulmonary effects of very low nicotine content cigarettes with and without access to e-cigarettes in vulnerable populations. *Prev Med.* 2025 Dec;201:108414. doi: 10.1016/j.ypmed.2025.108414. Epub 2025 Sep 20. PMC12694701.
188. Cornacchione Ross J, Denlinger-Apte RL, Bello MS, Tidey JW, Colby SM, Cassidy RN. The relationship between cannabis use and demand for cigarettes in adolescents who smoke cigarettes. *Drug Alcohol Depend.* 2025 Dec 1;277:112959. doi: 10.1016/j.drugalcdep.2025.112959. Epub 2025 Nov 8.

## **2026**

189. Klemperer EM, Luo X, Cao Q, Carroll DM, McClernon FJ, Benowitz NL, Strasser AA, Tidey JW, Donny EC, Hatsukami DK. Sustained effects of reduced nicotine cigarettes and co-use of alternative nicotine delivery systems: a one-month follow-up to a randomized clinical trial. *Drug Alcohol Depend.* 2026 Jan 16;279:113051. doi: 10.1016/j.drugalcdep.2026.113051. Epub ahead of print.
190. Fazzino TL, Stratton M, Lange M, Gearhardt A, Tidey J. Regulatory science methods can test the addictive properties of food: A proof-of-concept pilot study. *Exp Clin Psychopharm.* In press.
191. Benowitz N, Hu J, Luo X, McClernon J, Tidey J, Strasser AA, Colby SM, Donny EC, Hatsukami DK. Titration of nicotine intake in smokers switching to reduced nicotine content cigarettes with access to alternative nicotine systems. *Addiction.* In press.

## **BOOKS AND BOOK CHAPTERS**

1. Miczek KA, Tidey JW (1989). Amphetamines: aggressive and social behavior. In: Asghar K, DeSouza E (Eds.), Pharmacology and Toxicology of Amphetamine and Related Designer Drugs. National Institute on Drug Abuse Research Monograph, Washington, D. C.: U.S. Government Printing Office, 68-100. doi: 10.1037/e471612004-001
2. Miczek KA, Haney M, Tidey JW, Vivian JA, Weerts EM (1994). Neurochemistry and pharmacotherapeutic management of aggression. In: Reis A, Roth J (Eds.), Understanding and Preventing Violence. Volume 2: Biobehavioral Influences. Washington D. C.: National Academy of Science Press, 245-514.

3. Miczek KA, DeBold JF, Haney M, Tidey JW, Vivian JA, Weerts EM (1994). Alcohol, drugs of abuse, aggression and violence. In: Reis A, Roth J (Eds.), Understanding and Preventing Violence. Volume 3: Social Influences. Washington, D. C.: National Academy of Science Press, 377-570.
4. Higgins ST, Tidey JW, Stitzer ML (1998). Community reinforcement and contingency management interventions. In: Graham AW, Schultz TK (Eds.), ASAM Principles of Addiction Medicine, 2nd edition. Chevy Chase, MD: American Society of Addiction Medicine, 675-690.
5. Higgins ST, Roll JM, Wong CJ, Tidey JW, Dantona R (1999). Clinic and laboratory studies on the use of incentives to decrease cocaine and other substance use. In: Higgins ST, Silverman K (Eds.), Motivating behavior change among illicit-drug abusers: contemporary research on contingency-management interventions. Washington, D.C.: American Psychological Association.
6. Higgins ST, Tidey JW (2003). Community reinforcement and contingency management interventions. In: Graham AW, Schultz TK, Mayo-Smith M, Ries R, Wilford B (Eds.), ASAM Principles of Addiction Medicine, 3rd edition. Chevy Chase, MD: American Society of Addiction Medicine.
7. Tidey JW, Ries R (2008). Contingency management of substance abuse in people with major mental illness. In: Higgins S, Silverman K, Heil S (Eds.), Contingency Management in Substance Abuse Treatment. New York: Guilford Press.
8. Higgins ST, Tidey JW, Rogers, RE (2009). Contingency management and the community reinforcement approach. In: Ries R, Fiellin D, Miller S, Saitz R, (Eds.), ASAM Principles of Addiction Medicine, 4th edition. Philadelphia, PA: Lippincott Williams & Wilkins.
9. Higgins ST, Tidey JW, Rogers, RE (2011). Contingency management and the community reinforcement approach. In: Cavacuite, C (Ed), Essentials of Addiction Medicine. Philadelphia, PA: Lippincott Williams & Wilkins.

#### **NON-PEER REVIEWED PUBLICATIONS**

1. Tidey JW (2004) Contingency management interventions: Enhancing motivation through incentives. Brown University Digest of Addiction Theory and Application, 23, 8.
2. Colby S, Donny E, Tidey J (2006). Highlights from SRNT's 12<sup>th</sup> annual meeting. Society for Research on Nicotine and Tobacco Newsletter, 12(1), 1-4.
3. Donny EC, Colby SM, Tidey JW (2007). Recent progress in nicotine and tobacco research. Nicotine and Tobacco Research, 9, S91 – 101. PMID: 17365731.
4. Tidey JW (2011). Commentary on "Cigarette smoking and mortality risk in people with schizophrenia", Schizophr Bull. Jul;37(4):832-8. Evidence Based Mental Health, 14, 99.
5. Meinbresse M, Czabafy S, Gelberg L, Glasser I, Moller K, Stopa A, Tidey J, Venson R, Zywiak W (2016). "Nicotine Anonymous peer support groups – can they work in homeless service settings?" Report prepared for the Health Care for the Homeless Practice-Based Research Network, Nashville, TN.

6. Tidey JW, Muscat J, Foulds J, Evins AE, Gaalema DE, Denlinger-Apte R\* (2018). Nicotine reduction in people with serious mental illness. Comment submitted in response to FDA Docket No. FDA- 2017-N-6189, Tobacco Product Standard for Nicotine Level of Combusted Cigarettes. <https://www.federalregister.gov/documents/2018/03/16/2018-05345/tobacco-product-standard-for-nicotine-level-of-combusted-cigarettes>.
7. Steinberg ML, Weinberger AH, Tidey JW (2019). Non-pharmacological treatments for tobacco users with mental health symptoms (editorial). Nicotine & Tobacco Research 2019 Apr 17;21(5):557-558. doi: 10.1093/ntr/ntz024.
8. Tidey JW (2019). The bad and good news about tobacco treatment for people with comorbid conditions in the US healthcare system (editorial). Nicotine & Tobacco Research, 21(11), 1451-1452. doi: 10.1093/ntr/ntz150.
9. Tidey JW (2020). Advancing our understanding of tobacco use in vulnerable populations (editorial). Nicotine & Tobacco Research, 22(6):865-866. doi: 10.1093/ntr/ntaa045.
10. Monti PM, Tidey JW, Ahluwalia JS. Brown University COBRE Center for Addiction and Disease Risk Exacerbation. R I Med J. 2021 Apr 1;104(3):27-31. PMID: 33789405.
11. Tidey JW (2023). To prioritize health equity, we need to stay focused on combustible tobacco products (editorial). Nicotine Tob Res. 2023 Apr 6;25(5):847-848. doi: 10.1093/ntr/ntad025. PMC10077923.
12. Weerts EM, Haney M, Tidey JW, Vivian JA. Klaus A Miczek (1945-2024). Nature Neuroscience. 2025 Jan;28(1):1-2. doi: 10.1038/s41593-024-01837-7.

## **INVITED PRESENTATIONS**

### **Invited Presentations - Local or National**

1. "Effects of social defeat stress on mesocorticolimbic dopamine release and acquisition of cocaine self-administration". Colloquium presentation, Division of Behavioral Biology, Department of Psychiatry, Harvard Medical School, New England Regional Primate Research Center, Southborough, MA, 1995.
2. "Effects of dopamine full agonists, partial agonists and antagonists in monkeys trained to discriminate methamphetamine versus placebo". Colloquium presentation, Alcohol and Drug Abuse Research Center, Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA, 1996.
3. "Pharmacological interventions in psychomotor stimulant abuse". Colloquium presentation, Human Behavioral Pharmacology Laboratory, Department of Psychiatry, University of Vermont School of Medicine, Burlington, VT, 1996.
4. "Reducing smoking in schizophrenics: Results from four laboratory studies". Presented at the Harvard/Brown/Yale Research Forum, Exeter RI, October 2001.
5. "Reducing smoking in schizophrenics: What can laboratory studies tell us?" Colloquium presentation, Department of Psychology, Tufts University, February 2002.

6. "Using experimental methods to understand cigarette smoking in people with schizophrenia". Providence VAMC Mental Health Colloquium presentation, September 2003.
7. "Effects of abstinence and transdermal nicotine on smoking cue reactivity and topography in smokers with schizophrenia". Behavioral Pharmacology Research Seminar Series, Johns Hopkins School of Medicine, Behavioral Pharmacology Research Unit (BPRU), March 2004.
8. "Schizophrenia and Smoking: A human laboratory approach to understanding this comorbidity". Featured presentation at the Department of Psychiatry and Human Behavior Annual Research Day, Brown Medical School, March 2005.
9. "Stress and nicotine interactions from a preclinical perspective". Invited symposium presentation at the 7<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Seattle, WA, March 2001.
10. "Combining motivational enhancement and contingency management for young adult smokers". In Krishnan-Sarin, S (symposium chair), Invited symposium presentation at the 12<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Orlando, FL, March 2006. Published in Nicotine and Tobacco Research, 9(Suppl 2), S107.
11. "Biobehavioral mechanisms of smoking in people with schizophrenia". Guest Seminar, Bristol-Myers Squibb Company, R & D/Neuroscience Biology, Wallingford, CT, March 2010.
12. "Biobehavioral mechanisms of smoking in people with schizophrenia". Guest Seminar, Division on Substance Abuse, New York State Psychiatric Institute & Department of Psychiatry, Columbia University, New York, NY, May 2010.
13. "Biobehavioral mechanisms of smoking in people with schizophrenia". Webinar presented to NIDA's Nicotine and Tobacco Interest Group, May 2010.
14. "Treating substance abuse and other problems among mentally-ill individuals". Incentives and Health US Navy Conference, Baltimore, Maryland, February 2011.
15. Invited speaker, Career Development Workshop sponsored by NIDA's Office of Extramural Affairs (OEA) at the annual CPDD meeting, Hollywood, Florida, June 2011.
16. "Nicotine Reduction in Vulnerable Populations". Nicotine Reduction Meeting, Bethesda, MD, October 2011.
17. "Developing Incentive-Based Smoking Cessation Treatments for Smokers with Schizophrenia". Grand Rounds, Center for Addiction Medicine, Massachusetts General Hospital, Boston, MA, October 2011.
18. "Contingency Management and Bupropion for Smoking in People with Schizophrenia". Invited talk at NIMH-, NIDA- and NCI-sponsored workshop entitled "Improving Smoking Cessation Treatment for People with Schizophrenia", April 3-4, 2013.
19. "Why Can't They Quit? Smoking Laboratory Research in People with Serious Mental Illness". Invited talk presented at the University of Vermont Human Behavioral Pharmacology Laboratory's 23<sup>rd</sup> annual NIDA T32 training retreat, July 16, 2013.
20. Discussant for the "Transdisciplinary Research" session at the Brown University Center for Alcohol and Addictions Studies 30<sup>th</sup> Anniversary Colloquium, September, 2013.
21. "Reducing the Nicotine Content of Cigarettes in Smokers with Serious Mental Illness". Invited talk presented at the Behavior Change, Health, and Health Disparities Conference, University of Vermont Departments of Psychiatry and Psychology, September 2013.

22. "Smoking and Serious Mental Illness: Research and Action". Featured presentation at the annual meeting of Tobacco Free Rhode Island, a state-wide network of 50 organizations working to reduce tobacco use in Rhode Island. October 2014.
23. "Schizophrenia and Smoking: Using Behavioral Laboratory Research to Inform Treatment Development". Invited talk for the Dartmouth Psychiatric Research Center, Dartmouth University-Geisel School of Medicine, November 2014.
24. "Nicotine Reduction to Reduce Tobacco Dependence in People with Psychiatric Disorders". Invited talk for the Behavioral Pharmacology Research Unit (BPRU) Addiction Research Seminar Series, Johns Hopkins University School of Medicine, December 2014.
25. "Smoking and Psychiatric Illness: Why is there a connection? What can we do about it?". Invited talk at Crossroads RI (homeless service provider), May, 2015.
26. "The behavioral economics of tobacco use among people with serious mental illness". In Leventhal A, Higgins S (symposium co-chairs), invited symposium presentation at the annual meeting of the College on Problems of Drug Dependence, Phoenix, AZ, June 2015.
27. "Laboratory Research on the Behavioral Economics of Tobacco among Individuals with Serious Mental Illness". Invited presentation at the Vermont Center on Behavior & Health's 3<sup>rd</sup> Annual Conference on Behavior Change, Health and Health Disparities, Burlington, VT, October 2015.
28. "Effects of reduced-nicotine content cigarettes on daily smoking rates, dependence and depression symptoms in depressed vs. non-depressed smokers." In Japuntich S (symposium chair), "Smoking and Psychopathology: Mechanisms and Treatment", invited symposium presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Chicago, IL, March 2016.
29. "Electronic Cigarettes: State of the Science". Miller M\* and Tidey J, symposium co-chairs. Collaborative Programming Symposium presented at the annual meeting of the American Psychological Association (APA), Denver, CO, August 2016.
30. "Nicotine Reduction in Smokers with Psychiatric Disorders". In Donny E (Chair), symposium entitled "Targeting the addictiveness of combusted tobacco: Could regulated reduction in nicotine content help end smoking?" Presented at the National Congress on Tobacco or Health, Austin, TX, March 2017.
31. "A Behavioral Economic Perspective on Persistent Tobacco Use in People with Psychopathology". J Tidey, symposium Chair. Presented at the 5<sup>th</sup> annual Collaborative Perspectives on Addiction meeting, Albuquerque, NM, March 2017.
32. "Effects of reduced-nicotine cigarettes on smoking and psychiatric symptoms in smokers with and without depression." In Dermody S (symposium chair), "Laboratory-based Clinical Studies to Inform Tobacco Cessation Interventions among Individuals with Psychiatric Conditions" Invited symposium presentation presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Baltimore, MD, February 2018.
33. "Translational Research on Smoking in People with Serious Mental Illness: From Lab to Policy". Seminar presented as part of the Mental Health and Behavioral Sciences Service (MHBSS) Seminar Series at the Providence VAMC, October 2018.
34. "Tobacco in People with Mental Health Conditions: What's the Latest?" Presentation at the Annual Networking Meeting of Tobacco Free Rhode Island, Barrington, RI, December 2018.

35. Discussant for “Impact of Tobacco use on Substance Use Disorders: Epidemiology to Mechanism”, Presidential Symposium, annual meeting of the College on Problems of Drug Dependence (CPDD), San Antonio, TX, June 2019.
36. “Effects of Very Low Nicotine Cigarettes in Vulnerable Populations”. In Donny E (Chair), symposium entitled “Reducing the addictiveness of cigarettes to reduce harm”. Presented at the National Congress on Tobacco or Health (NCTOH), Minneapolis, MN, August 2019.
37. Chair (invited), “Panel on Advances and Challenges of Reducing Tobacco Use in Vulnerable and Poly-Vulnerable Populations”. Panel presented at the annual Vermont Center on Behavior and Health meeting, Burlington VT, October 2019.
38. “Effects of Very Low Nicotine Content Cigarettes in People with Psychiatric Disorders”. Presented at the annual Vermont Center on Behavior and Health meeting, Burlington VT, October 2019.
39. Discussant for “Potential Impact of Nicotine Standards Policy II” panel presented at the NIH Tobacco Regulatory Science meeting, Bethesda, MD, October 2019.
40. “A Review of Tobacco Regulatory Science Research on Vulnerable Populations”. Presented with Higgins, S and Kurti, A. Invited webinar for Tobacco Regulatory Science grantees presented by the Center for Coordination of Analytics, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science, June 10, 2020.
41. Chair (invited), oral session “Tobacco and Mental Health Co-Morbidities”, NIH Tobacco Regulatory Science meeting, Bethesda, MD (virtual), October 19, 2020.
42. Panel Chair (invited), Paper Session 1, “Innovations in Tobacco Control and Regulatory Science to Decrease Cigarette Smoking”. Vermont Conference on Behavior and Health, Burlington VT, October 7, 2021.
43. “Nicotine Reduction and Smoking in Vulnerable Populations”, presented at the Vermont Conference on Behavior and Health, Burlington VT, October 7, 2021.
44. “Tobacco Research in People with Serious Mental Illness”. Seminar presentation to fellows in the NIDA-funded T32 postdoctoral training program at the University of Kentucky. April 28, 2022.
45. Session Chair (invited), “Rural Health Disparities” presented at the Vermont Conference on Behavior and Health, Burlington VT, October 6, 2022.
46. “Reducing Smoking in People with Psychiatric Disorders using Regulatory and Behavioral Interventions”. Chairman’s Grand Rounds, Wayne State University School of Medicine, Detroit, MI, December 14, 2022.
47. “Effects of Very Low Nicotine Cigarettes in Vulnerable Populations”. Presented at the Nicotine Product Standard Implementation Meeting, Minneapolis, MN, October 2, 2023.
48. “Response to a Nicotine Product Standard for Cigarettes Among Women and Girls”. Presented at the 11<sup>th</sup> Annual Vermont Conference on Behavior and Health, Burlington, VT, October 6, 2023.
49. Session Chair (invited), “Smoking and Other Tobacco Use Among Women and Girls”, Vermont Conference on Behavior and Health, Burlington VT, October 6, 2023.

50. "Policy Interventions to Reduce Tobacco Use Among People with Severe and Persistent Mental Illness". Colloquium to be presented at Fall 2024 Addiction Lecture Series, Cofrin Logan Center for Addiction Research and Treatment, University of Kansas, Lawrence, KS, Nov 8, 2024. (Note: Cancelled due to family illness).
51. "Resilience in Public Health Research". Panel presentation at the Brown University School of Public Health. Providence, RI, March 31, 2025.
52. "Reducing Smoking in People with Psychiatric Disorders Using Regulatory and Behavioral Interventions". Vermont Center on Behavior & Health Lecture Series, University of Vermont, Burlington, VT, Sept 17, 2025.

#### Invited Presentations - International

1. Tidey JW (2006, May). "Effects of biological and environmental challenges on smoking in schizophrenic versus non-psychiatric heavy smokers", In I Montoya & F Vocci (Co-Chairs), NIDA-sponsored symposium entitled "Nicotine Dependence and Schizophrenia, Neurobehavioral Pathways". Presented at the American Psychiatric Association Annual Meeting, Toronto, Canada.
2. Tidey JW (2009, May). "Using contingent incentives to reduce smoking in people with schizophrenia: From laboratory to treatment interventions." In A. DeFulio (Chair), symposium entitled "Developing Behavior Analytic Interventions for Medical Application: Examples and lessons from the Treatment of Drug Addiction" Presented at the 35<sup>th</sup> annual meeting of the International Association for Behavioral Analysis, Phoenix, AZ.
3. Tidey JW, Colby SM (2013, March). Behavioral and subjective effects of 72-h abstinence and smoking reinstatement in smokers with schizophrenia and controls. In JW Tidey (Chair), symposium entitled "Smoking and Psychiatric Comorbidity: Beyond the Self-Medication Hypothesis". Presented at the International meeting of the Society for Research on Nicotine and Tobacco (combined meeting of SRNT and SRNT-Europe), Boston, MA.
4. Leventhal AM, Tidey JW, Sussman S, Kahler CW (2013, March). Anhedonia, positive affect, and motivation to initiate and maintain smoking on a lab-based smoking task. In JW Tidey (Chair), symposium entitled "Smoking and Psychiatric Comorbidity: Beyond the Self-Medication Hypothesis". Presented at the International meeting of the Society for Research on Nicotine and Tobacco (combined meeting of SRNT and SRNT-Europe), Boston, MA.
5. Tidey JW (2013, October). Contingent incentives for reducing smoking among people with schizophrenia. In Sigmon SC (Chair), symposium entitled "A Behavioral Economic Approach to Promoting Health Behavior Change in Patients with Co-occurring Disorders". Presented at the III International Congress on Dual Disorders, Barcelona, Spain.
6. Cassidy RN, Denlinger-Apte R\*, Colby SM, Tidey J, Jackson K, Cioe P, Krishnan-Sarin S, Hatsukami D (2017, March). Effects of nicotine dose in cigarettes on perceived health risk and subjective response in adolescent smokers. In Mercincavage M (Chair) symposium entitled "Attitudes and Perceptions toward a reduced nicotine product standard for cigarettes". Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the Society for Research on Nicotine and Tobacco-Europe, Florence, Italy.

7. Denlinger-Apte RL\*, Tidey JW, Koopmeiners J, Hatsukami DK, Donny EC (2017, March). Acceptability of a reduced nicotine product standard for cigarettes among smokers provided reduced nicotine cigarettes for six weeks. In Mercincavage M (Chair) symposium entitled "Attitudes and Perceptions toward a reduced nicotine product standard for cigarettes". Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the Society for Research on Nicotine and Tobacco-Europe, Florence, Italy.
8. Tidey JW (2017, December). A behavioral economic perspective on tobacco dependence in people with serious mental illness. Presented at Addiction Rounds at the Peter Boris Centre for Addictions Research, McMaster University, Hamilton, ON, Canada.

## **OTHER PRESENTATIONS**

### Regular (Non-Invited) Presentations - Local or National

1. Tidey JW, Miczek KA (1989, October). *d*-Amphetamine and morphine withdrawal aggression: role of dopamine receptors. Presented at the 19<sup>th</sup> annual meeting of the Society for Neuroscience, Phoenix, AZ. Society for Neuroscience Abstracts, 15, 251.
2. Tidey JW, Miczek KA (1990, August). Mediation of morphine withdrawal aggression by dopaminergic agents. Presented at the annual meeting of the American Psychological Association, Div 28. Pharmacology Biochemistry and Behavior, 36, 436.
3. Tidey JW, Miczek KA (1990, October). Increased D<sub>1</sub> and D<sub>2</sub> receptor activity during opiate withdrawal: behavioral and binding evidence. Presented at the 20<sup>th</sup> annual meeting of the Society for Neuroscience, St. Louis, MO. Society for Neuroscience Abstracts, 16, 930.
4. Haney M, Tidey JW, Vivian J, Miczek K (1990, October). Behavioral analysis of D<sub>1</sub> receptor antagonism: interaction with *d*-amphetamine. Presented at the 20<sup>th</sup> annual meeting of the Society for Neuroscience, St. Louis, MO. Society for Neuroscience Abstracts, 16, 1052.
5. Tidey JW, Miczek KA (1991, November). Behavioral characterization of quinpirole and SKF 38393 under varying social and environmental demands. Presented at the 21<sup>st</sup> annual meeting of the Society for Neuroscience, New Orleans, LA. Society for Neuroscience Abstracts, 17, 678.
6. Tidey JW, Cohen CA, Kream R, Miczek KA (1993, November). Dopamine release in the nucleus accumbens during social stress: an *in vivo* microdialysis study. Presented at the 23<sup>rd</sup> annual meeting of the Society for Neuroscience. Society for Neuroscience Abstracts, 19, 1450.
7. Tidey JW, Miczek K (1994, November). Threat of attack increases *in vivo* dopamine release in prefrontal cortex and nucleus accumbens. Presented at the 24<sup>th</sup> annual meeting of the Society for Neuroscience, Miami Beach, FL. Society for Neuroscience Abstracts, 20, 1445.
8. Tidey JW, Bergman J (1995, June). Efficacy-related differences in behavioral effects of dopamine D<sub>1</sub> and D<sub>2</sub> agonists. Presented at the 57<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, Scottsdale, AZ. In: Harris LS (Ed.), Problems of Drug Dependence 1995, NIDA Research Monograph 162. Washington D.C.: U.S. Government Printing Office, 295.
9. Tidey JW, Carey G, Bergman J (1996, November). Some behavioral effects of clozapine and novel antipsychotics in monkeys. Presented at the 26<sup>th</sup> annual meeting of the Society for Neuroscience, Washington, DC. Society for Neuroscience Abstracts, 22, 1189.

10. Bergman J, Carey G, Tidey J (1996, December). Effects of clozapine and novel antipsychotics in monkeys. Presented at the 35<sup>th</sup> annual meeting of the American College of Neuropharmacology, San Juan, Puerto Rico.
11. Tidey JW, Higgins ST, Bickel WK (1997, June). Effects of an alternative reinforcer and varying response requirement on smoking by schizophrenics. Presented at the 59<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, Nashville, TN. Published in Harris LS (Ed.), Problems of Drug Dependence 1997, NIDA Research Monograph. No. 178. Washington D.C.: U.S. Government Printing Office, 161.
12. Roll JM, Higgins ST, Tidey JW (1997, June). Effects of an alternative reinforcer and caffeine on human cocaine self-administration. Presented at the 59<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, Nashville, TN. Published in Harris LS (Ed.), Problems of Drug Dependence 1997, NIDA Research Monograph No. 178. Washington D.C.: U.S. Government Printing Office, 286.
13. Tidey JW, Higgins ST (1998, June). Effects of varying response requirement and abstinence on cigarette smoking by schizophrenics. Presented at the 60<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, Scottsdale, AZ. In Harris LS (Ed.), Problems of Drug Dependence 1998, NIDA Research Monograph No. 179. Washington D.C.: U.S. Government Printing Office, 211.
14. Sigmon, SC, Higgins, ST, Steingard, S, Wong, CJ, Tidey JW (1998, June). Reducing marijuana use in schizophrenics. Presented at the 60<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, Scottsdale, AZ. Published in Harris LS (Ed.), Problems of Drug Dependence 1998, NIDA Research Monograph No. 179. Washington D.C.: U.S. Government Printing Office, 314.
15. Tidey JW and Higgins ST (1998, May). Effects of an alternative reinforcer, smoking abstinence and response requirement on cigarette smoking in schizophrenics. Presented at the annual meeting of the Behavioral Pharmacology Society, Philadelphia, PA.
16. Tidey JW, O'Neill SC, Higgins ST (1999, August). *d*-Amphetamine increases choice of cigarette smoking versus monetary reinforcement. Presented at the annual meeting of the American Psychological Association, Div 28, Boston, MA. Pharmacology, Biochemistry and Behavior, 64, 643-651.
17. Heil SH, Tidey JW, Higgins ST (2000, August). Effects of contingent reinforcement on smoking abstinence and nicotine withdrawal. Presented at the annual meeting of the American Psychological Association, Div 28. Pharmacology, Biochemistry and Behavior, 64, 643-651.
18. Tidey JW, Rohsenow D, Swift, R, Monti P, Kaplan G (2001, March). Smoking cue reactivity among people with schizophrenia. Presented at the 7<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Seattle, WA.
19. Tidey, JW & Higgins, ST (2002, February) Nicotine withdrawal symptoms and smoking urges in smokers with schizophrenia. Presented at the 8<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Savannah, GA.
20. Gwaltney, C, O'Leary, T, Tidey, J, Colby, S, Ziegler, J, Miranda, R, Kahler, C, Barnett, N, Monti, P (2002, February). Contingency management for adolescent smoking: A pilot study. Presented at the 8<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Savannah, GA.

21. Tidey JW, Rohsenow D, Monti P, Swift R, Kaplan G (2002, June). Effects of abstinence and smoking cues in smokers with schizophrenia. Presented at the 41<sup>st</sup> annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
22. Miranda R Jr., Rohsenow D, Monti P, Tidey J, Swift R (2003, February). Effects of repeated days of smoking cue exposure on subjective and physiologic reactivity. Presented at the 9<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA.
23. Tidey JW, Rohsenow DJ, Swift RM, Kaplan GB, Scallon AB (2003, June). Effects of abstinence on smoking urges and smoking behavior in schizophrenic versus non-psychiatric smokers. In Le Foll, B and Tidey, JW (Co-Chairs), oral communications session entitled "Right on Cue". Presented at the 65<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, Bal Harbour, FL.
24. Monti, P & Tidey, JW (2003, June). Ecological and laboratory assessment of alcohol urges and drinking: Effects of naltrexone. Symposium presentation at the 26<sup>th</sup> annual meeting of the Research Society on Alcoholism, Ft. Lauderdale, FL.
25. Tidey JW, Rohsenow DJ, Kaplan, GB & Swift, RM (2004, February). Schizophrenic vs. non-psychiatric smokers: Effects of abstinence and nicotine replacement on smoking urges and topography. Presented at the 10<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Scottsdale, AZ.
26. Tidey JW (2004, June). Sensitivity of schizophrenic smokers to nicotine abstinence and replacement. In Kaplan, GB (Chair), Tidey, JW & George TP (Co-Chairs), symposium entitled "Schizophrenia and Nicotine: Neurobiological Mechanisms and their Treatment Implications". Presented at the 66<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, San Juan, Puerto Rico.
27. Tidey JW and Rohsenow DJ (2004, June). Cigarette smoking urges and smoking behavior in people with schizophrenia. Oral presentation at the annual meeting of the International Study Group Investigating Drugs as Reinforcers (ISGIDAR), San Juan, Puerto Rico.
28. Monti PM, Rohsenow D, Tidey J, McGeary J, Swift R (2004, June). Naltrexone, craving for alcohol and drinking: laboratory and ecological assessments. Symposium presentation. Published in Alcoholism, Clinical and Experimental Research, 28 Suppl, 65A.
29. Tidey, J (2004, October). Contingent reinforcement plus bupropion-SR for smoking reductions in schizophrenics. Poster presentation at the Future Directions in Contingency Management Research conference, Burlington, VT.
30. Tidey J, Rohsenow D, Kaplan G, Swift R (2005, June). Contingency management plus bupropion for smoking reductions in outpatients with schizophrenia. In Sonne S (Chair), and Tidey JW (Co-Chair), oral communications session entitled "Comorbidity: Double Trouble". Presented at the 67<sup>th</sup> Annual meeting of the College on Problems of Drug Dependence, Orlando, FL.
31. Tidey J, Tevyaw, TO, Colby SM, Kahler CW, Barnett NP, Rohsenow DJ, Monti PM (2005, June). Fishbowl versus cash schedule methods of delivering contingency management for young adult smokers. In Walsh, S (Chair), oral communications session entitled "Late-Breaking Research News". Presented at the 67<sup>th</sup> Annual meeting of the College on Problems of Drug Dependence, Orlando, FL.

32. Tidey J, Tevyaw, TO, Colby SM, Kahler CW, Barnett NP, Rohsenow DJ, Monti PM (2005, June). Contingent incentives for reducing smoking in young adults. In Sigmon, S (Chair), workshop entitled "Contingency Management Working Group". Presented at the 67<sup>th</sup> Annual meeting of the College on Problems of Drug Dependence, Orlando, FL.
33. Martin R, Rohsenow D, Tidey J, Monti P (2005, June). Contingency management for smoking among substance abusers in treatment. In Sigmon, S (Chair), workshop entitled "Contingency Management Working Group". Presented at the 67<sup>th</sup> Annual meeting of the College on Problems of Drug Dependence, Orlando, FL.
34. Tidey J, Rohsenow D, Kaplan G, Swift R (2006, March). Effects of smoking cues, acute abstinence and bupropion in smokers with schizophrenia and non-psychiatric controls. In Williams J (Chair) and Tidey J (Co-Chair), oral communications session entitled "Smoking and Psychiatric Comorbidity". Presented at the 12<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Orlando, FL. Published in Nicotine and Tobacco Research, 9(Suppl 2), S131.
35. Tidey J, Rohsenow D, Kaplan G, Swift R (2006, June). Effects of contingent incentives and bupropion on smoking in outpatients with schizophrenia. Presented in Tidey J (Chair) and Upadhyaya H (Co-Chair), Dual Diagnosis: The trouble is more than double. Oral Communications session at the 68<sup>th</sup> Annual meeting of the College on Problems of Drug Dependence, Scottsdale, AZ.
36. Metrik J, Tevyaw T, Tidey J, Colby S, Rohsenow D, Barnett N, Kahler C, Monti P (2006, June). Marijuana use and expectancies' association with risk taking. Presented at the 68<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, Scottsdale, AZ.
37. Sirota A, Rohsenow D, MacKinnon S, Martin R, Kaplan G, Monti P, Almeida A, Tidey J, Swift R. (2007, March). Tolerance for Smoking Discomfort: A new questionnaire of ability to handle nicotine withdrawal and cravings. Presented at the annual meeting of the Society of Behavioral Medicine, Washington, D.C.
38. Miranda R, Monti P, Swift R, MacKillop J, Tidey J, Gwaltney C, McGeary J, Ray L, Rohsenow D (2006, December). Dose dependent effects of topiramate on alcohol cue reactivity and the subjective effects of drinking. Presented at the 41<sup>st</sup> annual meeting of the American College of Neuropsychopharmacology. Published in Neuropsychopharmacology, 31, Supplement 1.
39. Tidey J, Rohsenow D (2007, February). Smoking outcome expectancies in smokers with schizophrenia and controls. Presented at the 13<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
40. Adolfo A\*, Cathers E, Reid N, Tidey J (2007, February). Social support for quitting and motivation to quit smoking in outpatients with schizophrenia. Presented at the 13<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Austin, TX.
41. Tidey J, Monti P, Rohsenow D, Gwaltney C, Miranda R, McGeary J, MacKillop J, Swift R (2007, July). Naltrexone's effects on drinking in the natural environment: mediators and moderators. Presented at the 30<sup>th</sup> annual meeting of the Research Society on Alcoholism, Chicago, IL. Alcoholism: Clinical and Experimental Research, 31, 56A.
42. Tidey J, Rohsenow D, Swift R, Kaplan G (2008, February). Effects of sensorimotor replacement for smoking in smokers with schizophrenia. Presented at the 14<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Portland, OR.

43. AhnAllen CG\*, Tidey JW (2008, February). Subjective and physiological responses to personalized smoking environments in smokers with schizophrenia. Presented at the 14<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco, Portland, OR.
44. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM (2008, June). Bupropion plus incentives for smoking reductions in outpatients with schizophrenia. Presented at the 70<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, San Juan, Puerto Rico.
45. Adolfo A\*, Tidey JW, AhnAllen CG (2008, June). Smoking cues increase caffeine urges in outpatients with schizophrenia. Presented at the 70<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, San Juan, Puerto Rico.
46. AhnAllen CG\*, Tidey JW (2008, June). High-dose nicotine and sensorimotor replacement effects on cognition in smokers with schizophrenia. Presented at the 70<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, San Juan, Puerto Rico.
47. Tidey JW (2008, June). Cigarette smoking urges and smoking behavior in people with schizophrenia. Oral presentation at the annual meeting of the International Study Group Investigating Drugs as Reinforcers (ISGIDAR), San Juan, Puerto Rico.
48. Ray LA, Miranda R, Tidey J, Gwaltney C, McGeary JE, MacKillop J, Rohsenow DJ, Swift RM, Monti PM (2008, June). The ASN40ASP SNP of the mu-opioid receptor gene (OPRM1) and the subjective effects of alcohol in the natural environment. Presented at the 31<sup>st</sup> annual meeting of the Research Society on Alcoholism, Washington, DC. Published in Alcoholism: Clinical and Experimental Research, 32(6), 208A.
49. Ray LA, Miranda R, MacKillop J, McGeary JE, Tidey J, Rohsenow D, Gwaltney C, Swift R, Monti PM (2008, June). Pharmacogenetics of topiramate: examining adverse events. Presented at the 31<sup>st</sup> annual meeting of the Research Society on Alcoholism, Washington, DC. Alcoholism: Clinical and Experimental Research, 32(6), 143A.
50. MacKillop J, Miranda RM, Monti PM, McGeary JE, Ray LA, Swift RM, Rohsenow DJ, Tidey JW, Gwaltney CJ (2008, June). DRD4 VNTR and OPRM1 genotypes as moderators of alcohol cue reactivity and responses to alcohol. Presented at the 31<sup>st</sup> annual meeting of the Research Society on Alcoholism, Washington, DC. Alcoholism: Clinical and Experimental Research, 32(6), 209A.
51. MacKillop J, Miranda RM, Monti PM, Swift RM, Murphy JG, Rohsenow DJ, Tidey JW, Gwaltney, C.J., McGeary, J.G., Ray, L.A. (2008, June). Individual differences in behavioral economic demand for alcohol and delay discounting in AUD+ individuals and heavy drinking controls. Presented at the 31<sup>st</sup> annual meeting of the Research Society on Alcoholism, Washington, DC. Alcoholism: Clinical and Experimental Research, 32(6), 53A.
52. MacKillop J, Miranda RM, Monti PM, Swift RM, Murphy JG, Rohsenow DJ, Tidey JW, Gwaltney C, McGeary J, Ray L (2008, June). Short-term test-retest reliability of a behavioral economic purchase task. Presented at the 31<sup>st</sup> annual meeting of the Research Society on Alcoholism, Washington, DC. Alcoholism: Clinical and Experimental Research, 32(6), 53A.
53. Rohsenow D, Martin R, Tidey J, Monti P, Swift R, McGeary J. (2008, June). Pilot study of varenicline vs. patch for sober alcoholic smokers. Presented at the 31<sup>st</sup> annual meeting of the Research Society on Alcoholism, Washington, DC. Alcoholism: Clinical and Experimental Research, 32(6), 257A.
54. Tidey JW, Gwaltney CJ, Colby SM (2009, June). Ecological momentary assessment of smoking cessation in smokers with schizophrenia. Presented at the 71<sup>st</sup> annual meeting of the College on Problems of Drug Dependence, Reno, NV.

55. MacKillop J, Tidey JW (2010, February). Tobacco demand and delayed reward discounting in nicotine dependent individuals with serious mental illness and controls. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco, Baltimore, MD.
56. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM (2010, June). Sensorimotor replacement reduces cigarette craving, withdrawal symptoms and smoking in smokers with schizophrenia. In Tidey J (Chair) and Zawertailo L (Co-Chair), oral communications session entitled "Treatments for Nicotine Addiction: More than Smoke and Mirrors". Presented at the 72<sup>nd</sup> annual meeting of the College on Problems of Drug Dependence, Scottsdale, AZ.
57. Rohsenow D, McGeary J, Tidey J, Martin RA, Swift R, Miranda R, Hutchison K, Monti PM (2010, June). Effects of ondansetron and naltrexone on urge to drink before and after drinking are moderated by family history and DRD4 VNTR. In J. Kramer (Chair), symposium entitled "Craving: Its Measurement, Biological Causes, and Role in Alcohol Dependence". Presented at the annual meeting of the Research Society on Alcoholism (RSA), San Antonio, TX. Published in Alcoholism: Clinical and Experimental Research, 34(6), 281A.
58. Carter AC, Miranda R, Gwaltney C, Tidey J, Rohsenow DJ, Swift R, Monti P (2010, June). Naltrexone's impact on alcohol expectancies in heavy drinkers. Presented at the annual meeting of the Research Society on Alcoholism (RSA), San Antonio, TX. Published in Alcoholism: Clinical and Experimental Research, 34(6), 176A.
59. Barnett N, Tidey J, Murphy J, Swift R, Colby S (2010, June). Contingent reinforcement for reducing drinking among heavy drinkers using continuous alcohol monitoring: Feasibility and initial efficacy. Presented at the annual meeting of the Research Society on Alcoholism (RSA), San Antonio, TX. Published in Alcoholism: Clinical and Experimental Research, 34(6), 231A.
60. Kahler CW, Metrik J, Spillane NS, Leventhal AM, McKee SA, Tidey JW, McGeary JE, Knopik VS, Rohsenow DJ (2010, November). Expectancy effects of alcohol use on smoking relapse risk: A laboratory analogue study using the balanced placebo design. In C. Kahler, J. Metrik (Chairs), symposium presented at the annual meeting of the Association for Behavioral and Cognitive Therapies (ABCT), San Francisco, CA.
61. Tidey JW, Colby SM (2011, June). Nicotine reinforcement before and after 72-h smoking abstinence in smokers with schizophrenia. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Hollywood, FL.
62. Bidwell LC, MacKillop J, Murphy JG, Tidey JW, Colby SM (2011, June). Examining the factor structure of a behavioral economic demand curve measure of nicotine reinforcement in adolescent smokers. Presented at the annual meeting of the College on Problem of Drug Dependence (CPDD), Hollywood, Florida.
63. Meade EB\*, Tidey JW, Swift R, Colby SM, Barnett NP (2011, June). Contingent reinforcement using continuous alcohol monitoring successful with both alcohol dependent and non-dependent heavy drinkers. Presented at the annual meeting of the Research Society on Alcoholism (RSA), Atlanta, Georgia. Published in Alcoholism: Clinical and Experimental Research, 35(6), 87A.
64. Rohsenow DJ, Martin RA, Tidey J, Colby S, Monti P (2011, June). Comparison of the cigarette dependence scale with FTND for relationship to smoking history and short-term outcome in US smokers with AUD. Presented at the annual meeting of the Research Society on Alcoholism (RSA), Atlanta, Georgia. Published in Alcoholism: Clinical and Experimental Research, 35(6), 168A.

65. Miranda R, MacKillop J, Meehan A, Justus A, Tidey J, et al. (2011, June). Biobehavioral effects of topiramate among heavy drinkers. Presented at the annual meeting of the Research Society on Alcoholism (RSA), Atlanta, Georgia. Published in Alcoholism: Clinical and Experimental Research, 35(6), 21A.
66. Barnett N, Tidey J, Murphy J, Swift R, Colby S (2011, June). Contingent reinforcement for reducing alcohol use using transdermal alcohol monitoring: Results of a controlled trial. In: N. Barnett (chair), symposium entitled "New Developments in Research with Transdermal Alcohol Sensors: Laboratory, Field and Clinical Applications". Presented at the annual meeting of the Research Society on Alcoholism (RSA), Atlanta, Georgia. Published in Alcoholism: Clinical and Experimental Research, 35(6), 276A.
67. Edwards S., Clifford J, Fricchione SR, Tavares T, Tidey J, Kenna GA, Zywiak WH, Swift RM, Leggio L (2011, October). Are smokers and drinkers happy? A relationship between subjective happiness and drinking and smoking levels. Presented at the 51st Annual Meeting of the New England Conference on the Teaching of Psychology (NECTOP) and the New England Psychological Association (NECTOP/NEPA), Fairfield, CT.
68. Leventhal AM, Munafò M, Tidey JW, Sussman S, Monterosso JR, Sun P, Kahler CW (2011, December). Anhedonia predicts diminished sociocognitive reward processing in abstinent cigarette smokers. Presented at the annual meeting of the American College of Neuropsychopharmacology (ACNP), Waikoloa, Hawaii.
69. Leventhal AM, Munafò M, Tidey JW, Sussman S, Monterosso JR, Sun P, Kahler CW (2012, March). Anhedonia predicts diminished sociocognitive reward processing in abstinent cigarette smokers. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Houston, Texas.
70. Glasser I, Zywiak W, Tidey J (2012, May). A study of a lack of diffusion: The case of Nicotine Anonymous. Presented at the annual National Health Care for the Homeless Conference, Kansas City, Missouri.
71. Bidwell LC, Leventhal AM, Tidey JW, Brazil L, Niaura RS, Colby SM. (March, 2012). Effects of abstinence in adolescent tobacco smokers: withdrawal symptoms, reactive irritability, and cue reactivity. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Houston, Texas.
72. Leventhal AM, Munafò M, Tidey JW, Sussman S, Monterosso JR, Sun P, Kahler CW (2012, March). Anhedonia predicts diminished sociocognitive reward processing in abstinent cigarette smokers. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Houston, TX.
73. Goodwin C, Edwards S, Fricchione SR, Shoaff J, Tavares T, Zywiak WH, Tidey JW, Swift RM, Kenna GA, Leggio L (2012, April). Exploring the relationship between subjective happiness, drinking, and smoking levels in a sample of alcoholic smokers. Presented at the Public Health Research Day, Brown University, Providence, RI.
74. Tidey JW, Colby SM (2012, June). Acute topography characteristics of very low nicotine cigarettes with and without nicotine replacement vs. usual-brand cigarettes in smokers with schizophrenia and controls. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Palm Springs, CA.
75. Rohsenow DJ, Martin RA, Tidey JW, Colby SM, Monti PM (2012, June). Contingent vouchers for smoking in substance abusers as adjunct to nicotine patch. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Palm Springs, CA.

76. Miranda R, Ray L, Reynolds E, Monti P, Justus A, Tidey J, Gwaltney C, Swift R, Chun T, Blanchard A (2012, June). Effects of naltrexone on adolescent drinking. Presented at the annual meeting of the Research Society on Alcohol (RSA), San Francisco, CA.
77. MacKillop J, Monti PM, Tidey J, Swift RM, Ray LA, Miranda R. (2012, June). Behavioral economic analysis of topiramate's effects on motivation for alcohol. Presented at the annual meeting of the Research Society on Alcohol (RSA), San Francisco, CA.
78. Tidey JW, Colby SM, Xavier EM\* (2013, April). Smoking abstinence and lapse effects in smokers with schizophrenia and controls. Presented at the annual meeting of the Behavioral Pharmacology Society, Boston, MA.
79. Tidey JW, Colby SM, Xavier EM\* (2013, June). Smoking abstinence and lapse effects in smokers with schizophrenia and controls. Presented at the annual meeting of the International Study Group Investigating Drugs as Reinforcers (ISGIDAR), San Diego, CA.
80. Tidey JW, Williams DM, Goodwin CA (2013, June). Effects of walking on cigarette craving, nicotine withdrawal symptoms and affect in smokers with schizophrenia. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), San Diego, CA.
81. Rohsenow DJ, Martin RA, Tidey JW, Colby SM, Monti PM (2013, June). Contingent vouchers, patch and brief advice for smokers in SUD treatment: Preliminary results. Presented to the Contingency Management Working Group at the annual meeting of the College on Problems in Drug Dependence (CPDD), San Diego, CA.
82. Kahler CW, Metrik J, Spillane NS, Day A, Tidey JW, Rohsenow DJ, Leventhal AM, McKee SA, McGeary JE, Knopik, VS (2014, February). Acute effects of low and high dose alcohol on smoking lapse behavior in a laboratory analogue task. Symposium presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Seattle, WA.
83. Tidey JW, Cassidy RN, Bidwell LC (2014, February). Smoking topography comparison of usual-brand and very low nicotine cigarettes across a 5-hr period in heavy smokers with and without schizophrenia. Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Seattle, WA.
84. MacKillop J, Monti P, Tidey J, Swift R, Miranda R (2014, June). Understanding topiramate's mechanisms via the subjective effects of alcohol: A Mellanby approach. Presented at the annual meeting of the Research Society on Alcoholism (RSA), Bellevue, WA.
85. Cassidy RN, Colby SM, Tidey JW, Kahler CW, Wray TB (2014, June). Increasing the value of an alternative monetary reinforcer reduces choice for cigarettes in adolescents. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), San Juan, Puerto Rico.
86. Day AM, Kahler CW, Metrik J, Spillane NS, Tidey JW, Rohsenow DJ (2014, June). Working memory moderates association of smoking urge and smoking behavior alcohol administration in a laboratory analogue task. Presented at the annual meeting of the Research Society on Alcoholism (RSA), Bellevue, WA.
87. Tidey JW (2014, October). Smoking topography of menthol and non-menthol cigarettes in people with and without schizophrenia. Poster presentation at the 2<sup>nd</sup> annual Vermont Center on Behavior and Health Conference, Burlington, VT.
88. Cassidy RN, Colby SM, Tidey JW, Kahler CW, Wray TB (2014, October). Increasing the value of an alternative monetary reinforcer reduces cigarette choice in adolescents". Poster presentation at the 2<sup>nd</sup> annual Vermont Center on Behavior and Health Conference, Burlington, VT.

89. Farokhnia M, Edwards SM, Bollinger J, Amodio J, Zywiak WH, Tidey JW, Swift RM, Kenna GA, Leggio L. (2014, December). Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: A double-blind, placebo-controlled, randomized Trial. Presented at the 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Phoenix, AZ. Neuropsychopharmacology. 2015 May;40(6):1560. doi:10.1038/npp.2015.29. PMC4397411.
90. Tidey JW, Goodwin CA, Williams DM (2015, February). Effects of treadmill walking on cigarette craving, withdrawal symptoms and smoking behavior in people with schizophrenia. Paper presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Philadelphia, PA.
91. Brunette MF, Robinson DG, Coletti DJ, Patrick ME, Tidey JW (2015, February). Are people with schizophrenia responsive to regulatory efforts? Paper presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Philadelphia, PA.
92. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Monti PM (2015, February). Varenicline helps smokers with SUD stop smoking without harming recovery. Paper presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Philadelphia, PA.
93. Donny EC, Denlinger RL, Hatsukami D, Koopmeiners J, Lane T, al'Absi M, Benowitz N, Cinciripini P, Dermody S, Drobos D, Hecht S, Jensen J, McClernon J, Murphy S, Robinson J, Stitzer M, Strasser A, Tidey J, Tindle J, Vandrey R (authors 6-20 in alphabetical order). (2015, February). Symposium presentation at the annual meeting of the Society for Research on Nicotine and Dependence (SRNT), Philadelphia, PA.
94. Dermody SS, Vandrey R, Tidey J, Denlinger R, Koopmeiners J, Hatsukami D, Donny EC. The impact of smoking very low nicotine content cigarettes on alcohol use (2015, February). Paper presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Philadelphia, PA.
95. Meinbresse M, Glasserl, Venson R, Gelberg L, Tidey J, Zywiak W, Czabafy S (2015, May). Results of three-month feasibility study of Nicotine Anonymous (NicA) in Health Care for the Homeless settings. Presented at the National Health Care for the Homeless Conference and Policy Symposium, Washington, DC.
96. Cassidy RN, Colby SM, Rohsenow DJ, Tidey JW, Monti PM, Barnett NP, Miller ME\*. (2015, May). Contingency management for college student smokers: Predictors of abstinence during treatment. Paper presented at the annual meeting of the Association for Behavior Analysis (ABA), San Antonio, TX.
97. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Monti PM (2015, June). Varenicline versus nicotine patch plus brief advice for sober smokers in substance treatment. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Phoenix, AZ.
98. Martin RA, Rohsenow DJ, Tidey JW, Colby SM, Monti PM (2015, June). Treating smokers in substance treatment with contingent vouchers, nicotine replacement and brief advice adapted for sobriety settings. Paper presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Phoenix, AZ.
99. Tidey JW, Strasser A, Donny E, Hatsukami D (2015, June). Cigarette smoking topography in men and women with and without current depression: Findings from a 10-site clinical trial. Paper presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Phoenix, AZ. Published in Drug and Alcohol Dependence, 156, e221.

100. Pacek L, Vandrey R, Tidey J, Drobles D, Koopmeiners J, Umbricht A, Hatsukami D, Donny E (2015, June). The impact of nicotine dose assignment on affect and depression during extended exposure to experimental Spectrum cigarettes: findings from CENIC Project 1 Study 1. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Phoenix, AZ.
101. Tidey JW, Benowitz NL, Cassidy RN, Denlinger RL\*, Dermody SS, Hatsukami DK, Koopmeiners JS, Pacek LR, Vandrey R, Donny EC (2015, October). Key moderators of the effects of 6-week use of reduced-nicotine cigarettes on daily smoking rate and nicotine intake. Panel presentation, NIH Tobacco Regulatory Science conference, Bethesda, MD.
102. Nardone N, Donny EC, Hatsukami DK, Koopmeiners JS, Strasser AA, Tidey JW, Vandrey R, Benowitz N (2015, October). Estimations and predictors of compliance in switchers to reduced nicotine content cigarettes. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
103. Pacek LR, Lemieux A, al'Absi M, Vandrey R, Drobles D, McClernon FJ, Tidey JW, Denlinger RL, Dermody S, Koopmeiners J, Hatsukami DK, Donny EC (2015, October). Impact of nicotine reduction during a 6-week randomized clinical trial on smoking characteristics and behavior: cannabis-users vs. non-users. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
104. Streck JM, Sigmon SC, Heil SH, Stitzer ML, Tidey JW, Gaalema DE, DeSarno MJ, Balas K, Durand HJ, Higgins ST (2015, October). Does nicotine function differently in opioid-dependent versus nondependent smokers? Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
105. Dermody SS, Drobles DJ, Hatsukami DK, Pacek LR, Vandrey R, Tidey JW, Donny E (2015, October). The impact of smoking very low nicotine content cigarettes on alcohol use. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
106. Strasser AA, Tidey JW, Benowitz NL, Hatsukami DK, Donny EC (2015, October). Characterizing smoking topography in response to smoking novel low nicotine content research cigarettes. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
107. Miller ME\*, Tidey JW, Rohsenow DJ, Higgins ST (2015, October). Smoking outcome expectancies of electronic and combustible cigarettes in smokers with severe psychological distress and controls. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
108. Gaalema DE, Tidey JW, Tyndale RF, Heil SH, Sigmon SC, Stitzer ML, DeSarno MJ, Durand HJ, Kretzer EL, Higgins ST (2015, October). Nicotine metabolite ratio and associations with demographics and smoking topography. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
109. Cassidy RN, Tidey JW, Colby SM (2015, October). Initial development of an e-cigarette purchase task. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
110. Arger CA, Heil SH, Sigmon SC, Tidey JW, Stitzer ML, Gaalema DE, DeSarno MJ, Durand JH, Ruggieri EK, Higgins ST (2015, October). Validity of the Cigarette Evaluation Questionnaire in predicting the reinforcing effects of cigarettes that vary in nicotine content under double-blind conditions. Panel presentation at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.

111. Smith TT, Cassidy RN, Tidey JW, Luo X, Le CT, Hatsukami DK, Donny EC (2015, October). Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: Results from a multi-site clinical trial. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
112. Davis DR, Heil SH, Sigmon SC, Tidey JW, Stitzer ML, Gaalema DE, DeSarno MJ, Durand H, Tromblee MA, Higgins ST (2015, October). Investigating changes in smoking topography upon initial exposure to very low nicotine content cigarettes. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
113. Zvorsky I, Redner R, Heil S, Sigmon S, Tidey JW, Stitzer M, Gaalema D, DeSarno M, Durand H, Bilodeau T, Higgins ST (2015, October). Demand for cigarettes varying in nicotine content in smokers from vulnerable populations: A pilot study. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
114. Jensen J, Koopmeiners J, Tidey J, Donny E, Hatsukami D (2015, October). Effects of reduced nicotine content cigarettes on measures of cigarette dependence. Presented at the annual NIH Tobacco Regulatory Science conference, Bethesda, MD.
115. Smith TT, Cassidy RN, Tidey JW, Luo X, Le CT, Hatsukami DK, Donny EC (2015, October). Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: Results from a multi-site clinical trial. Presented at the 3<sup>rd</sup> annual Vermont Center on Behavior and Health conference, Burlington, VT.
116. Miller ME\*, Tidey JW, Higgins ST (2016, March). Characterizing e-cigarette and other tobacco product use among smokers with anxiety and controls. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Chicago, IL.
117. Denlinger RL\*, Tidey JW, Hatsukami DK, Pacek LR, Donny EC (2016, March). The impact of smoking menthol cigarettes on health risk perceptions during a six-week clinical trial. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Chicago, IL.
118. Cassidy RN, Colby SM, Tidey JW, Jackson K, Cioe P, Krishnan-Sarin S, Hatsukami DK (2016, March). Adolescents' response to nicotine dose in cigarettes: Preliminary evidence from a within-subjects laboratory study (March, 2016). Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Chicago, IL.
119. DiGuseppi G, Cassidy RN, Tidey JW, Colby SM (2016, March). The impact of nicotine dose on the reinforcing value of cigarettes in adolescents: Results from a within-subjects laboratory study. Presented at the Rapid Fire Session at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Chicago, IL.
120. Streck JM, Sigmon SC, Heil SH, Stitzer ML, Tidey JW, Gaalema DE, DeSarno MJ, Balas K, Durand HJ, Higgins ST (2016, March). Does nicotine function differently in opioid-dependent versus nondependent smokers? Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Chicago, IL.
121. Strasser AA, Tidey JW, McClernon FJ, Benowitz NL, Hatsukami DK, Donny EC (2016, March). Characterizing smoking topography in response to smoking novel reduced nicotine content research cigarettes. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Chicago, IL.

122. Higgins ST, Heil SH, Sigmon SC, Tidey JW, Gaalema DE, Stitzer ML, Vandrey R, Durand H, De Sarno M, Arger CA, Miller ME\*, Pacek LR, Davis DR, Streck JM (2016, March). Response to varying the nicotine content level in cigarettes: Acute effects in vulnerable populations. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Chicago, IL.
123. Morford ZH, Gaalema DE, Balas K, Heil SH, Sigmon SC, Stitzer ML, Tidey JW, Higgins, ST (2016, May). Recruiting among vulnerable populations via Facebook for participation in tobacco regulatory science research. Presented at the NIH Tobacco Regulatory Science Conference, Bethesda, MD.
124. Tidey JT, Heil SH, Gaalema DE, Miller ME\*, Higgins ST (2016, May). Smoking behavior and subjective effects in women with vs. without affective disorders. Presented at the NIH Tobacco Regulatory Science Conference, Bethesda, MD.
125. Miller ME\*, Tidey JW, Gaalema DE, Higgins ST (2016, May). Predictors of menthol use among smokers with mental illness. Presented at the NIH Tobacco Regulatory Science Conference, Bethesda, MD.
126. Streck JM, Sigmon SC, Heil SH, Stitzer ML, Tidey JW, Gaalema DE, DeSarno MJ, Durand HJ, Higgins ST (2016, May). Subjective effects of smoking among opioid-maintained individuals: Results from a pilot study examining reduced nicotine content cigarettes. Presented at the NIH Tobacco Regulatory Science Conference, Bethesda, MD.
127. Tidey JW, Denlinger-Apte R\*, Hatsukami D, Donny E (2016, June). Environmental smoke exposure among daily smokers with low vs. high educational attainment. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Palm Springs, CA.
128. Denlinger-Apte R\*, Tidey JW, Hatsukami D, Donny E (2016, June). Associations between educational attainment, smoking quit attempts and interest in quitting. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Palm Springs, CA.
129. Donny EC, Smith TT, Cassidy RN, Tidey JW, Luo X, Le CT, Hatsukami DK (2016, June). Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: Results from a multi-site clinical trial. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Palm Springs, CA.
130. Claborn KR, Tidey J, Ramsey S (2016, June). Qualitative study investigating provider perspectives on care coordination for people living with HIV who use drugs. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Palm Springs, CA.
131. Miller ME, Cassidy R, Tidey J, Colby S, Denlinger-Apte R\* (2016, October). Associations between cigarette price sensitivity and little cigar use in adolescents. Presented at the 4<sup>th</sup> annual Vermont Center on Behavior and Health conference, Burlington, VT.
132. Miller ME\*, Tidey J, Denlinger-Apte R\*, Hatsukami D, Donny EC (2016, November). Little cigar and cigarillo use among vulnerable populations. Presented at the annual Tobacco Centers for Regulatory Science (TCORS) grantee meeting, Bethesda, MD.
133. Villanti AC, Gaalema DE, Tidey JW, Heil SH, Sigmon SC, Hughes JR, Higgins ST (2017, August). Characteristics of young adult cigarette smokers in the U.S.: Findings from the 1st wave of the PATH Study, 2013-2014. Presented at the Northeast Regional Idea Conference 2017, Burlington, VT.

134. Murphy CM, MacKillop J, Martin RA, Tidey JW, Cassidy R, Rohsenow DJ. (2017, October). Brief assessment of cigarette demand (BACD): Initial development and validation results. Presented at the 5th Annual Conference of the Vermont Center on Behavior and Health: Tobacco Regulatory Science, Burlington, VT.
135. Cassidy RN, Tidey JW, Cao Q, Colby SM, McClernon FJ, Koopmeiners JS, Hatsukami D, Donny EC (2017, October). Young adult smokers' response to very low nicotine content cigarettes: Evidence from a randomized controlled trial. Presented at the Tobacco Centers for Regulatory Science grantee meeting, Bethesda, MD.
136. Davis D, Bergeria CL, Streck JM, Bunn JY, Gaalema DE, Heil SH, Sigmon SC, Stitzer M, Tidey JW, Higgins ST. (2017, October). Examining how users of mentholated and non-mentholated cigarettes rate research and usual brand cigarettes. Presented at the Tobacco Centers for Regulatory Science grantee meeting, Bethesda, MD.
137. Smith TT, Koopmeiners JS, Tessier K, Denlinger-Apte RL\*, Lane T, Tidey JW, Murphy S, Hatsukami DK, Donny EC (2017, October). A clinical trial investigating the impact of very low nicotine content cigarettes and transdermal nicotine in smokers not trying to quit. Presented at the Tobacco Centers for Regulatory Science grantee meeting, Bethesda, MD.
138. Denlinger-Apte R\*, Cioe P, Goodwin C, Miller M, Tidey J (2017, October). Very low nicotine content cigarettes in smokers with schizophrenia and bipolar disorder: trial description and baseline participant characteristics. Presented at the Tobacco Centers for Regulatory Science grantee meeting, Bethesda, MD.
139. Donny EC, Smith TT, Koopmeiners JS, Tessier K, Denlinger-Apte RL\*, Lane T, Tidey JW, Murphy S, Hatsukami DK. Randomized trial of the impact of very low nicotine content cigarettes and transdermal nicotine (2018, February). Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Baltimore, MD.
140. Higgins ST, Sigmon SC, Tidey JW, Heil SH, Gaalema DE, Hughes JR, Stitzer ML, Arger CA, Miller ME, Bergeria CL, Davis DR, Streck J, Kurti AN, Redner R, Reed DD, Bunn JY, Priest JS, Skelly JM (2018, February). Nicotine levels and addiction potential of cigarette smoking in vulnerable populations. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Baltimore, MD.
141. Cassidy RN, Miller ME, Colby SM, Tidey JW, Jackson KJ, DiGuseppi G, Hatsukami DK (2018, February). The impact of nicotine dose on the reinforcing value of cigarettes in adolescents. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Baltimore, MD.
142. Rohsenow DJ, Martin RA, Tidey JW, Colby SM, Monti PM (2018, February). Very low nicotine cigarettes in smokers with SUD: Smoking, substance use effects. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Baltimore, MD.
143. Denlinger-Apte R\*, Tidey JW, Koopmeiners JS, Hatsukami DK, Donny EC (2018, February). Assessing support for smokers' opinions regarding a potential menthol cigarette ban among smokers enrolled in a clinical trial of reduced-nicotine cigarettes. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Baltimore, MD.
144. Cassidy RN, Long V, Tidey JW, Colby SM (2018, March). The value of vaping: Laboratory validation of an e-cigarette purchase task in tank-style vape users. Presented at the Collaborative Perspectives on Addiction Annual Conference, Tampa, FL.

145. Bergeria CL, Heil SH, Sigmon SC, Tidey JW, Gaalema DE, Hughes JR, Stitzer ML, Arger CA, Durand H, Bunn JY, Priest JS, Miller ME, Davis DR, Streck JM, Skelly JM, Tromblee M, Higgins ST (2018, June). Assessing correspondence between subjective effects measures and concurrent choice data in a laboratory study evaluating the effects of cigarettes with varying levels of nicotine Presented at the annual meeting of the Conference on Problems of Drug Dependence (CPDD), San Diego, CA.
146. Streck JM, Sigmon SC, Parker MA, Stitzer ML, Heil SH, Tidey JW, Gaalema DE, Bergeria CL, Davis DR, Priest J, Barrows A, Rothman M, Hughes JR, Higgins ST (2018, June). Subjective effects of cigarettes varying in nicotine content among opioid-maintained individuals. Presented at the annual meeting of the Conference on Problems of Drug Dependence (CPDD), San Diego, CA.
147. Rohsenow DJ, Martin RA, Colby SM, Gresko SA, Tidey JW (2018, June). Relationship of trait anger among smokers with SUD to nicotine dependence, barriers to quitting smoking, intolerance for discomfort, smoking, craving and compliance with smoking cessation medication. Presented at the annual meeting of the Conference on Problems of Drug Dependence (CPDD), San Diego, CA.
148. Tidey JW, Miller ME, Cassidy R, Denlinger-Apte R\*, (2018, June). Reinforcing efficacy of cigarettes vs. little cigars in smokers differing in socioeconomic status. Presented at the annual meeting of the Conference on Problems of Drug Dependence (CPDD), San Diego, CA.
149. Davis DR, Bergeria C, Streck J, Miller ME, Bunn J, Gaalema D, Heil SH, Sigmon SC, Stitzer ML, Tidey JW, Higgins ST (2018, June). Impact of mentholation as a moderator of nicotine dose on relative reinforcing and subjective effects. Presented at the annual meeting of the Conference on Problems of Drug Dependence (CPDD), San Diego, CA.
150. Tidey JW, Denlinger-Apte R\*, Colby SM, Cioe P, Goodwin C, Miller ME, Lindgren BR, Rubin N, Hatsukami DK, Donny EC (2018, June). Effects of 6-week use of very low nicotine content cigarettes in smokers with serious mental illness. Presented at the Tobacco Regulatory Science meeting, Bethesda, MD.
151. Cassidy RN, Long V, Tidey JW, Colby SM (2018, June). Validation of an e-cigarette purchase task in advanced generation device users. Presented at the Tobacco Regulatory Science meeting, Bethesda, MD.
152. Gaalema DE, Tidey JW, Sigmon SC, Heil SH, Stitzer ML, DeSarno M, Hughes JR, Higgins ST (2018, June). Anxiety and depressive symptomatology and nicotine dose: Effects on smoking topography within vulnerable populations. Presented at the Tobacco Regulatory Science meeting, Bethesda, MD.
153. Bloom EL, Hunt LE, Tidey J, Ramsey SE (2019, March). Pilot trial of contingency management for the prevention of weight gain after smoking cessation. Presented at the annual meeting of the Society for Behavioral Medicine, Washington, DC.
154. Cassidy RN, Aston ER, Tidey JW, Colby SM (2019, April). Behavioral economic predictors of cigarette dependence and use in adolescents. Presented at the annual Collaborative Perspectives on Addiction meeting, Providence, RI.
155. Denlinger-Apte R\*, Tidey J, Lindgren B, Rubin N, Moulding C, DeAtley T\*, Colby SM, Cioe P, Hatsukami D, Donny E (2019, Feb). Smoking topography characteristics during a six-week trial of very low nicotine content cigarettes in smokers with serious mental illness. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco, San Francisco, CA.

156. Denlinger-Apte RL\*, Kotlyar M, Koopmeiners JS, Tidey JW, Luo X, Jensen JA, Donny EC, Hatsukami DK (2019, Feb). Effects of menthol flavoring on smoking behavior and biomarkers of exposure in smokers using very low nicotine content cigarettes for 20 weeks. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco, San Francisco, CA.
157. Cassidy RN, Long V, Tidey JW, Colby SM (2019, Feb). Further validation of an e-cigarette purchase task: A within-subject comparison of two units of e-cigarette consumption. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco, San Francisco, CA.
158. Tidey JW, Denlinger-Apte R\*, Colby SM, Cioe P, Goodwin C, Lindgren BR, Rubin N, Hatsukami DK, Donny EC (2019, Feb). Effects of 6-week use of very low nicotine content cigarettes in smokers with serious mental illness. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco, San Francisco, CA.
159. Balestrieri SG, Stein LAR, Martin R, Clair-Michaud M, Lebeau R, Kahler C, Tidey J, Monti P, Rohsenow D (2019, March). Behavioral interventions for smoking cessation in incarcerated and at-risk youth. Presented at the annual meeting of the Society for Behavioral Medicine, Washington DC.
160. Rohsenow DJ, Martin RA, Tidey JW (2019, June). Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement. Presented at the annual meeting of the College on Problems of Drug Dependence, San Antonio, TX.
161. DeAtley T\*, Denlinger-Apte R, Cioe P, Colby S, Cassidy R, Clark M, Donny E, Tidey J (2019, October). Psychosocial mechanisms associated with tobacco use in smokers with and without serious mental illness. Presented at the 7<sup>th</sup> Annual Vermont Center on Behavior and Health Conference, Burlington, VT.
162. Rohsenow DJ, Martin RA, Tidey JW, Colby SM (2019, October). Effects of very low-nicotine cigarettes on smoking and substance use/cravings. Presented at the 7<sup>th</sup> Annual Vermont Center on Behavior and Health Conference, Burlington, VT.
163. Carroll DM, Dermody SS, Denlinger-Apte R\*, Cassidy R, Allen AM, Smith T, Lindgren B, Pacek L, Tidey JW, Donny EC, Hatsukami DK (2019, October). Does the optimal approach to nicotine reduction in cigarettes differ by race, gender, or education? Presented at the annual NIH Tobacco Regulatory Science meeting, Bethesda, MD.
164. Cassidy RN, Tidey JW, Cao Q, Colby SM, McClernon FJ, Smith TT, Dermody S, Koopmeiners JS, Donny EC, Hatsukami D (2019, October). Young adult smokers' behavioral responses to gradual and immediate reduction of nicotine in cigarettes. Oral presentation at the NIH Tobacco Regulatory Science meeting, Bethesda, MD.
165. Cioe PA, Kahler CW, Tidey JW, Mercurio AN, Constantino CC, Kahler CW (2019, October). An open pilot to examine the feasibility, acceptability and health effects of electronic cigarettes in HIV-positive smokers. Presented at the annual NIH Tobacco Regulatory Science meeting, Bethesda, MD.
166. Davis DR, DeSarno MJ, Bergeria CL, Streck JM, Tidey JW, Sigmon SC, Heil SH, Gaalema DE, Stitzer ML, Higgins ST (2019, October). Examining the malleability of cigarette product preference. Presented at the annual NIH Tobacco Regulatory Science meeting, Bethesda, MD.

167. DeAtley T\*, Denlinger-Apte R\*, Cioe P, Colby S, Cassidy R, Clark M, Donny E, Tidey J (2019, October). Psychosocial mechanisms associated with tobacco use in smokers with and without serious mental illness. Oral presentation at the annual NIH Tobacco Regulatory Science meeting, Bethesda, MD.
168. Denlinger-Apte RL, Cassidy R, Tidey J (2019, October). Using the Experimental Tobacco Marketplace to assess potential effects of a menthol cigarette ban on alternative product purchasing. Oral presentation at the annual NIH Tobacco Regulatory Science meeting, Bethesda, MD.
169. Gaalema DE, Davis DR, Tyndale R, Tidey JW, Sigmon SC, Heil SH, Stitzer ML, DeSarno MJ, Caves O, Hughes JR, Higgins ST (2019, October). Nicotine Metabolite Ratio: Characterization within vulnerable populations and interactions with nicotine dose on measures of reinforcing efficacy. Presented at the annual NIH Tobacco Regulatory Science meeting, Bethesda, MD.
170. Higgins ST, Davis DR, DeSarno M, Garavan H, Caarani B, Heil SH, Sigmon SC, Gaalema DE, Tidey JW, Kurti AN, Villanti AC, Hughes JR, Lee D (2019, October). Characterizing differences in motivation to smoke among those differing in tobacco dependence severity. Presented at the annual NIH Tobacco Regulatory Science meeting, Bethesda, MD.
171. Rohsenow DJ, Martin RA, Tidey JW, Colby SM (2019, October). Very low nicotine cigarettes for smokers with SUD have no harmful effects on substance use or cravings. Presented at the annual NIH Tobacco Regulatory Science meeting, Bethesda, MD.
172. Cioe PA, Kahler CW, Tidey JW, Mercurio AN, Constantino CC, Kahler CW (2019, November). An open pilot to examine the acceptability and health effects of electronic cigarettes in HIV-positive smokers. Presented at the annual meeting of the Association for Nurses in AIDS Care (ANAC), Portland, OR.
173. Cassidy RN, DiLorenzo J, Tidey J, Colby SM. Adolescent response to using SPECTRUM cigarettes: Qualitative results from an ongoing clinical trial (2020, March). Presented at the annual meeting of the Society of Research on Nicotine and Tobacco, New Orleans, LA.
174. DeAtley T\*, Denlinger-Apte R, Cioe P, Colby S, Cassidy R, Clark M, Donny E, Tidey J (2020, March). Psychosocial mechanisms associated with tobacco use in smokers with and without serious mental illness. Presented at the annual meeting of the Society of Research on Nicotine and Tobacco, New Orleans, LA.
175. Denlinger-Apte RL\*, Cassidy RN, Carey K, Kahler C, Tidey JW. Using the experimental tobacco marketplace to assess potential effects of a menthol cigarette ban on alternative tobacco product purchasing (2020, March). Oral presentation at the annual meeting of the Society of Research on Nicotine and Tobacco, New Orleans, LA.
176. Denlinger-Apte RL\*, Koopmeiners JS, Tidey JW, Donny EC, Hatsukami DK. The effects of immediate versus gradual cigarette nicotine reduction among menthol and non-menthol smokers (2020, March). Symposium presentation at the annual meeting of the Society of Research on Nicotine and Tobacco, New Orleans, LA.
177. Dermody SS, Tessier K, al'Absi M, Denlinger-Apte R\*, Drobles D, Jensen J, Meier E, Pacek L, Tidey J, Vandrey R, Donny E, Hatsukami D (2020, March). Effects of a 20-week nicotine reduction intervention on smoking and alcohol outcomes among smokers. Presented at the annual meeting of the Society of Research on Nicotine and Tobacco, New Orleans, LA.

178. Koopmeiners JS, Gearhart E, Ling S, Hobbs BP, Kaizer AM, Donny EC, Hatsukami DK, Tidey JW (2020, March). Utilizing supplemental data for more precise estimation of the effect of very low nicotine content cigarettes in smokers with serious mental illness. Presented at the annual meeting of the Society of Research on Nicotine and Tobacco, New Orleans, LA.
179. Rohsenow DJ, Martin RA, Tidey JW, Colby SM (2020, March). Very low-nicotine cigarettes for smokers with SUD. Presented at the annual meeting of the Society of Research on Nicotine and Tobacco, New Orleans, LA.
180. Denlinger-Apte RL, Koopmeiners JS, Tidey JW, Luo X, Smith TT, Pacek LR, McClernon FJ, Jensen J, Colby S, Severson H, Donny EC, Hatsukami DK (2020, March). Support for a nicotine reduction policy among smokers enrolled in a 20-week trial of very low nicotine content cigarettes. Oral presentation at the annual meeting of the American Society of Preventive Oncology, Tucson, AZ.
181. Higgins ST, Tidey JW, Sigmon SC, Heil SH, Gaalema DE, Lee D, Hughes JR, Villant AC, Bunn J, Bergeria CL, Davis DR, Streck JM, DeSarno M, Priest J, MacLeod D, Barrows A, Markesich C, Harfmann R (2020, March). Randomized clinical trial examining reduced nicotine content cigarettes among smokers with psychiatric conditions or socioeconomic disadvantage. Presented at the annual meeting of the Society of Research on Nicotine and Tobacco, New Orleans, LA.
182. Cassidy RN, Tidey JW, Jackson K, Cioe P, Murphy S, Hatsukami D, Donny EC, Colby SM (2020, October). Nicotine reduction and adolescents: State of the science. Presented at the annual NIH TCORS grantee meeting (virtual).
183. DeAtley T\*, Cassidy R, Tidey J (2020, October). The relative reinforcing effects of very low nicotine content cigarettes (VLNCs) among smokers with serious mental illness (SMI). Oral presentation at the annual NIH TCORS grantee meeting (virtual).
184. Streck JM, Tidey JW, Davis DR, Bergeria CL, Harfmann R, Sigmon SC, Heil SH, Gaalema DE, Lee D, Hughes JR, Villanti AC, Bunn JY, Higgins ST (2020, October). Effects of intolerance for smoking abstinence discomfort on adherence to very low nicotine content cigarettes among smokers with psychiatric symptoms or socioeconomic disadvantage. Presented at the annual NIH TCORS grantee meeting (virtual).
185. Gaalema DE, Tidey JW, Sigmon SC, Heil SH, Lee D, Bunn J, Park C, Hughes JR, Higgins St. (2020, October). Unintended side effects? Effects of nicotine dose on use of other substances. Presented at the annual NIH TCORS grantee meeting, Bethesda, MD (virtual).
186. Wiley RC, Oliver AC, Snow MB, Bunn JY, Barrows AJ, Tidey JW, Lee D, Sigmon SC, Gaalema DE, Heil SH, Markesich C, Villanti AC, Higgins ST (2020, October). Smoking behavior among vulnerable populations in response to the COVID-19 pandemic. Presented at the annual NIH TCORS grantee meeting (virtual).
187. Cioe PA, Tidey JW, Mercurio AN, Constantino CC, Kahler CW (2020, November). Effects of electronic cigarette use on cardiovascular disease-related inflammatory biomarkers in HIV-positive smokers. Presented at the annual meeting of the Association for Nurses in AIDS Care (ANAC) (virtual).
188. DeAtley T\*, Sokolovsky A, Tidey J (2021, February 27). Mediation pathways of tobacco use among adult smokers with psychiatric symptoms: testing longitudinal mediation using the Population Assessment of Tobacco and Health (PATH) survey. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (virtual).

189. Snell LM\*, Tidey J (2021, February 27). Associations between nicotine knowledge and tobacco use behaviors among US adult smokers. Presented at to the annual meeting of the Society for Research on Nicotine and Tobacco (virtual).
190. Oliver AC, DeSarno M, Irvin CG, Kaminsky D, Tidey JW, Sigmon SC, Heil SH, Gaalema D, Lee D, Bunn JY, Davis DR, Streck JM, Gallagher T, Higgins ST. (2021, February 24). Fractional exhaled nitric oxide (FeNO) outcomes from a randomized clinical trial examining reduced nicotine content cigarettes among daily smokers with psychiatric conditions or socioeconomic disadvantage. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (virtual).
191. Wiley RC, Sigmon SC, DeSarno MJ, Bunn JY, Davis DR, Streck JM, Bergeria CL, Parker M, Heil SH, Gaalema DE, Tidey JW, Lee D, Hughes JR, Markesich C, Nesheim-Case R, Higgins ST (2021, February 24). Investigating the impact of opioid maintenance medication on nicotine metabolite ratio among vulnerable smokers. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (virtual).
192. Harfmann R, Bunn JY, Davis DR, Streck JM, Bergeria CL, Parker MA, Heil SH, Sigmon SC, Gaalema DE, Tidey JW, Lee D, Hughtes JR, Barrows A, Markesich C, Higgins ST (2021, February 24). Characterizing use of e-cigarettes in a randomized clinical trial investigating reduced-nicotine content cigarettes among smokers with psychiatric conditions or socioeconomic disadvantage. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco (virtual).
193. Adkins-Hempel M, Lundtvedt C, Pratt R, Becker S, Helseth S, Fu S, Tidey J, Japuntich S. (2021, April 12). Client and staff views on implementing proactive outreach for tobacco treatment at community mental health centers. Presented at to the annual meeting of the Society for Behavioral Medicine (virtual).
194. DeAtley T\*, Denlinger-Apte R, Donny E, Tidey J (2021, June). Support for tobacco regulatory approaches among individuals with mental health conditions. Presented at the annual meeting of the College on Problems of Drug Dependence (virtual).
195. Wiley RC, Oliver AC, Snow MB, Bunn JY, Barrows AJ, Tidey JW, Lee D, Sigmon SC, Gaalema DE, Heil SH, Markesich C, Villanti AC, Higgins ST (2021, June). The impact of the COVID-19 pandemic on smoking among vulnerable populations. Presented at the annual meeting of the College on Problems of Drug Dependence (virtual).
196. Browning K, DeSarno M, Davis D, Streck J, Bergeria C, Harfmann R, Parker M, Heil S, Sigmon S, Gaalema D, Tidey J, Lee D, Hughes J, Tetreault H, Markesich C, Higgins S (2021, June). The relation between the Brief Wisconsin Inventory of Smoking Dependence Motives, individual differences in nicotine consumption, and the relative reinforcing value of cigarettes in vulnerable populations of smokers. Presented at the annual meeting of the College on Problems of Drug Dependence (virtual).
197. Harfmann R, Heil S, Bunn J, Tidey J, Snell LM\*, Davis D, Streck J, Bergeria C, Parker M, Sigmon S, Gaalema D, Lee D, Hughes J, Markesich C, Orr E, Higgins S (2021, June). Examining the effect of very low nicotine content cigarettes on weight among smokers with psychiatric conditions or socioeconomic disadvantage. Presented at the annual meeting of the College on Problems of Drug Dependence (virtual).
198. Monnig MA, Treloar Padovano H, Sokolovsky A, DeCost G, Aston E, Haass-Koffler C, Czapary C, Tidey J, Monti PM, Ahluwalia J (2021, June). Alcohol and opioid use are associated with adherence to CDC guidelines to reduce the spread of COVID-19. Presented at the annual meeting of the Research Society on Alcoholism (virtual).

199. Denlinger-Apte RL\*, Cassidy R, Tidey JW (2021, October). Decision-making during the Experimental Tobacco Marketplace task: A mixed-methods study with menthol smokers. Presented at the annual NIH Tobacco Regulatory Science meeting (virtual).
200. Snell LM\*, Reed G\*, Tidey J, Bunn J, Harfmann R, Heil S, Sigmon S, Gaalema D, Lee D, Villanti A, Hughes J, Higgins S (2021, October). Predictors of compliance among vulnerable populations of adults assigned to smoke very low nicotine content cigarettes. Presented at the annual NIH Tobacco Regulatory Science meeting (virtual).
201. Harfmann RF, Heil SH, Bunn JY, Tidey JW, Snell LM\*, Davis DR, Streck JM, Bergeria CL, Parker MA, Sigmon SC, Gaalema DE, Lee D, Hughes JR, Higgins ST (2021, October). Examining the effect of very low nicotine content cigarette exposure on weight among smokers with psychiatric conditions or socioeconomic disadvantage. Presented at the annual NIH Tobacco Regulatory Science meeting (virtual).
202. Mead-Morse E\*, Cassidy R, Tidey J, Delnevo C, Litt M (2021, October). Using the purchase task to examine the relative reinforcing values of cigarettes and cigars among young adult dual users. Presented at the annual NIH Tobacco Regulatory Science meeting (virtual).
203. Denlinger-Apte RL\*, Lockhart DE, Strahley AE, Cassidy RN, Donny EC, O'Connor RJ, Tidey JW (2022, March). "Why ban menthol cigarettes when you can smoke regular cigarettes?" – interviews about a menthol ban with people who smoke menthol cigarettes. Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco.
204. Lockhart DE, Denlinger-Apte RL\*, Stahley AE, Cassidy RN, Donny EC, O'Connor RJ, Tidey JW (2022, March). LGBTQ+ reaction to a menthol cigarette ban: A qualitative study. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco.
205. DeAtley T\*, Harrison A, Camacho B, Cassidy R, Kuo C, Higgins S, Tidey J (2022, March). Subjective experiences, contexts, and risk perceptions of very low nicotine content cigarettes and electronic cigarettes among people with affective disorders who smoke. Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco.
206. Snell LM\*, Reed G\*, Tidey J, Bunn J, Harfmann R, Heil S, Sigmon S, Gaalema D, Lee D, Villanti A, Hughes J, Higgins S (2022, March). Predictors of compliance among vulnerable populations of adults assigned to smoke very low nicotine content cigarettes. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco.
207. Erath T, Higgins ST, DeSarno M, Gaalema DE, Leventhal AM, Sigmon SC, Heil SH, Tidey JW, Lee D (2022, March). A behavioral economic examination of differences in the relative reinforcing value of cigarette smoking among those with cumulative vulnerabilities. Poster presentation at the annual meeting of the Society for Research on Nicotine and Tobacco.
208. Mead-Morse E\*, Cassidy R, Tidey J, Delnevo C, Litt M (2022, March). Using the purchase task to determine substitutability of little cigars/cigarillos and cigarettes in young adult dual users. Poster presentation at the annual meeting of the Society for Research on Nicotine and Tobacco.
209. Mead-Morse E\*, Cassidy R, Tidey J, Delnevo C, Litt M (2022, March). Validity of a little cigars/cigarillos purchase task in dual users of cigars and cigarettes. Poster presentation at the annual meeting of the Society for Research on Nicotine and Tobacco.
210. Wagener TL, Mehta T, Hinton A, Schulz J, Erath T, Tidey J, Villanti AC (2022, March). Addiction potential of combustible menthol cigarette alternatives: A randomized clinical trial. Poster presentation at the annual meeting of the Society for Research on Nicotine and Tobacco.

211. Katz BR, Gaalema DE, Tidey JW, Sigmon SC, Heil SH, Lee D, DeSarno M, Higgins ST (2022, March). Discrepancies in the relation between smoking and performance across different tests of executive function. Poster presentation at the annual meeting of the Society for Research on Nicotine and Tobacco.
212. Schulz JA, Erath T, Mehta T, Hinton A, Tidey J, Villanti AC, Wagener TL (2022, May 27). Abuse liability of potential menthol cigarette substitutes: A randomized controlled trial in adults who smoke menthol cigarettes. Poster presentation at the annual meeting of the Association for Behavior Analysis (ABAI), Boston, MA.
213. Sokolovsky AW\*, McQuaid EL, Ahluwalia JS, Monti PM, Tidey JW (2022, June 10). Complementary electronic cigarettes for harm reduction among adult smokers with asthma: A research protocol. Poster presentation at the 2022 IDeA Symposium: Emerging Areas of Science. Providence, RI.
214. Denlinger-Apte RL, Rubin N, Rubenstein D, Benowitz N, Carroll DM, Dermody S, Donny EC, Jenson JA, Koopmeiners J, Luo X, McClernon FJ, Smith TT, Tidey JW, Hatsukami DK. (2022, October 24). Dependence as a moderator of treatment effects after 20 weeks of exposure to very low nicotine cigarettes. Oral presentation at the Fall TCORS grantee meeting, Bethesda, MD.
215. Gaalema DE, Tidey JW, Sigmon SC, Heil SH, Lee DC, DeSarno M, Higgins ST (2022, October 24). Sex differences in measures of cigarette exposure. Presented at the Fall TCORS grantee meeting, Bethesda, MD.
216. Gaalema DE, Coleman S, Heil S, Lee D, Menson K, Sigmon S, Tidey J, Higgins S (2022, October 24). Research with vulnerable populations at the UVM TCORS – Approaches for Inclusion and Lessons Learned. Presented at the Fall TCORS grantee meeting, Bethesda, MD.
217. Katz BR, Middleton WA, Gaalema DE, Tidey JW, Sigmon SC, Heil SH, Lee DC, DeSarno M, Higgins ST (2022, October 24). Cigarette smoking and executive function: Experimental effects of very low nicotine content cigarettes. Presented at the Fall TCORS grantee meeting, Bethesda, MD (virtual).
218. Coby SM, Cassidy RN, Denlinger-Apte RL, Moulding CG, Godin J, Tidey JW (2022, October 24). Research in youth who use tobacco and nicotine vaping products: challenges and lessons learned. Presented at the Fall TCORS grantee meeting, Bethesda, MD (virtual).
219. Japuntich SJ, Helseth SA, Adkins-Hempel M, Gutierrez N, Pratt R, Fu S, Tidey J, Evins AE, Dunsiger S, Becker SJ (2022, December 13). Implementing chronic care treatment for tobacco into community mental health care. Paper presentation at AcademyHealth 2023 Annual Research Meeting, Seattle, WA.
220. Denlinger-Apte R, Cassidy R, Donny E, Godin J, Hatsukami D, Strahely A, Tidey J, Wiseman K, Colby S. “Reducing the amount of nicotine won’t decrease the amount of smokers” – qualitative reactions to a low nicotine product standard for cigarettes from adolescents who smoke. (2023, March 1). Presented at the annual conference of the Society for Research on Nicotine & Tobacco (SRNT), San Antonio, TX.
221. Japuntich SJ, Adkins-Hempel M, Gutierrez Sacasa N, Becker S, Helseth S, Pratt R, Dunsiger S, Tidey J, Evins AE, Fu S (2023, March 1-4). Effectiveness of proactive tobacco treatment in a certified community behavioral health clinic. Presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), San Antonio, TX.

222. Villanti AC, Hinton A, Schulz J, Erath TG, Mehta T, Tidey J, Businelle M, Wagener TL (2023, March 1-4). Substitutability of combustible menthol cigarette alternatives: A randomized clinical trial. Society for Research on Nicotine and Tobacco (SRNT), San Antonio, TX.
223. Erath TG, Schulz JA, Hinton A, Mehta T, Tidey J, Wagener TL, Villanti AC (2023, March 1-4). Predicting response effort to use usual brand menthol cigarettes under a simulated menthol cigarette ban. Society for Research on Nicotine and Tobacco (SRNT), San Antonio, TX.
224. Cassidy RN, Bello M, Tidey JW, Colby SM (2023, March 1-4). Using the experimental tobacco marketplace to model adolescent responses to a reduced nicotine product standard. Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), San Antonio, TX.
225. Snell LM, Avila JC, Tidey JW (2023, March 1-4). Investigating potential barriers to smoking cessation and harm reduction among adults with mental health conditions. Society for Research on Nicotine and Tobacco (SRNT), San Antonio, TX.
226. Bello MS, Colby SM, Tidey JW, Cassidy, RN (2023, March 1-3). Racial/ethnic differences in the effects of reduced nicotine content cigarettes among adolescents who smoke. In MS Bello (Chair), Novel interventions for adolescent substance use. Symposium presentation at the 11th Collaborative Perspectives on Addiction annual scientific meeting (APA Division 50). Albuquerque, NM.
227. Katz BR, Middleton WA, Gaalema DE, Tidey JW, Sigmon SC, Heil SH, Lee DC, DeSarno M, Higgins ST (2023, June 17-21). Cigarette smoking and executive function: Experimental effects of very low nicotine content cigarettes. Conference on Problems of Drug Dependence, Denver, CO.
228. Gaalema DE, Tidey JW, Sigmon SC, Heil SH, Lee DC, DeSarno M, Higgins ST (2023, June 17-21). Effects of nicotine dose in cigarettes on symptoms of depression and anxiety. Conference on Problems of Drug Dependence, Denver, CO.
229. Godin J, Tidey J, DeSarno M (2023, Oct 5-6). Associations between gender and recent cannabis use on reported depression and anxiety symptoms within individuals who smoke cigarettes. Presented at the Vermont Conference on Behavior and Health, Burlington VT.
230. Carroll DM, Jensen J, Luo X, Cao Q, Hecht S, Murphy S, Tidey J, Colby S, Strasser AA, Benowitz N, McClernon FJ, Donny EC, Hatsukami DK (2023, Oct 16-18). Randomized controlled trial of a nicotine product standard in cigarettes in the context of a diverse nicotine and tobacco marketplace. Tobacco Regulatory Science Meeting, Bethesda, MD.
231. Gaalema D, Katz B, Tidey J, Sigmon S, Heil S, Lee D, DeSarno M, Higgins S (2023, Oct 16-18). Effects of nicotine dose in cigarettes on symptoms of depression and anxiety. Tobacco Regulatory Science Meeting, Bethesda, MD.
232. Thrailkill EA, Khadanga S, Tidey JW (2023, Oct 16-18). Perceptions of 22<sup>nd</sup> Century VLNC cigarette marketing materials among vulnerable populations. Tobacco Regulatory Science Meeting, Bethesda, MD.
233. Higgins ST, Tidey JW, Sigmon SC, Gaalema DE, Lee D, Heil SH, DeSarno M, Wiley R, Plucinski S, Orr E, Cioe P, Klemperer EM (2023, Oct 16-18). Availability of e-cigarettes and flavored e-liquids may enhance the effects of a nicotine product standard on smoking in vulnerable populations. Tobacco Regulatory Science Meeting, Bethesda, MD.

234. Helseth S, Pratt R, Adkins-Hempel M, Lundtvedt C, Becker S, Fu S, Tidey J, Evins AE, Dunsiger S, Japuntich S (2024, June 29-July 2). Acceptability of integrating tobacco cessation services into community behavioral health clinics: Client and provider perspectives. Poster presented at the 16<sup>th</sup> Annual Conference on the Science of Dissemination and Implementation, Washington DC.
235. Nolder KA, Sigmon SC, Heil SH, Tidey JW, Gaalema DE, DeSarno MJ, Higgins ST (2025, March 15). Reduced nicotine content cigarettes and access to e-cigarettes in vulnerable populations: Effects on the modified cigarette and e-cigarette evaluation questionnaires. Oral presentation at the Society for Research on Nicotine and Tobacco annual meeting, New Orleans, LA.
236. Smith TT, Luo X, Benowitz NL, McClernon FJ, Strasser AA, Tidey JW, Donny EC, Hatsukami DK (2025, March 13). The impact of nicotine reduction on cigarette reinforcement value within a marketplace containing alternative nicotine delivery products: A secondary analysis of a multi-site trial. Poster presentation Society for Research on Nicotine and Tobacco annual meeting, New Orleans, LA.
237. Klemperer EM, DeSarno M, Plucinski S, Feinstein MJP, Wiley RC, Sigmon SC, Tidey JW, Heil SH, Gaalema DE, Lee DC, Higgins ST (2025, March 12-15). Cigarette reduction: frequency of e-cigarette use mediates effects in 3 randomized controlled trials of reduced nicotine cigarettes with tobacco vs. preferred flavored e-cigarettes in high-risk populations. Oral presentation at the Society for Research on Nicotine and Tobacco annual meeting, New Orleans, LA.
238. Bello MS, Boyle HK, Chavez SJ, Strowger M, Maglalang DD, Murphy CM, Tidey JW, Colby SM, Cassidy RN (2025, March 14). Impact of reduced-nicotine content cigarettes on behavioral economic demand for cigarettes: differences among sexual minority and heterosexual youth who smoke. Poster presentation at the Society for Research on Nicotine and Tobacco annual meeting, New Orleans, LA.
239. Wiley RC, DeSarno MJ, Higgins ST, Sigmon SC, Tidey JW, Heil SH, Gaalema DE, Lee DC, Klemperer EM, Menson KE, Cioe PA, Plucinski S, Orr E (2025, March 14). Use of cooling flavored e-cigarettes associated with greatest decreases in cigarette consumption in 3 randomized controlled trials of reduced nicotine cigarettes. Poster presentation at the Society for Research on Nicotine and Tobacco annual meeting, New Orleans, LA.
240. Gaalema DE, Menson K, Katz BR, Tidey JW, Sigmon SC, Heil SH, Lee DC, Plucinski S, DeSarno M, Higgins ST (2025, March 12-15). Cardiopulmonary effects of very low nicotine content cigarettes with and without access to e-cigarettes in vulnerable populations. Poster presentation at the Society for Research on Nicotine and Tobacco annual meeting, New Orleans, LA.
241. Cassidy RN, Bello MS, Tidey JW, Colby SM (2025, April 3-5). Demand for cigarettes and Juul pods among early young adults who use both products. Poster presentation at the Collaborative Perspectives on Addiction (APA Div 50) Annual Meeting, Providence, RI.
242. Godin J, Colby SM, Cassidy RN, Tidey JW, Padovano HT, Bello MS, Goodwin G (2025, April 3-5). The relationship between smoking and vaping expectancies and depression in emerging young adults. Poster presentation at the Collaborative Perspectives on Addiction (APA Div 50) Annual Meeting, Providence, RI.

243. Klemperer EM, Luo X, Strayer LG, Cao Q, Carroll DM, Donny EC, McClernon FJ, Benowitz NL, Strasser A, Tidey J, Hatsukami DK (2025, June). Dual use and combusted tobacco abstinence one month after a randomized clinical trial of reduced nicotine cigarettes in a marketplace with alternative nicotine delivery systems. Oral presentation at the College on Problems of Drug Dependence annual meeting, New Orleans, LA.
244. Cioe PA, Lechner W, Stang GS, Kahler CW, Tasima KT, Tidey JW (2025, Nov 2-5). The effects of switching to the standardized research electronic cigarette (SREC) in people with HIV who smoke. American Public Health Association Annual Meeting, Washington, DC.
245. Arthur K, Padovano HT, Bello M, Tidey J, Cioe P, Donny E, Colby S, Cassidy R (2026, March 7). The impact of reducing nicotine content on emerging adults' use of cigarettes and alternative nicotine products: Results from a randomized clinical trial. Poster presentation at the Society for Research on Nicotine and Tobacco annual meeting, Baltimore, MD.
246. Silva M, Siegel L, Li K, Donny E, Hatsukami D, Higgins ST, Tidey JW, Koopmeiners JS, Huling J. Estimating the effect of very low nicotine content cigarettes from representative samples of the United States population of people who smoke. Society for Research on Nicotine and Tobacco annual meeting, Baltimore, MD.
247. Stang GS, Lechner WV, Kahler CW, Tashima KT, Eissenberg T, Tidey JW, Cioe PA (2026, March 7). Perceived health risks of cigarettes, e-cigarettes, and no tobacco use among people with HIV. Poster presentation at the Society for Research on Nicotine and Tobacco annual meeting, Baltimore, MD.
248. Regnier SD, Stoops WW, Tillson MD, Surratt HL, Knudsen HK, Tidey JW (2026, March 6). Creating a path toward effective tobacco treatment for people with disabilities. Oral presentation at the Society for Research on Nicotine and Tobacco annual meeting, Baltimore, MD.
249. White CM, Koopmeiners JS, Cassidy RN, Colby SM, Denlinger-Apte RL, McClernon FJ, Strasser AA, Tidey JW, Hatsukami DK, Donny EC. Early nonadherence and e-cigarette use are significantly associated with smoking outcomes in a 12-week randomized controlled trial mimicking nicotine marketplace conditions under a low-nicotine cigarette standard. Society for Research on Nicotine and Tobacco annual meeting, Baltimore, MD.
250. Nolder KA, Sigmon SC, Heil SH, Tidey JW, Gaalema DE, Lee DC, Klemperer EM, DeSarno MJ, Higgins ST (August 6-8, 2026). Response to reduced nicotine cigarettes and e-cigarettes: effects of sex. American Psychological Association, Division 208, annual meeting, Washington, DC.

#### Regular (Non-Invited) Presentations - International

1. Tidey JW, O'Neill SC, Higgins ST (1999, June). Effects of contingent monetary reinforcement and transdermal nicotine on cigarette smoking by schizophrenics. Presented at the 61<sup>st</sup> annual meeting of the College on Problems of Drug Dependence, Acapulco, Mexico. In Harris LS (Ed.), Problems of Drug Dependence 1999, NIDA Research Monograph No. 180. Washington D.C.: U.S. Government Printing Office, 203.
2. Tidey JW, Rohsenow D, Swift R, Monti P, Kaplan G (2002, June). Affective and physiological responses to smoking cues in smokers with schizophrenia. Presented at the 64<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, Quebec, Canada. Drug and Alcohol Dependence, 66, S182.

3. Rohsenow DJ, Tidey J, Miranda R, Monti P, and Swift R (2005, March). Effects of olanzapine on urge to smoke, withdrawal and smoking reinforcement. Paper presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the European Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
4. Rohsenow DJ, Martin R, Tidey J, Monti P, Colby S and Swift R (2005, March). Motivational and contingency interventions for unmotivated smokers in substance abuse treatment. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the European Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
5. Tidey J, Rohsenow D, Kaplan G, Swift R (2005, March). Smoking topography in schizophrenics, reliabilities and correlations among measures. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the European Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
6. Tidey J, Rohsenow D, Kaplan G, Swift R (2005, March). Smoking urges and topography in schizophrenics who take typical vs. atypical antipsychotics. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the European Society for Research on Nicotine and Tobacco, Prague, Czech Republic.
7. McGeary JE, Rohsenow DJ, Tidey JW, Miranda, R, Swift RM, Sirota AD, Monti PM (2006, October). A pharmacogenetic study of olanzapine for urge to smoke and nicotine withdrawal. Presented at the annual meeting of the World Congress of Psychiatric Genetics, Cagliari, Italy.
8. McGeary C, McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Miranda, R, MacKillop J, Swift RM (2006, October). Alcohol endophenotypes and the val158met polymorphism of the COMT gene. Presented at the annual meeting of the World Congress of Psychiatric Genetics, Cagliari, Italy.
9. Sirota A, Rohsenow D, MacKinnon S, Martin R, Kaplan G, Monti P, Almeida A, Tidey J, Swift R (2007, June). Tolerance for smoking discomfort: A new questionnaire of ability to handle nicotine withdrawal and cravings. Presented at the 69<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, Quebec City, Quebec, Canada.
10. Tidey J, Rohsenow D, Kaplan G, Swift R (2007, June). Depression relief from smoking in smokers with schizophrenia compared to non-psychiatric heavy-smoking controls. In Tidey J (Chair) and Martins S (Co-Chair), oral communications session entitled Comorbidity: Double Trouble. Presented at the 69<sup>th</sup> annual meeting of the College on Problems of Drug Dependence, Quebec City, Quebec, Canada.
11. Tidey JW, Rohsenow DJ (2008, September). Intention to quit moderates the effects of bupropion on urge to smoke. Presented at the 8<sup>th</sup> annual meeting of the European Society for Research on Nicotine and Tobacco, Rome, Italy.
12. Brazil LA, Colby SM, Murphy JG, Tidey JW, Kahler CW (2009, April). A comparison of two approaches to measuring the relative reinforcement value of smoking in adolescent smokers. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and European Society for Research on Nicotine and Tobacco, Dublin, Ireland.
13. Colby S, Murphy J, Brazil L, Tidey J, Kahler C, Rohsenow D, Monti P (2009, April). The Cigarette Purchase Task: Validating a measure of the relative reinforcing efficacy of smoking in adolescents. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and European Society for Research on Nicotine and Tobacco, Dublin, Ireland.

14. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM (2009, April). Sensorimotor and nicotine replacement for smoking in smokers with schizophrenia versus controls. In Tidey, J (Chair), symposium entitled "Smokers with Serious Mental Illness: How can laboratory studies inform the development of novel treatments for these smokers?" Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and European Society for Research on Nicotine and Tobacco, Dublin, Ireland.
15. Rohsenow DJ, McGeary J, Tidey J, Martin R, Swift R, Miranda R, Monti P (September 2010). Effects of ondansetron and naltrexone on craving and mood before and after drinking are moderated by family history and DRD4 VNTR. Presented at the International Society of Biomedical Research on Alcoholism, Paris, France. Alcoholism: Clinical and Experimental Research, 34(8), 169A.
16. Colby SM, Barnett NP, Tidey JW, O'Leary Tevyaw TA, Monti PM (2010, September). Smoking intervention studies involving varenicline, patch, or no pharmacotherapy: College students' interests and concerns. Presented at the annual meeting of Society for Research on Nicotine and Tobacco - Europe, Bath, England.
17. Colby SM, Barnett NP, Tidey JW, O'Leary Tevyaw TA, Rohsenow DJ, Kahler CW, Gwaltney C, Monti PM (2010, September). Correlates of readiness to quit smoking among college student smokers. Presented at the annual meeting of Society for Research on Nicotine and Tobacco - Europe, Bath, England.
18. Kahler CW, Metrik J, Spillane NS, Leventhal AM, McKee SA, Tidey JW, McGeary JE, Knopik VS, Rohsenow DJ (2011, February). Sex differences in stimulus expectancy and pharmacological effects of alcohol on smoking lapse risk in a laboratory analogue study. Paper presented at the annual meeting of the Society for Research on Nicotine and Tobacco, Toronto, Canada.
19. Tidey JW, Colby SM (2011, February). Characterization of 72-hr abstinence effects in smokers with schizophrenia and controls. Paper presented at the annual meeting of the Society for Research on Nicotine and Tobacco, Toronto, Canada.
20. Tidey JW (2011, September). Contingency management for smoking reductions in smokers with and without schizophrenia. Paper presented at the 13<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco - Europe, Antalya, Turkey.
21. Glasser I, Zywiak W, Tidey J (2011, November). A study of a lack of diffusion: The case of Nicotine Anonymous. Presented at the 110<sup>th</sup> annual meeting of the American Anthropological Association, Montreal, Quebec.
22. AhnAllen C\*, Tidey J (2013, March). Acute effects of very low nicotine content cigarettes on cognition in smokers with and without schizophrenia. Presented at the International meeting of the Society for Research on Nicotine and Tobacco (combined meeting of SRNT and SRNT-Europe), Boston, MA.
23. Denlinger RL\*, Hatsukami DK, Tidey JW, et al. (2013, March). Feasibility and compliance related to extended evaluation of novel tobacco products: A pilot study using Carlton cigarettes. Presented at the International meeting of the Society for Research on Nicotine and Tobacco (combined meeting of SRNT and SRNT-Europe), Boston, MA.
24. Tidey JW (2014, September). Menthol vs. non-menthol cigarette smoking topography in smokers with schizophrenia and heavy smokers without psychiatric illness. In Tidey J (Chair), oral session at the 15<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco (SRNT)-Europe, Santiago de Compostela, Spain.

25. Rohsenow DJ, Tidey JW, Kahler CW, Martin RA, Colby SM, Sirota AD (2014, September). Intolerance for withdrawal discomfort and motivation predict voucher-based smoking treatment outcomes for smokers with substance use disorders. Presented at the 15<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco (SRNT)-Europe, Santiago de Compostela, Spain.
26. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Monti PM (2014, September). Voucher-based smoking treatment with nicotine replacement and motivational advice for smokers in substance treatment. Presented at the 15<sup>th</sup> annual meeting of the Society for Research on Nicotine and Tobacco (SRNT)-Europe, Santiago de Compostela, Spain.
27. Miller ME\*, Tidey JW (2015, August). Smoking reduction and readiness to quit among smokers with schizophrenia and controls. Presented at the annual meeting of the American Psychological Association, Toronto, Canada.
28. Cassidy RN, Tidey JW, Hatsukami D, Donny EC (2015, August). Young adult smokers' perceptions of reduced-nicotine content cigarettes: Evidence from a multi-dose randomized controlled trial. Presented at the annual meeting of the American Psychological Association, Toronto, Canada.
29. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Monti PM. (September 2015). Varenicline is safe and effective for sober smokers in substance treatment. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco - Europe, Maastricht, The Netherlands.
30. Cassidy RN, Tidey JW, Colby SM (2015, Sept). Development of an e-cigarette purchase task: A qualitative study. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco - Europe, Maastricht, The Netherlands.
31. Tidey JW, Miller ME\*, Denlinger-Apte RL\* (2017, March). Menthol effects on withdrawal and craving in smokers with schizophrenia. In Tidey JW, Stroud L (Co-Chairs), symposium entitled "Examining links between menthol use and smoking persistence in vulnerable populations". Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the Society for Research on Nicotine and Tobacco-Europe, Florence, Italy.
32. Rohsenow DJ, Martin RA, Colby S, Tidey J (2017, March). Predictors of adherence to varenicline or nicotine patch among smokers with substance use disorders. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the Society for Research on Nicotine and Tobacco-Europe, Florence, Italy.
33. Rohsenow DJ, Tidey J, Martin RA, Colby S, Eissenberg T (2017, March). Electronic cigarettes effects on smoking, CO and motivation: A pilot study. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the Society for Research on Nicotine and Tobacco-Europe, Florence, Italy.
34. Davis D, Bergeria C, Streck J, Gaalema D, Heil S, Sigmon S, Stitzer M, Tidey J, Higgins S (2017, March). Examining the influence of mentholation on the reinforcing effects of usual brand and research cigarettes of varying nicotine content in vulnerable populations. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the Society for Research on Nicotine and Tobacco-Europe, Florence, Italy.

35. Dermody SS, McClernon FJ, Benowitz N, Tidey J, Lo X, Vandrey R, Hatsukami D, Donny EC (2017, March). Effects of non-adherence with exclusively smoking very low nicotine content cigarettes on withdrawal symptoms. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the Society for Research on Nicotine and Tobacco-Europe, Florence, Italy.
36. Smith TT, Cassidy RN, Koopmeiners JS, Luo X, Rupprecht LE, Sved AF, Tidey JW, Hatsukami DK, Donny EC. (2017, March). Behavioral economic assessments of the impact of nicotine reduction on rat self-administration and human smoking. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the Society for Research on Nicotine and Tobacco-Europe, Florence, Italy.
37. Smith TT, Donny EC, Koopmeiners JS, Benowitz NL, Cinciripini P, Dermody SS, Luo X, Tidey J, Drobos D, McClernon FJ, Hatsukami DK (2017, March). Baseline dependence moderates the impact of nicotine reduction on changes in nicotine dependence. Presented at the combined meeting of the Society for Research on Nicotine and Tobacco and the Society for Research on Nicotine and Tobacco-Europe, Florence, Italy.
38. Sigmon S, Streck J, Heil S, Stitzer M, Tidey J, Gaalema D, Higgins S (2017, June). Subjective effects of smoking among opioid-maintained individuals: Results from a pilot study examining reduced nicotine content cigarettes. Presented at the annual meeting of the College on Problems of Drug Dependence, Montreal, Canada.
39. Davis D, Bergeria C, Strck J, Bunn J, Gaalema D, Heil S, Sigmon S, Stitzer M, Tidey J, Higgins S (2017, June). The influence of mentholation on usual brand and research cigarettes of varying nicotine content in vulnerable populations. Presented at the annual meeting of the College on Problems of Drug Dependence, Montreal, Canada.
40. Higgins S, Heil S, Sigmon S, Tidey J, Gaalema D, Hughes J, Stitzer M, Durand H, Bunn J, Priest J, Arger C, Miller M, Bergeria C, Davis D, Streck J Reed D, Skelly J, Tursi L (2017, June). Evaluating reduced-nicotine standards on the addiction potential of cigarettes in vulnerable populations. Presented at the annual meeting of the College on Problems of Drug Dependence, Montreal, Canada.
41. Stein LAR, Martin R, Clair-Michaud M, Lebeau R, Gingras M, Rohsenow D, Tidey J, Monti P (2017, June). Behavioral intervention for cigarette smoking among juvenile detainees. Presented at the annual meeting of the College on Problems of Drug Dependence (CPDD), Montreal, Canada.
42. Cioe PA, Kahler CW, Tidey JW, Mercurio AN, Constantino CC, Kahler CW (2019, September). An open pilot to examine the acceptability and health effects of electronic cigarettes in HIV-positive smokers. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco-Europe.
43. Cassidy RN, Reed G, Bello M, Tidey JW, Colby SM (2023, Sept 11-13). Understanding how a reduced nicotine policy standard for cigarettes would impact youth use of alternative products. Presented at the annual meeting of the Society for Research on Nicotine and Tobacco-Europe, London, England.
44. Hatsukami D, Carroll DM, Luo X, Cao Q, Jensen J, Strayer L, Hecht S, Murphy S, White C, Tidey J, Strasser AA, Benowitz N, McClernon FJ, Donny E (2024, March 21). Patterns of non-combusted nicotine delivery system use in an experimental marketplace with very low vs. normal nicotine content cigarettes. Oral presentation (SYM4-5) at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Edinburgh, Scotland.

45. Cassidy RN, Tidey JW, Denlinger-Apte R, Cioe P, Hatsukami D, Moulding C, Godin J, Bello MS, Swift R, Donny E, Colby SM (2024, March 21). Modeling the impact of e-cigarette characteristics on youth choice to smoke in the context of a nicotine reduction policy. Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Edinburgh, Scotland.
46. Carroll DM, Luo X, Hu J, Cao Q, Jensen J, Hecht SS, Murphy S, Tidey J, Colby S, Bello M, Strasser AA, Benowitz N, McClernon FJ, Denlinger-Apte RL, Donny EC, Hatsukami DK (2024, March 20-23). A health equity centered evaluation of a randomized controlled trial of very low nicotine content cigarettes in adults who smoke daily. Oral presentation (SYM4-4) at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Edinburgh, Scotland.
47. Koopmeiners JS, Ji Z, Denlinger-Apte R, Vock D, Wolf J, Cassidy R, Donny E, Higgins S, Tidey J, Hatsukami D (2024, March 21). Minimal evidence of compensatory smoking during clinical trials of very low nicotine content cigarettes: A machine-learning approach. Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Edinburgh, Scotland.
48. Mead-Morse E, Cassidy RN, Moore T, Tidey JW, Delnevo CD, Litt M (2024, March 23). Abuse liability of flavored cigarillos in young adult dual users: a cross-over trial using the purchase task. Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Edinburgh, Scotland.
49. Higgins ST, Tidey JW, Sigmon SC, Gaalema DE, Lee D, Heil SH, DeSarno M, Wiley R, Plucinski S, Orr E, Cioe P, Klemperer EM (2024, March 21). Availability of e-cigarettes and flavored e-liquids may enhance the effects of a nicotine product standard on smoking in vulnerable populations. Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Edinburgh, Scotland.
50. Bello MS, Rubenstein D, Gebru NM, Gilmore AN, Colby SM, Tidey JW, Snell LM, McClernon FJ, Leventhal AM, Cassidy RN (2024, March 23). Health equity implications of a nicotine reduction policy standard: Racial/ethnic differences in the acute and extended effects of reduced nicotine content cigarettes on cigarette reinforcement. Poster presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Edinburgh, Scotland.
51. Thrailkill EA, Khadanga S, Tidey JW. Influence of experience with 22<sup>nd</sup> Century VLN cigarettes on demand for VLN and usual-brand cigarettes (2024, March 23). Poster presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Edinburgh, Scotland.
52. Good K, Murphy CM, Kolbasov L, Ahluwalia J, Monti P, Tidey J (2024, March 23). Clustering of unhealthful eating and activity behaviors as a function of smoking status. Poster presentation at the annual meeting of the Society for Research on Nicotine and Tobacco (SRNT), Edinburgh, Scotland.
53. Bello MS, Jao NC, Colby SM, Tidey JW, Cassidy RN (2024, June 15-19). Tobacco withdrawal and cigarette reinforcement as mechanisms underlying the effects of reduced nicotine content cigarettes on adolescent smoking behavior. Poster presentation at the annual meeting of the College on Problems of Drug Dependence, Montreal, Canada.

54. Padovano HT, Colby SM, Tidey JW, Cassidy RN (2024, July 19-21). Disentangling in-the-moment effects of cannabis co-use on antecedents and responses to cigarette smoking and alternative tobacco use among youth. Paper presentation at the annual meeting of the Research Society on Marijuana, Toronto, Canada.

**GRANTS**

<b>Summary Table of External Grant Funding</b>	
<b>Active</b>	<b>Completed</b>
<p><b>PI or MPI</b></p> <ul style="list-style-type: none"> <li>• T32DA016184 (MPI with Rohsenow)</li> </ul>	<p><b>PI or MPI</b></p> <ul style="list-style-type: none"> <li>• U01DA045514 (MPI with Cioe)</li> <li>• T32DA016184 (MPI with Rohsenow)</li> <li>• R21DA041114</li> <li>• R21DA031283</li> <li>• R21DA026829</li> <li>• R01DA014002 (2005-2011)</li> <li>• R01DA014002 (2001-2005)</li> <li>• R01DA017566</li> </ul> <p><b>Non-Federal:</b></p> <ul style="list-style-type: none"> <li>• American Lung Association of VT</li> </ul>
<p><b>Core Lead</b></p> <ul style="list-style-type: none"> <li>• P20GM130414 (PI Monti)</li> </ul>	<p><b>Core Lead</b></p> <ul style="list-style-type: none"> <li>• P20GM130414 (2019-2024)</li> </ul>
<p><b>Co-I, Site PI, Consultant or Advisor</b></p> <ul style="list-style-type: none"> <li>• R01DA059562 (PI Klemperer), Site PI</li> <li>• P20AG089308 (MPIs Just/Shireman), Co-I</li> <li>• R01CA276696 (PI Tackett), Consultant</li> </ul>	<p><b>Co-I, Site PI, Consultant or Advisor</b></p> <ul style="list-style-type: none"> <li>• U54DA036114 (PI Higgins), Site PI</li> <li>• P50DA036114 (PI Higgins), Site PI</li> <li>• U54DA031659 (MPIs Donny/Hatsukami), Site PI</li> <li>• P50DA031659 (MPIs Donny/Hatsukami), Site PI</li> <li>• R01DA045492 (MPIs Stroud/Salisbury), Co-I</li> <li>• R34DA046078 (PI Japuntich), Co-I</li> <li>• R01DA047356 (MPIs Cassidy/Colby), Co-I</li> <li>• R21DA046333 (MPIs Wagener/Villanti), Co-I</li> <li>• R03DA043596 (PI Japuntich), Co-I</li> <li>• R03DA041820 (PI Cassidy), Co-I</li> <li>• P20GM103644 (PI Higgins), Site PI</li> <li>• R01DA034628 (PI Rohsenow), Co-I</li> <li>• R43DA032167 (PI Dweik), Consultant</li> <li>• R01AA007850 (PI Miranda), Co-I</li> </ul>

	<ul style="list-style-type: none"> <li>• R03AA20169 (PI Leggio), Co-I</li> <li>• R01DA026831 (PI Leventhal), Co-I</li> <li>• R01DA026778 (PI Miranda), Co-I</li> <li>• R21AA015980 (PI Barnett), Co-I</li> <li>• R01DA023995 (PI Rohsenow), Co-I</li> <li>• R01DA024652 (PI Rohsenow), Co-I</li> <li>• R01AA016978 (PI Kahler), Co-I</li> <li>• R01DA020731 (PI Stein), Co-I</li> <li>• R01AA007850 (PI Monti), Co-I</li> <li>• VA Merit (PI Rohsenow), Co-I</li> <li>• R01DA016737 (PI Colby), Co-I</li> <li>• R01AA013880 (PI Rohsenow), Co-I</li> <li>• R01DA011204 (PI Monti), Co-I</li> <li>• VA Merit (PI Rohsenow), Co-I</li> <li>• R01DA013616 (PI Rohsenow), Co-I</li> <li>• R01AA07850 (PI Monti), Co-I</li> </ul> <p><b>Non-Federal:</b></p> <ul style="list-style-type: none"> <li>• ABMRF, (PI Leggio), Cp-I</li> <li>• ABMRF, (PI MacKillop), Co-I</li> </ul>
<p><b>Primary Mentor</b></p> <ul style="list-style-type: none"> <li>• K01CA294580 (PI Snell)</li> <li>• P20GM130414 / 7782 (Murphy)</li> <li>• P20GM130414 / 7005 (Sokolovsky)</li> </ul>	<p><b>Primary Mentor</b></p> <ul style="list-style-type: none"> <li>• F31DA049460 (PI DeAtley)</li> <li>• R36DA045183 (PI Denlinger)</li> </ul>
<p><b>Co-Mentor or Advisor</b></p> <ul style="list-style-type: none"> <li>• K01DA056494 (PI Davis)</li> <li>• K99DA060267 (PI Regnier)</li> </ul>	<p><b>Co-Mentor or Advisor</b></p> <ul style="list-style-type: none"> <li>• K01DA048494 (PI Mead-Morse)</li> <li>• K23DA045078 (PI Murphy)</li> <li>• K01AA026874 (PI Goodyear Chavanne)</li> <li>• K01CA189300 (PI Cassidy)</li> <li>• K23DA033302 (PI Bidwell)</li> <li>• K02DA031766 (PI Lile)</li> <li>• K23AA016936 (PI MacKillop)</li> <li>• K23AA014966 (PI Miranda)</li> </ul>

Current Grants

1. Center for Addiction and Disease Risk Exacerbation (CADRE) Phase II (2P20GM130414)  
Sponsor: National Institute of General Medical Sciences  
Principal Investigator: Peter M. Monti, PhD  
Total costs: \$11,962,500 (total costs for Clinical Laboratory Core: \$4,000,589)  
Project period: 9/1/2024 – 7/31/2029  
Role: Clinical Laboratory Core Director
2. A Randomized Trial of Reduced Nicotine Cigarettes and E-Cigarettes in Dual Users (R01DA059562)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Elias Klemperer, PhD  
Total costs: \$3,945,408 (across both sites); \$1,436,120 (subcontract to Brown)  
Project period: 1/1/24 – 12/31/29  
Role: Site PI
3. Substance Abuse Intervention Outcome Research Training (T32 DA016184)  
Sponsor: National Institute on Drug Abuse  
Principal Investigators: Jennifer Tidey, PhD, Damaris Rohsenow, PhD (MPIs)  
Total costs: \$2,068,249  
Project period: 7/1/23 – 6/30/28  
Role: MPI/Contact PI
4. Abuse Liability, Topography, and Toxicology of Ice Flavors and Non-Menthol Cooling Agents in E-Cigarette Products (R01 CA276696)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Alayna P. Tackett, PhD  
Project period: 8/1/23 – 7/31/28  
Role: Consultant
5. CHAIRS-C: Climate, Health, and Aging Innovation and Research Solutions for Communities (P20 AG089308)  
Sponsor: National Institute of Aging  
Principal Investigators: Allan Just, PhD, Theresa Shireman, PhD (MPIs)  
Total costs: \$3,849,201  
Project period: 9/31/24 – 8/31/27  
Role: Co-Investigator
6. Assessing the Abuse Liability of a Hyper-Palatable Ultraprocessed Food in People With vs. Without Affective Disorders  
Sponsor: Brown University Division of Research (Research Resilience Award)  
Total costs: \$75,000  
Project period 1/1/26 – 12/30/26  
Role: PI

Current Mentoring Roles on Grants

7. Using Wearables and EMA to Examine the Links between Cannabis and Depression (P20GM130414, Project Subcode 7005)  
Sponsor: National Institute of General Medical Sciences  
Principal Investigator: Alexander Sokolovsky, Project PI, Peter Monti, COBRE PI  
Total costs (this project): \$716,366  
Project period: 12/1/24 – 11/30/27  
Role: Primary Mentor
8. A Comparison of Electronic Cigarettes and Combination Nicotine Replacement Therapy among Individuals with Obesity who Smoke (P20GM130414, Project Subcode 7782)  
Sponsor: National Institute of General Medical Sciences  
Principal Investigator: Cara Murphy, Project PI, Peter Monti, COBRE PI  
Total costs (this project): \$717,750  
Project period: 8/1/24 – 7/31/27  
Role: Primary Mentor
9. Sex Differences in E-Cigarette Flavor Sensory Perception as it Relates to Appeal and Reinforcing Efficacy among Adult Smokers (K01 DA056494)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Danielle R. Davis, PhD  
Project period: 7/15/22 – 6/30/27  
Role: Advisory Committee Member
10. Adapting and Testing a Smoking Cessation Intervention in Adults with Intellectual and Developmental Disabilities (K99DA060267).  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Sean Regnier, PhD  
Project period: 7/1/24 – 6/31/29  
Role: Co-Mentor
11. Development and Assessment of Continuum of Risk Education on Tobacco Use among Socioeconomically-Disadvantaged Adults (K01CA294580)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: L. Morgan Snell, PhD  
Project period: 8/1/24 – 7/31/29  
Role: Primary Mentor

Completed Grants

1. Impact of Cigar Flavor on Tobacco Use Behaviors and Addiction in Dual Users (K01 DA048494)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Erin Mead-Morse, Ph.D.  
Project period: 6/1/19 – 5/31/25 (NCE)  
Role: Co-Mentor

2. A Multiple Health Behavior Change Intervention for Overweight and Obese Smokers (K23DA045078)

Sponsor: National Institute on Drug Abuse  
Principal Investigator: Cara Murphy, PhD  
Project period: 2/1/19 – 1/31/25 (NCE)  
Role: Co-Mentor

3. Center for Addiction and Disease Risk Exacerbation (P20GM130414)

Sponsor: National Institute on General Medical Sciences  
Principal Investigator: Peter M. Monti, Ph.D.  
Project period: August 2019 – August 2024  
Total costs: \$12,302,042  
Role: Director of Clinical Laboratory Core; Research Project Mentor

4. Vermont Center on Tobacco Regulatory Science (2U54DA036114)

Sponsor: National Institute on Drug Abuse  
Principal Investigator: Stephen Higgins, Ph.D.  
Project period: September 2018 – August 2024 (NCE)  
Total costs: \$19,381,385; Total costs of Brown subcontract: \$2,472,141  
Role: Center Associate Director and Overall PI of Project 3

5. Evaluating New Nicotine Standards for Cigarettes (2U54DA031659)

Sponsor: National Institute on Drug Abuse  
Center Principal Investigators: Eric Donny, Ph.D., Dorothy Hatsukami, Ph.D.  
Center Project period: March 2017 – February 2024 (NCE)

Project 1: Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace  
Principal Investigator: Dorothy Hatsukami, Ph.D.  
Total costs of Brown subcontract: \$1,108,034  
Role: Site MPI

Project 3: Effects of Very Low Nicotine Content Cigarettes and E-Cigarette  
Characteristics on Smoking in Adolescents  
Total costs of Brown subcontract: \$2,153,311  
Role: MPI

Administrative Core  
Total costs of Brown subcontract: \$159,436  
Role: Site PI

6. Electronic Cigarettes During Pregnancy: Impact on Fetal Development (R01DA045492)

Sponsor: National Institute on Drug Abuse  
Principal Investigators: Laura Stroud, PhD, Amy Salisbury PhD  
Project period: September 2018 – August 2024 (NCE)  
Total costs (Brown subcontract): \$385,230  
Role: Co-I

7. Neural Mechanisms Associated with Alcohol and Cigarette Craving in Alcohol Use Disorder Smokers During Oxytocin Treatment (K01 AA026874)  
Sponsor: National Institute on Alcohol Abuse and Alcoholism  
Principal Investigator: Kimberly Goodyear Chavanne, PhD  
Project period: May 2019 – April 2024  
Role: Co-Mentor
8. Health Effects of the Standardized E-Cigarette on Harm Reduction in Smokers with HIV (U01DA045514)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Patricia Cioe, PhD  
Project period: May 2018 – April 2024 (NCE)  
Total costs: \$1,091,291  
Role: MPI
9. Implementation of Proactive Tobacco Cessation Treatment in Community-Based Mental Health Centers (R34DA046078)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Sandra Japuntich, Ph.D.  
Project period: December 2019 – November 2023  
Total costs of Brown subcontract: \$192,809  
Role: Co-I/Site PI
10. Perceptions of 22<sup>nd</sup> Century VLN Cigarette Marketing Materials among Vulnerable Populations  
Sponsor: University of Vermont Tobacco Center for Regulatory Science  
Principal Investigator: Eric Thraikill, PhD  
Project period September 2022 – August 2023  
Role: Mentor
11. Substance Abuse Intervention Outcome Research Training (T32 DA016184)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Damaris Rohsenow, Ph.D.  
Total costs: \$1,110,066  
Project period: July 2018 – June 2023  
Role: MPI and Associate Training Director
12. Biopsychosocial Factors Associated with Cigarette and E-cigarette Use in Smokers with Affective Disorders (F31 DA049460).  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Teresa DeAtley, MPH  
Project period: June 2019 – August 2021  
Total costs: \$135,048  
Role: Primary Mentor
13. Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm from Tobacco (R01DA047356)  
Sponsor: National Institute on Drug Abuse  
Principal Investigators: Rachel Cassidy, Ph.D., Suzanne Colby, Ph.D.  
Project period: September 2018 – August 2022  
Total costs: \$1,451,590

Role: Co-I

14. Addiction and Behavior Related to Menthol Cigarette Substitutes (R21 DA046333)  
Sponsor: National Institute on Drug Abuse  
Principal Investigators: Theodore Wagener, Ph.D., Andrea Villanti, Ph.D.  
Project period: September 2018 – August 2020  
Total costs of Brown subcontract: \$19,911  
Role: Co-I/Site PI
15. Acceptance and Commitment Therapy for Tobacco Cessation Initiated in a Psychiatric Partial Hospital (R03DA043596)  
Sponsor: National Institute on Drug Abuse  
Principal Investigators: Ernestine Jennings, Ph.D., Sandra Japuntich, Ph.D.  
Project period: September 2018 – August 2020  
Role: Consultant
16. Assessing Tobacco Product Choice when the Cost of Menthol Cigarettes Increases (R36 DA045183)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Rachel Denlinger-Apte  
Project period: February 2018 – August 2019  
Total costs: \$52,893  
Role: Primary Mentor
17. Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia (R21 DA041114)  
Sponsor: National Institute on Drug Abuse  
Project period: July 2017 – May 2019  
Total costs: \$436,921  
Role: PI
18. Psychometric Validation of an E-Cigarette Purchase Task in Users of Advanced Generation Devices (R03 DA041820)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Rachel N. Cassidy, Ph.D.  
Project period: April 2016 – March 2018  
Direct costs: \$150,000; Total award: \$243,750  
Role: Co-I
19. Evaluation of Very Low Nicotine Content Cigarettes in Adolescent Smokers (K01 CA189300)  
Sponsor: National Cancer Institute  
Principal Investigator: Rachel Cassidy, Ph.D.  
Project period: September 2014 – August 2019  
Total costs: \$992,132  
Role: Co-Mentor

20. Vermont Center on Behavior, Incentives and Health (P20 GM103644)  
Sponsor: National Institute on General Medical Sciences  
Center Principal Investigator: Stephen T. Higgins, Ph.D.  
Project period: September 2013 – July 2018  
Total of Brown subcontract: \$243,664  
Role: Site PI
21. Very Low Nicotine Cigarettes in Smokers with SUD: Smoking, Substance Use (R01 DA034628)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Damaris Rohsenow, Ph.D.  
Project period: September 2013 – June 2018  
Direct costs: \$1,956,504; Total costs: \$3,130,407  
Role: Co-I
22. Deconstructing Smoking and ADHD Comorbidity: A Multilevel Genetic Approach (K23 DA033302)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Cinnamon Bidwell, Ph.D.  
Project period: July 2012 – June 2017  
Direct costs: \$871,007; Total award: \$923,097  
Role: Co-Mentor
23. Physician Monitoring System for Nicotine and Metabolites (Phase I SBIR) (R43 DA032167)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Badawi Dweik, Ph.D./Giner, Inc.  
Project period: May 2012 – April 2013  
Project direct costs: \$80,344; Total awarded: \$179,880  
Role: Consultant
24. Acute Effects of Exercise in Smokers with Schizophrenia (R21 DA031283)  
Sponsor: National Institute on Drug Abuse  
Project period: February 2012 – January 2015 (NCE)  
Total award: \$445,500; Direct costs: \$275,000  
Role: PI
25. Evaluating New Nicotine Standards for Cigarettes (U54 DA031659)  
Sponsor: National Institute on Drug Abuse  
Center Co-Principal Investigators: Eric Donny, Ph.D., Dorothy Hatsukami, Ph.D.  
Center project period: September 2011 – February 2017 (NCE)  
Total costs (Brown subcontract only): \$3,163,682  
Roles: Center Co-I, Project 1 Site PI, & Project 3 PI  
  
Project 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes  
Principal Investigator: Eric Donny, Ph.D.  
Project period: September 2011 – August 2013  
  
Project 3: Very Low Nicotine Cigarettes in Smokers with Schizophrenia  
Principal Investigator: Jennifer Tidey Ph.D.  
Project period: September 2014 – February 2017 (NCE)

26. Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms (R01 AA007850)  
Sponsor: National Institute on Alcohol Abuse and Alcoholism  
Principal Investigator: Robert Miranda, Jr., Ph.D.  
Project period: September 2011– August 2016  
Direct costs: \$2,102,535; Total award: \$3,405,597  
Role: Co-I
27. Medications Development for Cannabis-Use Disorders: Clinical Studies (K02 DA031766)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Joshua Lile, Ph.D.  
Project period: July 2011 – June 2016  
Role: Preceptor
28. Examining a Unique Pharmacotherapy Intervention for Heavy Drinking Alcohol Dependent Individuals Who Smoke  
Sponsor: Alcoholic Beverage Medical Research Foundation (ABMRF)  
Principal Investigator: Lorenzo Leggio, M.D., M.Sc.  
Project period: January 2010 – December 2012  
Project direct costs: \$100,000  
Role: Significant Contributor
29. Effects of Baclofen on Alcohol Cue-Elicited Urges to Drink and Smoke (R03 AA20169)  
Sponsor: National Institute on Alcohol Abuse and Alcoholism  
Principal Investigator: Lorenzo Leggio, M.D., M.Sc.  
Project period: September 2010 – August 2012  
Total awarded: \$40,500  
Role: Significant Contributor
30. Mechanisms Linking Anhedonia and Tobacco Addiction (R01 DA026831)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Adam Leventhal, Ph.D.  
Project period: August 2009 – May 2012  
Project direct costs: \$750,000; Total awarded: \$1,217,709  
Role: Co-I/Consultant
31. Smoking Abstinence and Lapse Effects in Smokers with Schizophrenia and Controls (R21 DA026829)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Jennifer W. Tidey, Ph.D.  
Project period: June 2009 – May 2012  
Project direct costs: \$275,000; Total awarded: \$444,750  
Role: PI
32. Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents (R01 DA026778)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Robert Miranda, Jr., Ph.D.  
Project period: June 2009 – May 2012  
Project direct costs: \$691,094; Total awarded: \$1,117,259  
Role: Co-I

33. Enhancing Alcoholism Pharmacotherapy Research via Behavioral Economics (K23 AA016936)  
Sponsor: National Institute on Alcohol Abuse and Alcoholism  
Principal Investigator: James MacKillop, Ph.D.  
Project period: September 2008 – August 2013  
Direct costs: \$691,210; Total awarded: \$746,507  
Role: Advisor
34. Contingency Management for Alcohol Abuse Using Transdermal Alcohol Detection (R21 AA015980)  
Sponsor: National Institute on Alcohol Abuse and Alcoholism  
Principal Investigator: Nancy Barnett, Ph.D.  
Project period: September 2008 – March 2011  
Project direct costs: \$275,000; Total awarded: \$437,250  
Role: Co-I
35. Contingent Vouchers for Smoking in Substance Abusers as Adjunct to Nicotine Patch (R01 DA023995)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Damaris Rohsenow, Ph.D.  
Project period: July 2008 – May 2014  
Direct costs: \$2,252,702; Total award: \$3,511,976  
Role: Co-I
36. Varenicline and Motivational Advice for Smokers with SUD (R01 DA024652)  
Sponsor: National Institute on Drug Abuse  
Principle Investigator: Damaris Rohsenow, Ph.D.  
Project period: June 2008 – March 2014  
Direct costs: \$2,241,138; Total award: \$3,506,761  
Role: Co-PI
37. Mechanisms Linking Alcohol Use and Smoking Relapse Risk (R01 AA016978)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Christopher Kahler, Ph.D.  
Project period: April 2008 – March 2013  
Project direct costs: \$1,221,901; Total awarded: \$1,941,922  
Role: Co-I
38. Motivation and Skills for Detained Teen Smokers (R01 DA020731)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Lynda Stein, Ph.D.  
Project period: September 2007 – June 2012  
Project direct costs: \$179,765; Total awarded: \$285,827  
Role: Co-I
39. Understanding Craving for Alcohol via Behavioral Economics  
Sponsor: Alcoholic Beverage Medical Research Foundation (ABMRF)  
Principal Investigator: James MacKillop, Ph.D.  
Project period: July 2007 – June 2009  
Project direct costs: \$86,932; Total awarded: \$99,972  
Role: Co-I

40. Biological and Behavioral Mechanisms of Smoking in Schizophrenia (2R01 DA14002)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Jennifer W. Tidey, Ph.D.  
Project period: June 2006 – March 2011  
Project direct costs: \$725,000; Total awarded: \$1,148,677  
Role: PI
41. Biobehavioral Mechanisms of Topiramate and Drinking (R01 AA007850)  
Sponsor: National Institute on Alcohol Abuse and Alcoholism  
Principal Investigator: Peter M. Monti, Ph.D.  
Project period: January 2006 – December 2011  
Project direct costs: \$2,043,580; Total awarded: \$3,076,890  
Role: Co-I
42. Baclofen Effects on Smoking Urge, Withdrawal and Preference  
Sponsor: Department of Veterans Affairs  
Principal Investigator: Damaris Rohsenow, Ph.D.  
Project period: October 2005 – June 2008  
Project direct costs: \$450,000; Total awarded: \$450,000  
Role: Co-I
43. Elucidating Mechanisms of Pharmacotherapy for Alcoholism (K23 AA014966)  
Sponsor: National Institute on Alcohol Abuse and Alcoholism  
Principal Investigator: Robert Miranda, Jr., Ph.D.  
Project period: April 2004 – March 2009  
Project direct costs: \$637,595; Total awarded: \$688,602  
Role: Advisor
44. Smoking versus Alternative Reinforcers in Adolescents (R01 DA016737)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Suzanne Colby, Ph.D.  
Project period: September 2003 – July 2009  
Project direct costs: \$1,250,000; Total awarded: \$1,931,258  
Role: Co-PI
45. Incentives plus Bupropion for Smoking in Schizophrenics (R01 DA017566)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Jennifer W. Tidey, Ph.D.  
Project period: September 2003 – March 2009  
Project direct costs: \$837,135; Total awarded: \$1,291,759  
Role: PI
46. Ondansetron and Naltrexone: Cue Reactivity and Drinking (R01 AA013880)  
Sponsor: National Institute on Alcohol Abuse and Alcoholism  
Principal Investigator: Damaris Rohsenow, Ph.D.  
Project period: June 2003 – May 2009  
Project direct costs: \$925,000; Total awarded: \$1,438,450  
Role: Co-I

47. Contingency Management and MET for Adolescent Smoking (R01 DA011204)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Peter M. Monti, Ph.D.  
Project period: July 2002 – July 2008  
Project direct costs: \$2,259,891; Total awarded: \$3,538,230  
Role: Co-I
48. Effects of Olanzapine on Cigarette Cue Reactivity and Reinforcement  
Sponsor: Department of Veterans Affairs  
Principal Investigators: Damaris J. Rohsenow, Ph.D., Peter M. Monti, Ph.D.  
Project period: October 2001 – September 2004  
Direct costs: \$417,400; Total awarded: \$417,400  
Role: Co-I
49. Transdermal Nicotine and Bupropion-SR in Schizophrenics (R01 DA14002)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Jennifer W. Tidey, Ph.D.  
Project period: September 2001 – June 2006  
Direct costs: \$600,000; Total awarded: \$929,574  
Role: PI
50. Motivating Substance Abusers to Quit Smoking (R01 DA13616)  
Sponsor: National Institute on Drug Abuse  
Principal Investigator: Damaris J. Rohsenow, Ph.D.  
Project period: April 2001 – January 2006  
Direct costs: \$2,026,780; Total awarded: \$3,157,705  
Role: Co-I
51. Naltrexone, Craving and Drinking: Ecological Assessment (R01 AA07850)  
Sponsor: National Institute on Alcohol Abuse and Alcoholism  
Principal Investigator: Peter M. Monti, Ph.D.  
Project period: April 2000 – April 2005  
Direct costs: \$1,812,009; Total awarded: \$2,654,442  
Role: Co-I and Project Director
52. Does Transdermal Nicotine Help Schizophrenics Reduce Smoking?  
Sponsor: American Lung Association of Vermont  
Principal Investigator: Jennifer W. Tidey, Ph.D.  
Project period: July 1998 – July 1999  
Total awarded: \$5,000  
Role: PI

## **UNIVERSITY TEACHING AND MENTORING ROLES**

### Brown University Post-Doctoral Training Program

- MPI/Contact PI, CAAS NIDA T32 in Substance Abuse Intervention Research, 2023 – present.
- MPI, CAAS NIDA T32 in Substance Abuse Intervention Research, 2021 – 2023.
- Associate Training Director, CAAS NIAAAA/NIDA Postdoctoral Training Program, 2021 – present
- Associate Director, CAAS NIDA T32 in Substance Abuse Intervention Research, 2013 – 2021.

### Brown University Post-Doctoral Seminars

- “Responding to Pink Sheets” Combined T32 Core Seminar Series (annually since 2001)
- “Research Ethics: Diminished Capacity” Combined T32 Core Seminar Series (biannually since 2018)
- “Behavioral Economics: A Framework for Understanding Smoking and Other Drug Use” (co-led with Rachel Cassidy, Ph.D., March 2015)
- “Treatment of Tobacco Dependence” (November 2012, November 2014)
- “Behavioral Pharmacology of Opiates, Cocaine, Nicotine, and Other Drugs” (Dec 2002, Dec 2003, March 2005, March 2007)
- “Pharmacotherapy for Dependence on Nicotine, Cocaine or Opiates” (Jan 2003, Jan 2004, April 2005, March 2007)
- “Contingency Management Interventions” (April 2002, April 2003, Oct 2004, Oct 2008)
- “Smokers with Schizophrenia in the Human Behavioral Pharmacology Lab” (May 2003)
- “Tips for IRB success” (November 2004, November 2005, November 2006)
- “How to Give an Effective Presentation” (Oct 2003)

### Brown University Graduate/Undergraduate Seminars

- “Vulnerability to Tobacco and Other Substance Use in People with Schizophrenia” Guest lecture for PHP1550, Substance Use and Vulnerability to Addiction, March 2022.
- “Tobacco Regulatory Science” Guest lecture for Tobacco, Disease and the Industry (PHP 1610; Instructor J. Ahluwalia), Brown University, March 2018, March 2019, March 2020
- “Neurobiology of Addictions” Guest lecture for Etiology of Substance Use Disorders (PHP 2370; Instructor P. Monti), Brown University, Sept 2015.
- “Neurobiology and Psychopharmacology of Stimulants, Nicotine and Cross-Addictions.” Guest seminar for Alcohol Use and Misuse (PHP 1540; Instructor P. Monti), Brown University, Feb 2003, Feb 2004, Feb 2005, Feb 2006, Feb 2008, Feb 2010.
- “Biological and Behavioral Effects of Nicotine” Guest seminar for Tobacco, Smoking, and the Evil Empire (PHP 1680; Instructor D. Williams), Brown University, Feb 2007.
- “Physiology of Addictions”. Guest lecture for Anthropology of Addictions (ANTH 1300; Instructor I. Glasser), Brown University, September 2013.

Faculty Mentoring

2025 – present	K99 Award Co-Mentor for Sean Regnier, Ph.D., Assistant Professor of Behavioral Science, University of Kentucky College of Medicine
2024 – present	CADRE COBRE Project Mentor for Cara Murphy, Ph.D., Assistant Professor of Behavioral and Social Sciences, Brown University
2024 – present	CADRE COBRE Project Mentor for Alexander Sokolovsky, Ph.D., Assistant Professor of Behavioral and Social Sciences, Brown University
2024 – present	K01 Award Co-Mentor for L. Morgan Snell, Ph.D., Assistant Professor of Health Policy, Virginia Commonwealth University
2016 – present	Secondary Faculty Mentor for Mollie Monnig, Ph.D., Assistant Professor of Behavioral and Social Sciences, Brown University
2015 – 2025	Secondary Faculty Mentor for Patricia Cioe, Ph.D., Associate Professor of Behavioral and Social Sciences, Brown University
2019 – 2025	K23 Award Co-Mentor for Cara Murphy, Ph.D., Assistant Professor of Behavioral and Social Sciences, Brown University
2019 – 2025	K01 Award Co-Mentor for Erin Mead, Ph.D., Assistant Professor of Medicine, University of Connecticut Health Center
2019 – 2024	K01 Award Co-Mentor for Kimberly Goodyear Chavanne, Ph.D., Assistant Professor of Behavioral and Social Sciences, Brown University
2013 – 2019	K01 Award Co-Mentor for Rachel Cassidy, Ph.D., currently Associate Professor of Behavioral and Social Sciences, Brown University
2012 – 2017	K23 Award Co-Mentor for Cinnamon Bidwell, Ph.D., currently Assistant Professor, Institute of Cognitive Sciences, University of Colorado – Boulder
2011 – 2016	K02 Award Preceptor for Joshua Lile, Ph.D., currently Professor of Psychiatry and Behavioral Science at the University of Kentucky College of Medicine
2008 – 2013	K23 Award Advisor for James MacKillop, PhD, currently Peter Boris Chair in Addictions Research, McMaster University, Hamilton, Ontario, Canada
2004 – 2009	K23 Award Advisor for Robert Miranda, Jr., PhD, currently Professor of Psychiatry and Human Behavior, Brown University

Post-Doctoral Mentoring

2022 – 2025	Secondary mentor for Sarah Maloney, Ph.D., NIDA T32 Postdoctoral Training Program, Brown University Center for Alcohol & Addictions Studies
2020 – 2022	Primary mentor for L. Morgan Snell, Ph.D., NIDA T32 Postdoctoral Training Program, Brown University Center for Alcohol & Addictions Studies
2014 – 2017	Primary mentor for Mollie Miller, Ph.D., currently Social Scientist at the FDA's Center for Tobacco Products
2006 – 2009	Primary mentor for Christopher AhnAllen, Ph.D., currently Assistant Professor of Psychiatry at Harvard University and Director of Inpatient Psychiatry and Training at Brigham and Women's Faulkner Hospital, Boston

PhD Student Mentoring

- 2017 – 2021 Primary PhD Advisor for Teresa DeAtley, MPH, Department of Behavioral and Social Health Sciences, Brown University School of Public Health
- Recipient of a 2021 Nora Kahn Piore Award, 2021 CPDD Travel Award, and 2020 SRNT Health Disparities Network Travel Scholarship. Currently an Assistant Professor at the University of Utah
- 2015 – 2019 Primary PhD Advisor for Rachel Denlinger-Apte, MPH, Department of Behavioral and Social Health Sciences, Brown School of Public Health
- Recipient of the 2020 Brown University School of Public Health Impact Award, awarded to one exceptional doctoral student who has completed the degree requirements in the past academic year while making a notable impact through scholarship, service, and citizenship and professional contributions. Currently Assistant Professor at Wake Forest University

MSc or MPH Student Mentoring

- 2016 – 2017 MSc Advisor for Claire Walker, MPH, Department of Behavioral and Social Health Sciences, Brown University School of Public Health. Thesis title: “ADHD and Sensation Seeking as Risk Factors for Poly-tobacco Use among Adolescents: An Analysis of the PATH Study”
- 2007 – 2008 MPH Advisor for Amy Adolfo, PhD, Department of Behavioral and Social Health Sciences, Brown University School of Public Health. Thesis title: “Social Support for Quitting among Smokers with Schizophrenia and Non-Psychiatric Heavy Smokers”
- 2013 – 2014 MSc Advisor for Emily Xavier, MSc, Department of Behavioral and Social Health Sciences, Brown University School of Public Health. Thesis title: “Effects of Smoking Abstinence on Cigarette Craving, Nicotine Withdrawal, and Smoking in Male and Female Heavy Smokers”

Undergraduate Research Advising

- 2017 Emily Springfield, Independent Study, Brown University
- 2009 – 2010 Justina Gamache, Senior Capstone Project Advisor, Brown University
- 2018 (summer) Zoe Risher, Solsbery Fellowship Advisor, Brown University

Service on Master’s Thesis and PhD Dissertation Committees

- November 2014 MS Thesis External Committee Member for Kristen Michelle Mackowick, MS, University of Toronto, Toronto, Canada
- January 2015 PhD Dissertation External Committee Member for Vanessa Clark, PhD, University of Newcastle, Callaghan, NSW, Australia

Other Mentoring

- January 2010 Co-Leader of Breakout Session, Faculty Development Workshop “Navigating

- Promotion at Brown Successfully”
- October 2010 Faculty Discussion Leader, BioMed Women Junior Faculty Advancement Program “Advancing from Assistant to Associate Professor”
- Sept 2011, Apr 2012 Co-facilitator, BioMed Women Faculty Peer Mentoring Event
- December 2021 Completed Advance-CTR Mentoring Training Program (8 hrs)

### Adjunct Teaching

1997 – 1999, Adjunct Lecturer, Trinity College, Burlington, VT

- Psy 101: General Psychology (Fall 1998 and Spring 1999, 4 total sections)
- Psy 233: Disorders of Childhood and Adolescence (Spring 1997)

1995 – 1996, Adjunct Assistant Professor, Massachusetts Bay Community College, Wellesley, MA

- Psy 240: Abnormal Psychology (Fall 1995, Spring 1996)

### **MEDIA ENGAGEMENT**

Science News 1/18/25 <https://www.sciencenews.org/article/cigarettes-smoking-less-nicotine-quit>

Feature on Carney Institute website 1/23/25 <https://carney.brown.edu/news/2025-01-23/addiction-advocacy>

Rhode Island Current, 2/12/24: <https://rhodeislandcurrent.com/2024/02/12/if-rhode-island-raises-the-cigarette-tax-will-smokers-quit-not-really/>

Humans in Public Health, 12/13/23: <https://podcasts.apple.com/us/podcast/tobacco-nicotine-and-the-lesser-of-two-evils/id1561779028?i=1000638308966>  
<https://sph.brown.edu/news/2023-12-13/hiph-transcript-ahluwalia-and-tidey>

GoLocal Live, 8/17/17: <https://www.youtube.com/watch?v=SByclpZTSIc>

Rhode Island Monthly, Oct 2002 “Waging a New War”

George Street Journal, 15(6). Feb 8-21, 2002. “Treating Schizophrenic Smokers: A Particular Challenge”